Platform Specialty Products Corp Form 10-Q November 07, 2016

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 10-Q

 \circ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2016

OR

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number: 001-36272

(Exact name of Registrant as specified in its charter)

Delaware 37-1744899

(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)

1450 Centrepark Boulevard, Suite 210

West Palm Beach, Florida

33401

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code: (561) 207-9600

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ý No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer," and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ý Accelerated filer o Non-Accelerated filer o Smaller reporting company o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes o No \circ

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practical date.

Class November 1, 2016 Common Stock, par value \$0.01 per share 278,470,487 shares

Table of Contents

Glossary		Page
	Glossary of Defined Terms	<u>G-1</u>
<u>Part I.</u>	Financial Information	
<u>Item 1.</u>	Financial Statements (Unaudited)	
	Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2016 and 2015 (Unaudited)	<u>1</u>
	Condensed Consolidated Statements of Comprehensive Income (Loss) for the three and nine months ended September 30, 2016 and 2015 (Unaudited)	<u>2</u>
	Condensed Consolidated Balance Sheets as of September 30, 2016 and December 31, 2015 (Unaudited)	3
	Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2016 and 2015 (Unaudited)	<u>4</u>
	Condensed Consolidated Statements of Changes in Stockholders' Equity for the three and nine months ended September 30, 2016 (Unaudited)	<u>5</u>
	Condensed Consolidated Statements of Changes in Stockholders' Equity for the three and nine months ended September 30, 2015 (Unaudited)	<u>6</u>
	Notes to the Condensed Consolidated Financial Statements (Unaudited)	<u>7</u>
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	<u>41</u>
<u>Item 3.</u>	Quantitative and Qualitative Disclosures About Market Risk	<u>60</u>
<u>Item 4.</u>	Controls and Procedures	<u>60</u>
<u>Part II.</u>	Other Information	
<u>Item 1.</u>	Legal Proceedings	<u>62</u>
	<u>. Risk Factors</u>	<u>62</u>
	<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	<u>66</u>
<u>Item 3.</u>	<u>Defaults Upon Senior Securities</u>	<u>66</u>
<u>Item 4.</u>	Mine Safety Disclosures	<u>66</u>
<u>Item 5.</u>	Other Information	<u>66</u>
<u>Item 6.</u>	<u>Exhibits</u>	<u>68</u>
<u>Signatur</u>	<u>es</u>	<u>69</u>

Glossary of Defined Terms

Terms **Definitions**

Platform; We; Us; Platform Specialty Products Corporation, a Delaware corporation, and its subsidiaries,

Our; the Company collectively.

Agriphar Acquisition, Alent Acquisition, Arysta Acquisition, CAS Acquisition, MacDermid Acquisitions

Acquisition, OMG Acquisition and OMG Malaysia Acquisition, collectively.

Percival and its agrochemical business, Agriphar. Agriphar

Agriphar

Annual Report

Asset-Lite.

Acquisition of a 100% interest in Agriphar, completed on October 1, 2014. Acquisition

AIs Active ingredients.

Alent Alent plc, a formerly public limited company registered in England and Wales.

Acquisition of a 100% interest in Alent, completed on December 1, 2015 under the U.K. Alent Acquisition

Companies Act 2006, as amended.

Platform's credit agreement dated April 12, 2007, as amended and/or restated on June 7, 2013,

Amended and October 31, 2013 (Amendment No. 1), August 6, 2014 (Second Amended and Restated Credit Agreement and the further amendments pursuant to Amendment No. 2), October 1, 2014 Restated Credit (Incremental Amendment No. 1), February 13, 2015 (Amendment No. 3), December 3, 2015 Agreement

(Amendment No. 4) and October 14, 2016 (Amendment No. 5).

Platform's annual report on Form 10-K for the fiscal year ended December 31, 2015, filed with

the SEC on March 11, 2016. **AROs** Asset retirement obligations.

Arysta LifeScience Limited, a formerly Irish private limited company. Arysta Arysta Acquisition Acquisition of a 100% interest in Arysta, completed on February 13, 2015.

Nalozo, L.P., an affiliate of the Original Arysta Seller who became the seller in the Arysta Arysta Seller

Acquisition pursuant to an amendment to the share purchase agreement dated February 11, 2015.

Platform's philosophy and business model focused on dedicating extensive resources to research and development and highly technical customer service teams, while limiting investments in

High-Touch fixed assets and capital expenditures.

ASU Accounting Standards Update. **Board** Platform's board of directors.

CAS The Chemtura AgroSolutions business of Chemtura.

Acquisition of a 100% interest in CAS, completed on November 3, 2014. **CAS** Acquisition

Chemtura Chemtura Corporation, a Delaware corporation.

The First Lien Credit Facility and the Revolving Credit Facility, collectively, available under the Credit Facilities

Amended and Restated Credit Agreement.

Platform's change of jurisdiction of incorporation from the British Virgin Islands to Delaware on Domestication

January 22, 2014.

Earnings before interest, taxes, depreciation and amortization. **EBITDA**

EPS Earnings per share.

Platform Specialty Products Corporation 2014 Employee Stock Purchase Plan, adopted by the

Board on March 6, 2014 and approved by Platform's stockholders at the annual meeting held on **ESPP**

June 12, 2014.

European Union. E.U.

Securities Exchange Act of 1934, as amended. Exchange Act

Exchange Exchange Agreement, dated October 25, 2013, between Platform and the fiduciaries of the

MacDermid, Incorporated Profit Sharing and Employee Savings Plan. Agreement

FASB Financial Accounting Standard Board. Foreign Corrupt Practices Act of 1977. **FCPA**

February 2015 Platform's private offering of \$1.10 billion aggregate principal amount of 6.50% USD Notes due Notes Offering 2022 and €350 million aggregate principal amount of 6.00% EUR Notes due 2023, completed on

February 2, 2015.

First Lien Credit

Facility

First lien credit facility available under the Amended and Restated Credit Agreement.

G-1

Terms **Definitions**

Founder

Mariposa Acquisition, LLC and Berggruen Holdings Ltd. and its affiliates, collectively.

Entities GAAP

Generally accepted accounting principles in the United States.

GBP

Platform's Global BioSolutions Portfolio within its Agricultural Solutions segment, which includes

biostimulants, innovative nutrition and biocontrol products.

Platform's Global Value Added Portfolio within its Agricultural Solutions segment, which includes

GVAP

products in the herbicides, insecticides, fungicides and seed treatment categories, based on patented

or proprietary off-patent AIs.

June 2015

Platform's underwritten public offering of 18,226,414 shares of its common stock at a public offering price of \$26.50 per share, which closed on June 29, 2015, raising gross proceeds of approximately

Equity Offering

\$483 million.

LTCB

Platform's Long Term Cash Bonus plan, established in March 2015.

MacDermid

MacDermid, Incorporated, a Connecticut corporation.

Platform's acquisition on October 31, 2013 of substantially all of the equity of MacDermid Holdings,

MacDermid which, at the time, owned approximately 97% of MacDermid. As a result, Platform became a

holding company for the MacDermid business. Platform acquired the remaining 3% of MacDermid Acquisition

on March 4, 2014, pursuant to the terms of the Exchange Agreement.

MacDermid

MacDermid European Holdings, B.V., a company organized under the laws of the Netherlands and a

Europe

subsidiary of Platform.

MacDermid

MacDermid Funding LLC, a limited liability company organized under the laws of Delaware and a

Funding

subsidiary of Platform.

MacDermid

MacDermid Holdings, LLC which, at the time of the MacDermid Acquisition, owned approximately

Holdings

97% of MacDermid, a subsidiary of MacDermid Holdings.

MAS Holdings

MacDermid Agricultural Solutions Holdings B.V., a company organized under the laws of the

Netherlands and a subsidiary of Platform.

NAV

Net asset value.

NAIP

Netherlands Agricultural Investment Partners LLC, a company organized under the laws of Delaware

and a subsidiary of Platform. New York Stock Exchange.

NYSE

November 2015 Platform's private offering of \$500 million aggregate principal amount of 10.375% USD Notes due

Notes Offering 2021, completed on November 10, 2015.

OMG

OM Group, Inc., a Delaware corporation.

OMG

OMG's Electronic Chemicals and Photomasks businesses, collectively, other than OMG Malaysia.

Businesses

OMG Electronic Chemicals (M) Sdn Bhd, a subsidiary of OMG located in Malaysia, acquired

separately by Platform in the OMG Malaysia Acquisition.

OMG

Platform's acquisition of 100% interest in the OMG Businesses completed on October 28, 2015.

Acquisition **OMG** Malaysia

OMG Malaysia

Platform's acquisition of 100% interest in OMG Malaysia completed on January 31, 2016.

Acquisition

Original Arysta Nalozo S.à.r.l., a Luxembourg limited liability company and the original seller in the Arysta

Seller

Acquisition. Platform Delaware Holdings, Inc., a subsidiary of Platform.

PDH PDH Common

Shares of common stock of PDH.

Stock

Percival

Percival S.A., a société anonyme incorporated and organized under the laws of Belgium, acquired by

Platform on October 1, 2014.

Ouarterly

This quarterly report on Form 10-Q for the fiscal quarter ended September 30, 2016.

Report

Retaining Each Holder of an equity interest of MacDermid Holdings immediately prior to the closing of the

Holder MacDermid Acquisition, not owned by Platform, who executed a RHSA.

Revolving Revolving Credit Facility (in U.S. Dollars or multicurrency) available under the Amended and

Credit Facility Restated Credit Agreement.

Retaining Holder Securityholders' Agreement, dated as of October 31, 2013, entered into by and between Platform and each Retaining Holder pursuant to which they agreed to exchange their

RHSA respective interests in MacDermid Holdings for shares of PDH Common Stock, at an exchange rate

of \$11.00 per share plus (i) a proportionate share of the \$100 million contingent consideration and

(ii) an interest in certain MacDermid pending litigation.

G-2

Definitions Terms

ROIC Return on invested capital.

RSUs Restricted stock units issued by Platform from time to time under the 2013 Plan.

SEC Securities and Exchange Commission.

Amended and Restated Pledge and Security Agreement, amended and restated as of October 31,

2013, as amended, supplemented and modified from time to time, entered into by Platform, Security Agreement

MacDermid and the guarantors listed therein.

Second Amended and Restated Credit Agreement

Second Amended and Restated Credit Agreement, dated as of August 6, 2014, among, inter alia, Platform, MacDermid Holdings, MacDermid, the subsidiaries of Platform and MacDermid Holdings from time to time parties thereto, the lenders from time to time parties thereto and

Barclays Bank PLC, as administrative agent and collateral agent.

Our 6.00% EUR Notes due 2023, 6.50% USD Notes due 2022 and 10.375% USD Notes due Senior Notes

2021, collectively.

September 2016 **Equity Offering**

Platform's underwritten offering of 48,787,878 shares of its common stock at a public offering price of \$8.25 per share, which closed on September 21, 2016, raising gross proceeds of

approximately \$402.5 million.

Series A Preferred Stock

2,000,000 shares of Platform's Series A convertible preferred stock which were automatically converted from ordinary shares held by the Founder Entities upon the Domestication, and which are convertible into shares of Platform's common stock, on a one-for-one basis, at any

time at the option of the Founder Entities.

Series B Convertible Preferred Stock

600,000 shares of Platform's Series B convertible preferred stock issued to the Arysta Seller in connection with the Arysta Acquisition on February 13, 2015, which are convertible into a maximum of 22,107,590 shares of Platform's common stock at the option of the Arysta Seller.

SERP Supplemental Executive Retirement Plan for executive officers of Platform.

TSR Total stockholder return.

Platform Specialty Products Corporation Amended and Restated 2013 Incentive Compensation

Plan adopted by the Board on October 31, 2013, as amended on December 16, 2013 and 2013 Plan

approved by Platform's stockholders at the annual meeting held on June 12, 2014.

2016 Q1 Form 10-Q

Platform's quarterly report on Form 10-O for the fiscal quarter ended March 31, 2016, as filed

with the SEC on May 10, 2016.

2016 Q2 Form 10-Q

Platform's quarterly report on Form 10-O for the fiscal quarter ended June 30, 2016, as filed with the SEC on August 9, 2016.

6.00% EUR Notes

Platform's 6.00% senior notes due 2023 denominated in Euros issued in the February 2015

Notes Offering. due 2023

6.50% USD Notes

due 2022

Platform's 6.50% senior notes due 2022 denominated in U.S. Dollars issued in the February

2015 Notes Offering.

10.375% USD Notes Platform's 10.375% senior notes due 2021 denominated in U.S. Dollars issued in the November

2015 Notes Offering. due 2021

G-3

Part I. Financial Information

Item 1. Financial Statements

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

(In millions, except income (loss) per share)

	Three Months Ended September 30,		Nine Mon September	
	2016	2015	2016	2015
		(as		(as
Net sales	\$890.5	restated) \$597.3	\$2,635.9	restated) \$1,807.3
Cost of sales	515.4	354.6	1,524.1	1,088.8
Gross profit	375.1	242.7	1,111.8	718.5
Operating expenses:	373.1	272.7	1,111.0	710.5
Selling, technical, general and administrative	274.3	194.8	823.5	593.2
Research and development	20.9	16.6	61.3	47.8
Total operating expenses	295.2	211.4	884.8	641.0
Operating profit	79.9	31.3	227.0	77.5
Other (expense) income:				
Interest expense, net	(98.5)	(52.7)	(289.7)	(143.2)
Loss on derivative contracts	(1.4)	(47.3)	(12.1)	(49.9)
Foreign exchange loss	(10.3)	(36.9)	(56.5)	(19.3)
Other income, net	116.6	1.4	120.4	19.8
Total other income (expense)	6.4	(135.5)	(237.9)	(192.6)
Income (loss) before income taxes and non-controlling interests	86.3	(104.2)	(10.9)	(115.1)
Income tax expense		(35.4)	(65.7)	(59.8)
Net income (loss)	65.9	(139.6)	(76.6)	(174.9)
Net loss (income) attributable to the non-controlling interests	5.9	(0.5)	4.7	(4.0)
Net income (loss) attributable to stockholders	71.8	(140.1)		(178.9)
Gain on amendment of Series B Convertible Preferred Stock	32.9	_	32.9	_
Net income (loss) attributable to common stockholders	\$104.7	\$(140.1)	\$(39.0)	\$(178.9)
Income (loss) per share				
Basic	\$0.45	\$(0.66)		\$(0.89)
Diluted	\$(0.15)	\$(0.66)	\$(0.71)	\$(0.89)
Weighted average shares outstanding				
Basic	234.4	210.9	231.2	198.6
Diluted	264.5	210.9	253.3	198.6

See accompanying notes to condensed consolidated financial statements

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) (In millions)

	Ended	Months aber 30,	Nine Me Ended S 30,	onths September	r
	2016	2015 (as restated)	2016	2015 (as restated)	1)
Net income (loss)	\$65.9	\$(139.6)	\$(76.6)	\$(174.9)
Other comprehensive (loss) income Foreign currency translation adjustments	(0.7)	(350.2)	451.8	(614.0)
Pension and post-retirement plans: Tax expense Pension and post-retirement plan, net of tax	_	_ _	_	(0.5 (0.5)
Unrealized (loss) gain on available for sale securities: Unrealized holding (loss) gain on available for sale securities Tax benefit Unrealized (loss) gain on available for sale securities, net of tax	(0.2) 0.1 (0.1)	_	0.8	1.2	
Derivative financial instruments revaluation: Unrealized hedging gain (loss), net Tax benefit Derivative financial instruments revaluation, net of tax	1.4 — 1.4	6.3	(15.4) — (15.4)	6.3)
Total other comprehensive income (loss), net of tax Other comprehensive loss (income) attributable to the non-controlling interests Other comprehensive income (loss) attributable to common stockholders	0.6 9.0 9.6	(361.0) 7.2 (353.8)	(12.7)	(625.1 14.3 (610.8	
Comprehensive income (loss) Comprehensive income attributable to the non-controlling interests Comprehensive income (loss) attributable to stockholders	75.5 5.9 \$81.4	(493.4) (0.5) \$(493.9)	4.7)

See accompanying notes to condensed consolidated financial statements

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In millions, except share and per share amounts)

Assets \$714.1 \$432.2 Restricted cash 0.9 0.3 Accounts receivable, net of allowance for doubtful accounts of \$28.7 1,141.0 1,023.0 Instand \$14.4 at September 30, 2016 and December 31, 2015, respectively 564.3 517.5 Note receivable — 125.0 Prepaid expenses and other current assets 2,600.6 2,705.5 Total current assets 2,600.6 2,705.5 Froperty, plant and equipment, net 472.7 491.6 Goodwill 4,366.3 3,314.3 Other assets 339.0 31,91.9 Total assets 18,09.0 19.1 Corner installments of long-term debt and revolving credit facilities 81,4 54,7 Accrued salaries, wages and employee benefits 81,4 54,7 Accrued salaries, wages and employee benefits 81,4 54,7 Accrued salaries, wages and other current liabilities 78.0 78.1 Accrued salaries, wages and employee benefits 81,4 54,7 Accrued ackemption liability 504.0 65.1 Preferred stock redempt	(in infinois, except share and per share amounts)	September 30, 2016	December 31, 2015
Restricted cash 0,9 3.3 Accounts receivable, net of allowance for doubtful accounts of \$28.7 1,141.0 1,023.0 Inventories 564.3 517.5 Note receivable — 125.0 Prepaid expenses and other current assets 180.3 17.5 Propaid expenses and other current assets 2,600.6 2,270.5 Propeity, plant and equipment, net 472.7 491.6 Goodwill 4,363.3 4,021.9 Intangible assets, net 3,393.2 3,314.3 Other assets 3,393.2 3,314.3 Other assets 3,393.2 3,314.3 Other assets 81.4 54.7 Current sistaliments of long-term debt and revolving credit facilities 81.4 54.7 Accrued aincome taxes payable 100.6 65.1 Current installments of long-term debt and revolving credit facilities 81.4 54.7 Accrued income taxes payable 100.6 65.1 Preferred stock redemption liability 504.0 78.0 Accrued alment is almitage and employee benefits 105.0			
Accounts receivable, net of allowance for doubtful accounts of \$28.7 and \$14.4 at September 30, 2016 and December 31, 2015, respectively 1,141.0 1,023.0 Inventories 564.3 \$17.5 Note receivable			
and \$14.4 at September 30, 2016 and December 31, 2015, respectively 1,194.0 1,025.0 Inventories 125.0 125.0 Prepaid expenses and other current assets 180.3 172.5 Total current assets 2,600.6 2,270.5 Property, plant and equipment, net 43.66.3 4021.9 Intangible assets, net 3,393.2 3,314.3 Other assets 310,920.7 \$10,190.2 Total assets \$10,920.7 \$10,190.2 Liabilities and Stockholders' Equity \$394.8 \$450.3 Accrued salaries, wages and employee benefits 81.4 54.7 Accrued income taxes payable 100.6 51. Current installments of long-term debt and revolving credit facilities 81.4 54.7 Accrued salaries, wages and employee benefits 81.4 54.7 Accrued income taxes payable 100.6 51.1 Accrued depenses and other current liabilities 504.0 — Accrued axpenses and employee benefits 81.4 54.7 Accrued expenses and other current liabilities 1,062.4 1,062.4		0.9	0.3
Inventories		1.141.0	1.023.0
Note receivable — 125.0 Prepaid expenses and other current assets 180.3 172.5 Total current assets 2,600.6 2,270.5 Property, plant and equipment, net 472.7 491.6 Goodwill 4,366.3 4,021.9 Intangible assets, net 33.93.2 33.93.2 31.91.3 Other assets \$10,92.6* \$10,190.2* \$10,190.2* Labilities and Stockholders' Equity \$394.8 \$450.3 \$450.3 Accounts payable \$394.8 \$450.3 \$450.3 Current installments of long-term debt and revolving credit facilities 81.4 \$4.7 Accrued salaries, wages and employee benefits 81.4 \$4.7 Accrued income taxes payable 100.6 65.1 Preferred stock redemption liability 504.0 — Preferred stock redemption liabilities 1,06.2 1,062.4 Long-term debt and capital lease obligations 5,196.2 1,768.2 Long-term deferred income taxes 696.7 678.8 Long-term cottingent consideration 75.0 77.0<	*		
Prepaid expenses and other current assets 2,600.6 2,270.5 Total current assets 2,600.6 2,270.5 Property, plant and equipment, net 472.7 491.6 Goodwill 4,366.3 4,021.7 Intangible assets, net 3,393.2 3,314.3 Other assets \$10,90.2 \$10,90.2 Total assets \$10,90.2 \$450.3 Current installments of Stockholders' Equity \$394.8 \$450.3 Current installments of long-term debt and revolving credit facilities 81.4 54.7 Accrued salaries, wages and employee benefits 78.0 78.1 Accrued income taxes payable 100.6 65.1 Accrued expenses and other current liabilities 409.4 414.2 Accrued expenses and other current liabilities 1,568.2 1,062.4 Total current liabilities 1,568.2 1,062.4 Long-term debt and capital lease obligations 5,196.9 5,173.6 Long-term debt and capital lease obligations 75.0 70.7 Long-term deferred income taxes 696.7 678.8 Long-t		564.3	
Total current assets 2,600.6 2,270.5 Property, plant and equipment, net 472.7 491.6 Goodwill 4,366.3 4,021.9 Intangible assets, net 3,393.2 3,314.3 Other assets 93.9 91.9 Total assets \$10,926.7 \$10,190.2 Liabilities and Stockholders' Equity \$394.8 \$450.3 Current installments of long-term debt and revolving credit facilities 81.4 54.7 Accrued salaries, wages and employee benefits 81.4 54.7 Accrued income taxes payable 65.1 65.1 Preferred stock redemption liability 504.0 — Accrued income taxes payable 409.4 414.2 Preferred stock redemption liabilities 1,568.2 1,062.4 Accrued expenses and other current liabilities 1,568.2 1,062.4 Long-term debt and capital lease obligations 5,196.9 5,173.6 Long-term deferred income taxes 696.7 75.8 80.5 Long-term deferred income taxes 253.8 205.0 70.7 Other			
Property, plant and equipment, net 472.7 491.6 Goodwill 4,366.3 4,21.9 Intangible assets, net 3,393.2 3,313.2 Other assets \$10,926.7 \$10,190.2 Total assets \$10,926.7 \$10,190.2 Liabilities and Stockholders' Equity \$394.8 \$450.3 Accounts payable \$394.8 \$450.3 Current installments of long-term debt and revolving credit facilities 81.4 54.7 Accrued salaries, wages and employee benefits 78.0 78.1 Accrued income taxes payable 100.6 65.1 Accrued expenses and other current liabilities 409.4 414.2 Accrued expenses and other current liabilities 1,568.2 1,062.4 Long-term debt and capital lease obligations 5,196.9 5,173.6 Long-term deferred income taxes 696.7 678.8 Long-term deferred income taxes 696.7 678.8 Long-term deferred income taxes 696.7 75.0 Other long-term liabilities 75.0 70.7 Other long-term liabilities 2			
Goodwill 4,366.3 4,021.9 Intangible assets, net 3,393.2 3,314.3 Other assets 93.9 91.9 Total assets \$10,926.7 \$10,100.2 Liabilities and Stockholders' Equity \$394.8 \$450.3 Current installments of long-term debt and revolving credit facilities 81.4 54.7 Accrued salaries, wages and employee benefits 78.0 78.1 Accrued income taxes payable 100.6 65.1 Accrued income taxes payable 100.6 65.1 Accrued income taxes payable 409.4 414.2 Accrued income taxes payable 409.4 414.2 Accrued expenses and other current liabilities 409.4 414.2 Total current liabilities 1,568.2 1,062.4 Long-term debt and capital lease obligations 5,196.9 5,173.6 Long-term deferred income taxes 696.7 678.8 Long-term deferred income taxes 696.7 70.7 Other long-term liabilities 253.8 205.0 Total liabilities 253.8 205.0		•	
Intangible assets, net 3,393.2 3,314.3 Other assets 93.9 91.9 Total assets \$10,926.7 \$10,109.2 Labilities and Stockholders' Equity \$394.8 \$450.3 Accounts payable \$1.4 54.7 Current installments of long-term debt and revolving credit facilities 81.4 54.7 Accrued salaries, wages and employee benefits 78.0 78.1 Accrued income taxes payable 100.6 65.1 Preferred stock redemption liability 504.0 — Accrued expenses and other current liabilities 409.4 414.2 Total current liabilities 1,568.2 1,062.4 Long-term debt and capital lease obligations 5,196.9 5,173.6 Long-term deferred income taxes 696.7 678.8 Long-term deferred income taxes 696.7 70.7 Other long-term liabilities 253.8 205.0 Total liabilities 7,866.4 7,271.0 Commitments and contingencies (Note 15) 2 645.9 Redeemable preferred stock - Series B 2			
Other assets 93.9 91.9 Total assets \$10,926.7 \$10,190.2 Liabilities and Stockholders' Equity \$394.8 \$450.3 Accounts payable \$394.8 \$450.3 Current installments of long-term debt and revolving credit facilities \$1.4 54.7 Accrued salaries, wages and employee benefits 78.0 78.1 Accrued income taxes payable 100.6 65.1 Preferred stock redemption liability 504.0 — Accrued expenses and other current liabilities 409.4 414.2 Total current liabilities 1,568.2 1,062.4 Long-term debt and capital lease obligations 5,196.9 5,173.6 Long-term deferred income taxes 696.7 678.8 Long-term deferred income taxes 696.7 678.8 Long-term contingent consideration 75.0 70.7 Other long-term liabilities 75.0 70.7 Commitments and contingencies (Note 15) 8.5 4.5 Redeemable preferred stock - Series B — 645.9 Stockholders' Equity 2.8		•	
Total assets \$10,926.7 \$10,190.2 Liabilities and Stockholders' Equity \$394.8 \$450.3 Current installments of long-term debt and revolving credit facilities 81.4 54.7 Accrued salaries, wages and employee benefits 78.0 78.1 Accrued income taxes payable 100.6 65.1 Preferred stock redemption liability 504.0 — Accrued expenses and other current liabilities 409.4 414.2 Total current liabilities 1,568.2 1,062.4 Long-term debt and capital lease obligations 5,196.9 5,173.6 Long-term deferred income taxes 696.7 75.8 80.5 Long-term contingent consideration 75.0 70.7 Other long-term liabilities 253.8 205.0 Total liabilities 7,866.4 7,271.0 Commitments and contingencies (Note 15) 8 253.8 205.0 Total liabilities 2 2,8 2.3 Commitments and contingencies (Note 15) 8 2 2.3 Redeemable preferred stock - Series B 2			
Liabilities and Stockholders' Equity \$394.8 \$450.3 Accounts payable \$394.8 \$450.3 Current installments of long-term debt and revolving credit facilities 81.4 54.7 Accrued salaries, wages and employee benefits 78.0 78.1 Accrued income taxes payable 100.6 65.1 Preferred stock redemption liability 504.0 — Accrued expenses and other current liabilities 409.4 414.2 Total current liabilities 1,568.2 1,062.4 Long-term debt and capital lease obligations 5,196.9 5,173.6 Long-term teitrement benefits, less current portion 75.8 80.5 Long-term deferred income taxes 696.7 678.8 Long-term contingent consideration 75.0 70.7 Other long-term liabilities 253.8 205.0 Total liabilities - 645.9 Redeemable preferred stock - Series B - 645.9 Redeemable preferred stock - Series B - - Common stock 400,000,000 shares authorized, 278,420,786 and 229,464,157 shares issued and outstanding at September 30, 2016 and Dece			
Accounts payable \$394.8 \$450.3 Current installments of long-term debt and revolving credit facilities 81.4 54.7 Accrued salaries, wages and employee benefits 78.0 78.1 Accrued income taxes payable 100.6 65.1 Preferred stock redemption liability 504.0 — Accrued expenses and other current liabilities 409.4 414.2 Total current liabilities 1,568.2 1,062.4 Long-term debt and capital lease obligations 5,196.9 5,173.6 Long-term retirement benefits, less current portion 75.8 80.5 Long-term deferred income taxes 696.7 678.8 Long-term contingent consideration 75.0 70.7 Other long-term liabilities 253.8 205.0 Total liabilities 7,866.4 7,271.0 Commitments and contingencies (Note 15) — 645.9 Redeemable preferred stock - Series B — 645.9 Stockholders' Equity — - - Preferred stock - Series A — - - Commo		\$10,926.7	\$10,190.2
Current installments of long-term debt and revolving credit facilities 81.4 54.7 Accrued salaries, wages and employee benefits 78.0 78.1 Accrued income taxes payable 100.6 65.1 Preferred stock redemption liability 504.0 — Accrued expenses and other current liabilities 409.4 414.2 Total current liabilities 1,568.2 1,062.4 Long-term debt and capital lease obligations 5,196.9 5,173.6 Long-term deferred income taxes 696.7 678.8 Long-term deferred income taxes 696.7 70.7 Long-term contingent consideration 75.0 70.7 Other long-term liabilities 253.8 205.0 Total liabilities 7,866.4 7,271.0 Commitments and contingencies (Note 15) Redeemable preferred stock - Series B — 645.9 Stockholders' Equity — — — Preferred stock - Series A — — — Common stock 400,000,000 shares authorized, 278,420,786 and 229,464,157 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively 3,921.1 </td <td>* *</td> <td></td> <td></td>	* *		
Accrued salaries, wages and employee benefits 78.0 78.1 Accrued income taxes payable 100.6 65.1 Preferred stock redemption liability 504.0 — Accrued expenses and other current liabilities 409.4 414.2 Total current liabilities 1,568.2 1,062.4 Long-term debt and capital lease obligations 5,196.9 5,173.6 Long-term ettirement benefits, less current portion 75.8 80.5 Long-term contingent consideration 75.0 70.7 Other long-term liabilities 75.0 70.7 Total liabilities 7,866.4 7,271.0 Commitments and contingencies (Note 15) — 645.9 Redeemable preferred stock - Series B — 645.9 Stockholders' Equity — - - Preferred stock - Series A — - - Common stock 400,000,000 shares authorized, 278,420,786 and 229,464,157 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively 3,921.1 3,520.4 Accumulated deficit (571.6) (532.7) Ac	- ·		
Accrued income taxes payable 100.6 65.1 Preferred stock redemption liability 504.0 — Accrued expenses and other current liabilities 409.4 414.2 Total current liabilities 1,568.2 1,062.4 Long-term debt and capital lease obligations 5,196.9 5,173.6 Long-term tetirement benefits, less current portion 75.8 80.5 Long-term deferred income taxes 696.7 678.8 Long-term contingent consideration 75.0 70.7 Other long-term liabilities 253.8 205.0 Total liabilities 7,866.4 7,271.0 Commitments and contingencies (Note 15) — 645.9 Redeemable preferred stock - Series B — 645.9 Stockholders' Equity — — Preferred stock - Series A — — Common stock 400,000,000 shares authorized, 278,420,786 and 229,464,157 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively 3,921.1 3,921.1 Accumulated deficit (571.6) (532.7) Accumulated other comprehensive loss	The state of the s		
Preferred stock redemption liability 504.0 — Accrued expenses and other current liabilities 409.4 414.2 Total current liabilities 1,568.2 1,062.4 Long-term debt and capital lease obligations 5,196.9 5,173.6 Long-term retirement benefits, less current portion 75.8 80.5 Long-term deferred income taxes 696.7 678.8 Long-term contingent consideration 75.0 70.7 Other long-term liabilities 253.8 205.0 Total liabilities 7,866.4 7,271.0 Commitments and contingencies (Note 15) — 645.9 Redeemable preferred stock - Series B — 645.9 Stockholders' Equity — 645.9 Preferred stock - Series A — — Common stock 400,000,000 shares authorized, 278,420,786 and 229,464,157 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively 3,921.1 3,520.4 Accumulated deficit (571.6) (532.7) Accumulated other comprehensive loss (464.1) (886.1) Total stockhol			
Accrued expenses and other current liabilities 409.4 414.2 Total current liabilities 1,568.2 1,062.4 Long-term debt and capital lease obligations 5,196.9 5,173.6 Long-term retirement benefits, less current portion 75.8 80.5 Long-term deferred income taxes 696.7 678.8 Long-term contingent consideration 75.0 70.7 Other long-term liabilities 253.8 205.0 Total liabilities 7,866.4 7,271.0 Commitments and contingencies (Note 15) - 645.9 Redeemable preferred stock - Series B - 645.9 Stockholders' Equity - - Preferred stock - Series A - - Common stock 400,000,000 shares authorized, 278,420,786 and 229,464,157 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively 3,921.1 3,520.4 Accumulated deficit (571.6) (532.7) Accumulated other comprehensive loss (464.1) (886.1) Total stockholders' equity 2,888.2 2,103.9 Non-controlling inte	* *		65.1
Total current liabilities 1,568.2 1,062.4 Long-term debt and capital lease obligations 5,196.9 5,173.6 Long-term retirement benefits, less current portion 75.8 80.5 Long-term deferred income taxes 696.7 678.8 Long-term contingent consideration 75.0 70.7 Other long-term liabilities 253.8 205.0 Total liabilities 7,866.4 7,271.0 Commitments and contingencies (Note 15) — 645.9 Redeemable preferred stock - Series B — 645.9 Stockholders' Equity — — Preferred stock - Series A — — Common stock 400,000,000 shares authorized, 278,420,786 and 229,464,157 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively 3,921.1 3,520.4 Accumulated deficit (571.6) (532.7) Accumulated other comprehensive loss (464.1) (886.1) Total stockholders' equity 2,888.2 2,103.9 Non-controlling interests 172.1 169.4 Total equity 3,060.3 <td>Preferred stock redemption liability</td> <td></td> <td>_</td>	Preferred stock redemption liability		_
Long-term debt and capital lease obligations 5,196.9 5,173.6 Long-term retirement benefits, less current portion 75.8 80.5 Long-term deferred income taxes 696.7 678.8 Long-term contingent consideration 75.0 70.7 Other long-term liabilities 253.8 205.0 Total liabilities 7,866.4 7,271.0 Commitments and contingencies (Note 15) — 645.9 Redeemable preferred stock - Series B — 645.9 Stockholders' Equity — - - Preferred stock - Series A — - - Common stock 400,000,000 shares authorized, 278,420,786 and 229,464,157 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively 3,921.1 3,520.4 Accumulated deficit (571.6) (532.7) Accumulated other comprehensive loss (464.1) (886.1) Total stockholders' equity 2,888.2 2,103.9 Non-controlling interests 172.1 169.4 Total equity 3,060.3 2,273.3	*	409.4	414.2
Long-term retirement benefits, less current portion 75.8 80.5 Long-term deferred income taxes 696.7 678.8 Long-term contingent consideration 75.0 70.7 Other long-term liabilities 253.8 205.0 Total liabilities 7,866.4 7,271.0 Commitments and contingencies (Note 15) — 645.9 Redeemable preferred stock - Series B — 645.9 Stockholders' Equity — — Preferred stock - Series A — — Common stock 400,000,000 shares authorized, 278,420,786 and 229,464,157 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively 3,921.1 3,520.4 Accumulated deficit (571.6) (532.7) Accumulated other comprehensive loss (464.1) (886.1) Total stockholders' equity 2,888.2 2,103.9 Non-controlling interests 172.1 169.4 Total equity 3,060.3 2,273.3	Total current liabilities	1,568.2	1,062.4
Long-term deferred income taxes 696.7 678.8 Long-term contingent consideration 75.0 70.7 Other long-term liabilities 253.8 205.0 Total liabilities 7,866.4 7,271.0 Commitments and contingencies (Note 15) — 645.9 Redeemable preferred stock - Series B — — - Stockholders' Equity — — — Preferred stock - Series A — — — Common stock 400,000,000 shares authorized, 278,420,786 and 229,464,157 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively 3,921.1 3,520.4 Accumulated deficit (571.6) (532.7) Accumulated other comprehensive loss (464.1) (886.1) Total stockholders' equity 2,888.2 2,103.9 Non-controlling interests 172.1 169.4 Total equity 3,060.3 2,273.3	Long-term debt and capital lease obligations	5,196.9	5,173.6
Long-term contingent consideration 75.0 70.7 Other long-term liabilities 253.8 205.0 Total liabilities 7,866.4 7,271.0 Commitments and contingencies (Note 15) — 645.9 Redeemable preferred stock - Series B — — Stockholders' Equity — — Preferred stock - Series A — — Common stock 400,000,000 shares authorized, 278,420,786 and 229,464,157 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively 2.8 2.3 Additional paid-in capital 3,921.1 3,520.4 — Accumulated deficit (571.6) (532.7) Accumulated other comprehensive loss (464.1) (886.1) Total stockholders' equity 2,888.2 2,103.9 Non-controlling interests 172.1 169.4 Total equity 3,060.3 2,273.3	Long-term retirement benefits, less current portion	75.8	80.5
Other long-term liabilities 253.8 205.0 Total liabilities 7,866.4 7,271.0 Commitments and contingencies (Note 15) — 645.9 Redeemable preferred stock - Series B — 645.9 Stockholders' Equity — — Preferred stock - Series A — — Common stock 400,000,000 shares authorized, 278,420,786 and 229,464,157 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively 2.8 2.3 Additional paid-in capital 3,921.1 3,520.4 Accumulated deficit (571.6) (532.7) Accumulated other comprehensive loss (464.1) (886.1) Total stockholders' equity 2,888.2 2,103.9 Non-controlling interests 172.1 169.4 Total equity 3,060.3 2,273.3	Long-term deferred income taxes	696.7	678.8
Total liabilities 7,866.4 7,271.0 Commitments and contingencies (Note 15) — 645.9 Redeemable preferred stock - Series B — 645.9 Stockholders' Equity — — Preferred stock - Series A — — Common stock 400,000,000 shares authorized, 278,420,786 and 229,464,157 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively 3,921.1 3,520.4 Accumulated deficit (571.6) (532.7) Accumulated other comprehensive loss (464.1) (886.1) Total stockholders' equity 2,888.2 2,103.9 Non-controlling interests 172.1 169.4 Total equity 3,060.3 2,273.3	Long-term contingent consideration	75.0	70.7
Commitments and contingencies (Note 15) — 645.9 Redeemable preferred stock - Series B — 645.9 Stockholders' Equity — — Preferred stock - Series A — — Common stock 400,000,000 shares authorized, 278,420,786 and 229,464,157 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively 2.8 2.3 Additional paid-in capital 3,921.1 3,520.4 Accumulated deficit (571.6) (532.7) Accumulated other comprehensive loss (464.1) (886.1) Total stockholders' equity 2,888.2 2,103.9 Non-controlling interests 172.1 169.4 Total equity 3,060.3 2,273.3	Other long-term liabilities	253.8	205.0
Redeemable preferred stock - Series B — 645.9 Stockholders' Equity — — Preferred stock - Series A — — Common stock 400,000,000 shares authorized, 278,420,786 and 229,464,157 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively 2.8 2.3 Additional paid-in capital 3,921.1 3,520.4 Accumulated deficit (571.6) (532.7) Accumulated other comprehensive loss (464.1) (886.1) Total stockholders' equity 2,888.2 2,103.9 Non-controlling interests 172.1 169.4 Total equity 3,060.3 2,273.3	Total liabilities	7,866.4	7,271.0
Stockholders' Equity Preferred stock - Series A — — — Common stock 400,000,000 shares authorized, 278,420,786 and 229,464,157 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively 2.8 2.3 Additional paid-in capital 3,921.1 3,520.4 Accumulated deficit (571.6) (532.7) Accumulated other comprehensive loss (464.1) (886.1) Total stockholders' equity 2,888.2 2,103.9 Non-controlling interests 172.1 169.4 Total equity 3,060.3 2,273.3	Commitments and contingencies (Note 15)		
Preferred stock - Series A — — — Common stock 400,000,000 shares authorized, 278,420,786 and 229,464,157 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively 2.8 2.3 Additional paid-in capital 3,921.1 3,520.4 Accumulated deficit (571.6) (532.7) Accumulated other comprehensive loss (464.1) (886.1) Total stockholders' equity 2,888.2 2,103.9 Non-controlling interests 172.1 169.4 Total equity 3,060.3 2,273.3	Redeemable preferred stock - Series B		645.9
Common stock 400,000,000 shares authorized, 278,420,786 and 229,464,157 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively Additional paid-in capital 3,921.1 3,520.4 Accumulated deficit (571.6) (532.7) Accumulated other comprehensive loss (464.1) (886.1) Total stockholders' equity 2,888.2 2,103.9 Non-controlling interests 172.1 169.4 Total equity 3,060.3 2,273.3	Stockholders' Equity		
and outstanding at September 30, 2016 and December 31, 2015, respectively Additional paid-in capital 3,921.1 3,520.4 Accumulated deficit (571.6) (532.7) Accumulated other comprehensive loss (464.1) (886.1) Total stockholders' equity 2,888.2 2,103.9 Non-controlling interests 172.1 169.4 Total equity 3,060.3 2,273.3	Preferred stock - Series A		
Additional paid-in capital 3,921.1 3,520.4 Accumulated deficit (571.6) (532.7) Accumulated other comprehensive loss (464.1) (886.1) Total stockholders' equity 2,888.2 2,103.9 Non-controlling interests 172.1 169.4 Total equity 3,060.3 2,273.3	Common stock 400,000,000 shares authorized, 278,420,786 and 229,464,157 shares issued	2.0	2.2
Accumulated deficit (571.6) (532.7) Accumulated other comprehensive loss (464.1) (886.1) Total stockholders' equity 2,888.2 2,103.9 Non-controlling interests 172.1 169.4 Total equity 3,060.3 2,273.3	and outstanding at September 30, 2016 and December 31, 2015, respectively	2.8	2.3
Accumulated other comprehensive loss (464.1) (886.1) Total stockholders' equity 2,888.2 2,103.9 Non-controlling interests 172.1 169.4 Total equity 3,060.3 2,273.3	Additional paid-in capital	3,921.1	3,520.4
Total stockholders' equity 2,888.2 2,103.9 Non-controlling interests 172.1 169.4 Total equity 3,060.3 2,273.3	Accumulated deficit	(571.6)	(532.7)
Non-controlling interests 172.1 169.4 Total equity 3,060.3 2,273.3	Accumulated other comprehensive loss	(464.1)	(886.1)
Non-controlling interests 172.1 169.4 Total equity 3,060.3 2,273.3	Total stockholders' equity	2,888.2	2,103.9
Total equity 3,060.3 2,273.3	_ · ·		
• •	-	3,060.3	2,273.3
-	Total liabilities, redeemable preferred shares and stockholders' equity	\$10,926.7	\$10,190.2

See accompanying notes to condensed consolidated financial statements

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited) (In millions)

	Nine Mo	
	Ended Se	eptember
	30,	2017
	2016	2015
		(as
		restated)
Cash flows from operating activities:	*	*=
Net loss	\$(76.6)	\$(174.9)
Reconciliation of net loss to net cash flows (used in) provided by operating activities:		
Depreciation and amortization	254.9	176.3
Deferred income taxes		(52.3)
Manufacturer's profit in inventory adjustment	11.7	58.0
Foreign exchange loss	47.8	57.5
Other, net	(53.9)	26.4
Changes in assets & liabilities, net of acquisitions:		
Accounts receivable		(68.5)
Inventories		(63.2)
Accounts payable and accrued expenses	,	195.6
Other changes in assets and liabilities, net	2.7	(23.8)
Net cash flows (used in) provided by operating activities	(24.0)	131.1
Cash flows from investing activities:		
Change in restricted cash		599.7
Capital expenditures	(32.8)	(32.1)
Investment in registrations of products	(22.4)	(26.2)
Proceeds from disposal of property, plant and equipment	12.5	12.1
Acquisition of businesses, net of acquired cash	1.3	(2,857.9)
Other, net	4.4	(1.4)
Net cash flows used in investing activities	(37.5)	(2,305.8)
Cash flows from financing activities:		
Debt proceeds, net of discount and premium	_	2,085.6
Change in revolving credit facilities, net	18.9	4.7
Repayments of borrowings		(15.5)
Proceeds from issuance of common stock, net	391.5	469.5
Payment of debt financing fees	(0.7)	(45.5)
Change in factored liabilities	(45.5)	(16.8)
Other, net	(0.8)	(1.0)
Net cash flows provided by financing activities	337.4	2,481.0
Effect of exchange rate changes on cash and cash equivalents	6.0	(21.6)
Net increase in cash and cash equivalents	281.9	284.7
Cash and cash equivalents at beginning of period	432.2	397.3
Cash and cash equivalents at end of period	\$714.1	\$682.0
Non-cash Investing Activities		
Settlement of Note Receivable in exchange for OMG Malaysia	\$125.0	\$
OMG Malaysia Acquisition through the settlement of Note Receivable	\$(125.0)	\$ —

See accompanying notes to condensed consolidated financial statements

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)

(In millions, except share and per share amounts)

Preferred Stock Common Stock

	Stock									
Dolongo et	Shares	An	n Silnat res	Amou	Additional u R aid-in Capital	Accumul Deficit	Accumulat Other ated Comprehe (Loss) Income	ed Total n Sitvæ kholde Equity	Non- ersontrollin Interests	Total ng Equity
Balance at December 31, 2015	2,000,000	\$ -	-2 29,464,157	\$ 2.3	\$3,520.4	\$ (532.7)) \$ (886.1)	\$2,103.9	\$169.4	\$2,273.3
Net (loss) income Other	-	_		_	_	(134.8) —	(134.8)	0.4	(134.4)
comprehensive income, net of taxes	_	_	_	_	_	_	298.4	298.4	11.7	310.1
Issuance of common stock to former non-founder director for exercise of stock options	_	_	7,642	_	_	_	_	_	_	_
Conversion of PDH Common Stock into common stock	_		16,499	_	0.2	_	_	0.2	(0.2)	_
Issuance of common stock under ESPP	_	_	35,399	_	0.2	_	_	0.2	_	0.2
Equity compensation	_	_	_	_	0.9	_	_	0.9	_	0.9
expense Balance at March 31, 2016	2,000,000	_	229,523,697	2.3	3,521.7	(667.5) (587.7)	2,268.8	181.3	2,450.1
Net (loss) income Other	-		_	_	_	(8.8) —	(8.8)	0.7	(8.1)
comprehensive income, net of taxes	_		_		_	_	114.0	114.0	10.0	124.0
Conversion of PDH Common Stock into common stock Issuance of	_	_	37,445	_	0.4	_	_	0.4	(0.4)	_
common stock under ESPP	_	_	36,104	_	0.2	_	_	0.2	_	0.2

Edgar Filing: Platform Specialty Products Corp - Form 10-Q

Equity compensation - expense	_		_	_	1.9	_	_	1.9	_	1.9	
Changes in non-controlling - interests	_	_	_	_	_	_	_	_	(0.2)	(0.2)
Balance at June 30, 2016	2,000,000		229,597,246	2.3	3,524.2	(676.3)	(473.7)	2,376.5	191.4	2,567.9	
Net income (loss)-				_		71.8	_	71.8	(5.9)	65.9	
Other											
comprehensive		_	_		_	_	9.6	9.6	(9.0)	0.6	
income, net of									()		
taxes Issuance of											
common stock at											
\$8.25 per share in			40.505.050	^ -	4000			100 7		400 7	
the September		_	48,787,878	0.5	402.0	_	_	402.5		402.5	
2016 Equity											
Offering											
Issuance costs in											
connection with					(11.6)			(11.6)		(11.6	`
the September - 2016 Equity	_	_	_	_	(11.6)	_	_	(11.0)	_	(11.6)
Offering											
Conversion of											
PDH Common			10,000		0.1			0.1	(0.1)		
Stock into	_		10,000		0.1	_	_	0.1	(0.1)	_	
common stock											
Issuance of			25.662		0.2			0.2		0.2	
common stock - under ESPP	_		25,662		0.2	_		0.2	_	0.2	
Equity											
compensation -			_		2.5	_	_	2.5		2.5	
expense											
Gain on											
amendment of											
Series B -		—				32.9		32.9		32.9	
Convertible											
Preferred Stock											
Changes in non-controlling			_		3.7	_		3.7	(4.3)	(0.6)
interests					5.1			J.,	(1.5)	(0.0)	,
Balance at											
September 30,	2,000,000	\$ -	2 78,420,786	\$ 2.8	\$3,921.1	\$(571.6)	\$ (464.1)	\$2,888.2	\$172.1	\$3,060.3	,
2016											

See accompanying notes to condensed consolidated financial statements

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (continued) (Unaudited)

(In millions, except share and per share amounts)

(III IIIIII oiio, exec	Preferred Stock	Stock Common Stock					Accumulated Other Total N				
	Shares	An	n Silnat res	Amou	Additional n P aid-in Capital	Accumu Deficit	lat € domp Loss	rehe	Total nsive Stockhold Equity	Non- ersontrol Interest	Total ling Equity s
Balance at December 31, 2014	2,000,000	\$ -	-182,066,980	\$ 1.9	\$2,812.4	\$(224.1) \$(130	.6)	\$2,459.6	\$93.0	\$2,552.6
Net (loss) income Other	e—		_		_	(26.7) —		(26.7	0.4	(26.3)
comprehensive loss, net of taxes (as restated) Issuance of	_	_	_		_	_	(344.4	.)	(344.4) (8.7) (353.1)
common stock to Founder Entities as stock dividend on Series A Preferred Stock declared on 12/31/14		_	10,050,290	_	_	_	_		_	_	_
Issuance of common stock to former non-founder director for exercise of stock options	_	_	75,000	_	0.9	_	_		0.9	_	0.9
Conversion of PDH Common Stock into common stock	_	_	21,316	_	0.2	_			0.2	(0.2) —
Issuance of common stock under ESPP	_		7,986	_	0.1	_	_		0.1	_	0.1
Equity compensation expense	_		_		0.7	_			0.7	_	0.7
Acquisition of non-controlling interest with Arysta Acquisition	_		_	_	_	_	_		_	24.6	24.6
Balance at March 31, 2015 (as restated)		_	192,221,572	1.9	2,814.3	(250.8) (475.0)	2,090.4	109.1	2,199.5

Net (loss) income Other	? —	_	_	_	_	(12.2) —	(12.2	3.1	(9.1)
comprehensive income, net of	_		_		_	_	87.4	87.4	1.6	89.0	
Issuance of common stock at \$26.50 per share in the June 2015 Equity Offering			18,226,414	0.2	482.8	_	_	483.0	_	483.0	
Issuance costs in connection with the June 2015 Equity Offering	_		_	_	(14.8)	_	_	(14.8) —	(14.8)
Conversion of PDH Common Stock into common stock	_	_	406,217	_	4.7	_	_	4.7	(4.7) —	
Issuance of common stock under ESPP	_	_	6,841	_	0.3	_	_	0.3	_	0.3	
Equity compensation expense	_	_	_		0.6		_	0.6		0.6	
Balance at June 30, 2015		_	210,861,044	2.1	3,287.9	(263.0) (387.6) 2,639.4	109.1	2,748.5	
Net (loss) income (as restated)		_	_	_	_	(140.1) —	(140.1	0.5	(139.6)
Other comprehensive loss, net of taxes	_	_	_		_	_	(353.8) (353.8) (7.2) (361.0)
Issuance of common shares to non-employee Conversion of	_		2,500	_	_	_	_	_	_	_	
PDH Common Stock into	_		6,343	_	_	_	_	_	_	_	
common stock Issuance of common stock under ESPP Purchase	_	_	9,710	_	0.1	_	_	0.1	_	0.1	
accounting adjustment to non-controlling interest for Arysta	_	_	_	_	_	_	_	_	6.4	6.4	
Acquisition Acquisition of remaining interest in Arysta	_		_	_	_	_	_	_	(3.3) (3.3)

Colombia Equity compensation (0.7)(0.7)(0.7))) —) expense Balance at 2,000,000 \$ -210,879,597 \$ 2.1 \$ 3,287.3 \$ (403.1) \$ (741.4) \$ 2,144.9 \$ 105.5 \$ 2,250.4 September 30, 2015 (as restated) See accompanying notes to condensed consolidated financial statements 6

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)

1. BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

Description of the Company and Business

Platform Specialty Products Corporation is a global, diversified producer of high-technology specialty chemical products and provider of technical services. The Company's business involves the formulation of a broad range of solutions-oriented specialty chemicals which are sold into multiple industries, including agricultural, animal health, electronics, graphic arts, plating, offshore oil and gas production and drilling. The Company refers to its products as "dynamic chemistries" due to their intricate chemical compositions which are used in a wide variety of niche markets. As further described in Note 19, Segment Information, the Company operates in two segments: Performance Solutions and Agricultural Solutions.

Until the MacDermid Acquisition on October 31, 2013, the Company had neither engaged in any operations nor generated any income. Following the MacDermid Acquisition, on January 22, 2014, the Company was domesticated in Delaware and on January 23, 2014, its common stock, par value \$0.01 per share, began trading on the NYSE under the ticker symbol "PAH."

Basis of Presentation

These unaudited interim Condensed Consolidated Financial Statements and related information have been prepared in accordance with GAAP for interim financial information and in accordance with the applicable rules and regulations of the SEC. Accordingly, they do not include all of the disclosures required in connection with annual financial statements. These unaudited interim Condensed Consolidated Financial Statements reflect all adjustments that are, in the opinion of management, normal, recurring and necessary for a fair statement of the Company's results of operations. These unaudited interim Condensed Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and the related notes thereto included in the Company's Annual Report. The year-end Condensed Consolidated Balance Sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP.

Principles of Consolidation

The accompanying unaudited interim Condensed Consolidated Financial Statements include Platform's accounts and all of its controlled subsidiaries. All subsidiaries are included in the unaudited interim Condensed Consolidated Financial Statements for the entire period or, if acquired, from the date on which the Company obtains control. The Company fully consolidates the income, expenses, assets, liabilities and cash flows of subsidiaries from the date it acquires control or becomes the primary beneficiary up to the date control ceases. All intercompany accounts and transactions have been eliminated in consolidation.

Recently Adopted Accounting Pronouncements

Compensation - Stock Compensation (Topic 718) - In March 2016, the FASB issued ASU No. 2016-09, "Improvements to Employee Share-Based Payment Accounting." This update changes the accounting treatment related to tax windfall and shortfalls associated with share-based awards. It also eliminates the requirement for entities to estimate future forfeiture rates associated with share-based awards and stipulates the requirement that cash payments made by employers when directly withholding shares for tax-withholdings purposes should be classified as a financing activity in the statement of cash flows. The guidance is effective for fiscal years and interim periods beginning after December 15, 2016 with early adoption permitted. The Company adopted this ASU as of April 1, 2016. This ASU did not have a material impact on the Company's financial statements.

Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40) - In April 2015, the FASB issued ASU No. 2015-05, "Customer's Accounting for Fees Paid in a Cloud Computing Arrangement." This update provides explicit guidance to customers utilizing a cloud computing solution to help determine whether such an arrangement includes a software license, in which case the accounting applied would be similar to that of other software license arrangements. Otherwise, the arrangement would be accounted for as a service contract. The Company adopted this ASU as of January 1, 2016. This ASU did not have a material impact on the Company's financial statements.

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)

Income Statement – Extraordinary and Unusual Items (Subtopic 225-20) - In January 2015, the FASB issued ASU No. 2015-1, "Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items." This update eliminates the requirement for entities to identify extraordinary events and transactions, those being both unusual in nature and infrequent in occurrence, and separately classify, present and disclose such items. The guidance is effective prospectively for fiscal years and interim periods beginning after December 15, 2015. The Company adopted this ASU as of January 1, 2016. The Company did not have any extraordinary or unusual income statement items recorded for any periods presented and therefore, this ASU did not have a material impact on the Company's financial statements.

Compensation – Stock Compensation (Topic 718) - In June 2014, the FASB issued ASU No. 2014-12, "Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period (a consensus of the FASB Emerging Issues Task Force)." Under the provisions of this update, a performance target that affects vesting and that could be achieved after the requisite service period are treated as a performance condition. The guidance is effective prospectively for fiscal years and interim periods beginning after December 15, 2015. The Company adopted this ASU as of January 1, 2016. This ASU did not have a material impact on the Company's financial statements as it had no share-based compensation awards that were effected by this pronouncement.

Recently Issued Accounting Pronouncements Not Yet Adopted

Consolidation (Topic 810) - In October 2016, the FASB issued ASU No. 2016-17, "Interests Held through Related Parties that are Under Common Control." This update clarifies how a reporting entity that is the single decision maker of a variable interest entity (VIE) should treat indirect interests in the entity held through related parties that are under common control with the reporting entity when determining whether it is the primary beneficiary of that VIE. The guidance is effective for fiscal years and interim periods beginning after December 15, 2016, with early adoption permitted. The Company is evaluating the impact of this ASU.

Income Taxes (Topic 740) - In October 2016, the FASB issued ASU No. 2016-16, "Intra-Entity Transfers of Assets Other than Inventory." This update stipulates that entities recognize the income tax consequences of intra-entity transfers of assets other than inventory when the transfer occurs. The amendments in this guidance apply to assets other than inventory, for example, intellectual property and property, plant and equipment. The guidance is effective for fiscal years beginning after December 15, 2017 and interim periods within those fiscal years, with early adoption permitted in the first quarter of an annual reporting period for which financial statements have not been issued or made available for issuance. The Company is evaluating the impact of this ASU.

Statement of Cash Flows (Topic 230) - In August 2016, the FASB issued ASU No. 2016-15, "Classification of Certain Cash Receipts and Cash Payments." This update was issued to reduce the differences in the classification of certain transactions in the statement of cash flows. The update addresses eight specific cash flow issues, including debt prepayment and extinguishment costs, zero coupon bond settlement, contingent consideration payments, insurance claim settlements, company-owned life insurance receipts/payments, distributions from equity method investments, beneficial interests in securitization transactions, and separately identifiable cash flows. The guidance is effective for fiscal years beginning after December 15, 2017 and interim periods within those fiscal years, with early adoption permitted. The Company does not expect this ASU to have a material impact on its financial statements. Financial Instruments - Credit Losses (Topic 326) - In June 2016, the FASB issued ASU No. 2016-13, "Measurement of Credit Losses on Financial Instruments." This update introduces new guidance for the accounting for credit losses on certain types of financial instruments, which are to be estimated based on the expected losses. It also modifies the impairment model for available-for-sale debt securities and provides for a simplified accounting model for purchased financial assets with credit deterioration since their origination. The guidance is effective on a modified retrospective basis for fiscal years and interim periods beginning after December 15, 2018. The Company is evaluating the impact of this ASU.

Investments - Equity Method and Joint Ventures (Topic 323) - In March 2016, the FASB issued ASU No. 2016-07, "Simplifying the Transition to the Equity Method of Accounting." This update simplifies transition accounting when the ownership level or degree of influence held in an investment qualifies that investment for equity method accounting. The guidance is effective prospectively for fiscal years and interim periods beginning after December 15, 2016, with early adoption permitted. The Company does not expect this ASU to have a material impact on its financial statements.

Derivatives and Hedging (Topic 815) - In March 2016, the FASB issued ASU No. 2016-06, "Contingent Put and Call Options in Debt Instruments (a consensus of the FASB Emerging Issues Task Force)." The ASU clarifies guidance around determining whether

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)

call or put options that can accelerate the repayment of principal on a debt or hybrid instrument that are considered embedded derivatives meet the "clearly and closely related" criterion for determining whether the embedded derivative is required to be separated from the host contract and accounted for separately as a derivative. The guidance is effective for fiscal years and interim periods beginning after December 15, 2016 with early adoption permitted. Adoption is required on a modified retrospective basis. The Company does not expect this ASU to have a material impact on its financial statements.

Derivatives and Hedging (Topic 815) - In March 2016, the FASB issued ASU No. 2016-05, "Effect of Derivative Contract Novations on Existing Hedge Accounting Relationships (a consensus of the FASB Emerging Issues Task Force)." This update stipulates that a change in the counterparty of a derivative instrument that has been designated as a hedging instrument under Topic 815 does not, in and of itself, require de-designation of that hedging relationship, provided that all other hedge accounting criteria continue to be met. The guidance is effective for fiscal years and interim periods beginning after December 15, 2016 and provides entities with the option to apply either a prospective or a modified retrospective approach. The Company does not expect this ASU to have a material impact on its financial statements.

Leases (Topic 842) - In February 2016, the FASB issued ASU No. 2016-02, "Leases." The updated guidance applies to capital (or finance) and operating leases, and requires the lessee to recognize a lease liability for the obligation to make lease payments and a right-of-use asset for the right to use the underlying asset for the lease term. The lessee can make an accounting policy choice to not recognize right of use assets and lease liabilities for short-term leases (leases with a lease term of 12 months or less). The guidance is effective for fiscal years and interim periods beginning after December 15, 2018, with early adoption permitted. The Company continues to evaluate the impact of this ASU. Financial Instruments - Overall (Subtopic 825.10) - In January 2016, the FASB issued ASU No. 2016-1, "Recognition and Measurement of Financial Assets and Financial Liabilities." This update addresses certain aspects of recognition, measurement, presentation, and disclosure of financial assets and liabilities. Provisions of this ASU include, among others, requiring the measurement of certain equity investments at fair value, with changes in value recognized in net income, and simplifying the impairment assessment of certain equity investments. The guidance is effective for fiscal years and interim periods beginning after December 15, 2017. The guidance is effective on a modified retrospective basis, except as it relates to equity securities without a readily determinable fair value, for which it is effective on a prospective basis. Early adoption is only permitted for provisions related to the recognition of changes in fair value of financial liabilities. The Company does not expect this ASU to have a material impact on its financial statements. Revenue from Contracts with Customers (Topic 606) - In August 2015, the FASB issued ASU No. 2015-14, "Deferral of the Effective Date," which defers the effective date of ASU No. 2014-09, "Revenue from Contracts with Customers (Topic 606)," for all entities by one year. As a result, the provisions of ASU No. 2014-09 will be effective prospectively for fiscal years and interim periods beginning after December 15, 2017. ASU No. 2014-09 (1) removes inconsistencies and weaknesses in revenue requirements, (2) provides a more robust framework for addressing revenue issues, (3) improves comparability of revenue recognition practices across entities, industries, jurisdictions, and capital markets, (4) provides more useful information to users of financial statements through improved disclosure requirements, and (5) simplifies the preparation of financial statements by reducing the number of requirements to which an entity must refer. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The FASB has issued the following amendments and supplements to the guidance of ASU Nos. 2014-09 and 2015-14, all of which become effective for fiscal years and interim periods beginning after December 15, 2017:

ASU No. 2016-08, "Principal versus Agent Considerations," issued in March 2016. This update improves the operability and understandability of the implementation guidance on principal versus agent considerations.

ASU No. 2016-10, "Identifying Performance Obligations and Licensing," issued in April 2016. This update provides clarification on the implementation guidance defining when a good or service is separately identifiable from other promises in the contract and on contracts with licenses of intellectual property.

ASU No. 2016-12, "Narrow-Scope Improvements and Practical Expedients," issued in May 2016. This update provides clarification on the collectability criterion, presentation of taxes, non-cash consideration and contract modification guidance espoused in ASU No. 2014-09. This update also clarifies the accounting treatment for completed contracts and retrospective application of the standard to prior reporting periods.

The Company continues to evaluate the impact of ASU Nos. 2014-09, 2015-14 and their subsequent amendments.

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)

Presentation of Financial Statements - Going Concern (Subtopic 205-40) - In August 2014, the FASB issued ASU No. 2014-15, "Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern." This update provides clarification on conditions and events that should be considered by management at each annual and interim reporting period in determining whether there exists substantial doubt as to an entity's ability to continue as a going concern. The guidance is effective for fiscal years and interim periods ending after December 15, 2016 with early adoption permitted. The Company does not expect this ASU to have a material impact on its financial statements. Out of Period Adjustment

In connection with the preparation of the Company's unaudited interim Condensed Consolidated Financial Statements for the period ended September 30, 2016, the Company identified an error that effected prior periods related to the allocation of expenses to non-controlling interests. On a cumulative basis since the first quarter of 2015, the Company determined \$6.1 million of expenses were not allocated to its non-controlling interests resulting in an overstatement of "Non-controlling Interests" and "Accumulated Deficit" in the Company's Condensed Consolidated Balance Sheets and an understatement of "Net loss attributable to non-controlling interests" and overstatement of "Net loss attributable to stockholders" in the Company's Condensed Consolidated Statements of Operations. Based on an analysis of qualitative and quantitative factors, management has concluded that this error was not material to the Company's unaudited interim Condensed Consolidated Financial Statements for 2015 and 2016 as well as the Company's Annual Report for the year ended December 31, 2015. As a result, the effects of the adjustment were corrected in the unaudited interim Condensed Consolidated Financial Statements for the period ended September 30, 2016.

Restatement

As previously disclosed in the Company's Annual Report, the Company restated its unaudited Condensed Consolidated Statement of Operations for the three and nine months ended September 30, 2015 and its unaudited Condensed Consolidated Balance Sheet as of September 30, 2015 that were previously included in the Company's quarterly report on Form 10-Q for the quarter ended September 30, 2015 to correct an error as a result of improperly recording a benefit on an unrealized loss associated with a foreign currency hedge entered into in connection with the Alent Acquisition for income tax accounting purposes, which resulted in an understatement of income tax expense of \$17.8 million. As a result of the error, "Loss per share" was understated by \$0.08 for the three and nine month periods ended September 30, 2015. In addition, "Prepaid expenses and other current assets" were overstated by \$19.6 million, "Other assets" were understated by \$2.8 million, and "Accrued income taxes payable" was understated by \$1.0 million.

2. ACQUISITIONS OF BUSINESSES

OMG Malaysia Acquisition

On January 31, 2016, the Company completed the OMG Malaysia Acquisition for approximately \$124 million, net of acquired cash and closing working capital adjustments.

The Company acquired OMG Malaysia to further enhance its Performance Solutions segment. OMG Malaysia, which is highly-synergistic with the OMG Businesses, is included in the Company's Performance Solutions business segment.

Alent Acquisition

On December 1, 2015, Platform completed the Alent Acquisition by acquiring all of the issued shares of Alent for approximately \$1.74 billion in cash, net of acquired cash, and 18,419,738 shares of the Company's common stock at \$12.56 per share, issued to Alent shareholders, including Cevian Capital II Master Fund LP, the then largest shareholder of Alent.

The Company acquired Alent to expand its product capabilities and offerings and improve its geographic outreach in surface treatments. Alent is a global supplier of specialty chemicals and engineered materials used primarily in electronics, automotive, industrial applications, and high performance consumable products and services. Alent is included in the Company's Performance Solutions business segment.

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)

OMG Acquisition

On October 28, 2015, Platform completed the OMG Acquisition for approximately \$239 million in cash, net of acquired cash, and purchase price adjustments.

The Company acquired the highly-synergistic OMG Businesses to bolster its Performance Solutions business segment. OMG's Electronic Chemicals business develops, produces and supplies chemicals for electronic and industrial applications. OMG's Photomasks products are used by customers to produce semiconductors and related products. These businesses are included in the Company's Performance Solutions business segment. Arysta Acquisition

On February 13, 2015, Platform completed the Arysta Acquisition for approximately \$3.50 billion, consisting of \$2.86 billion in cash, net of acquired cash and closing working capital adjustments, and including Arysta Seller transaction expenses paid by Platform, and the issuance to the Arysta Seller of \$600 million of Platform's Series B Convertible Preferred Stock with a fair value of \$646 million. On September 9, 2016, the Company entered into a settlement agreement with the Arysta Seller with respect to certain of its obligations relating to the Company's shares of Series B Convertible Preferred Stock. See Note 11, Stockholders' Equity, under the heading "Series B Convertible Preferred Stock."

The Company acquired Arysta to expand its presence in the agrochemical business, complementing the Agriphar and CAS Acquisitions. Arysta provides products and solutions utilizing globally managed patented and proprietary off-patent agrochemical AIs and biological solutions, or biosolutions, and off-patent agrochemical offerings. Biosolutions includes stimulants, or biostimulants, innovative nutrition and biological control, or biocontrol, products. Arysta is included in the Company's Agricultural Solutions business segment.

Acquisition Net Sales and Net Income (Loss)

Since the dates of their respective acquisitions, net sales contributed by the OMG Malaysia, Alent, OMG and Arysta Acquisitions for the three and nine months ended September 30, 2016 and 2015 were as follows:

	Three N	I onths	Nine Months		
	Ended		Ended		
	Septem	ber 30,	September 30,		
(amounts in millions)	2016	2015	2016	2015	
OMG Malaysia	\$8.5	\$—	\$21.4	\$ —	
Alent	243.9	_	693.0	_	
OMG	27.8	_	80.9	_	
Arysta	363.7	318.2	1,013.4	837.6	
Total	\$643.9	\$318.2	\$1,808.7	\$837.6	

Net income (loss) generated by the OMG Malaysia, Alent, OMG and Arysta Acquisitions, excluding corporate allocations, for the three and nine months ended September 30, 2016 and 2015 was as follows:

	Three N	Months	Nine Months		
	Ended		Ended Se	ptember	
	Septem	ber 30,	30,		
(amounts in millions)	2016	2015	2016	2015	
OMG Malaysia	\$1.2	\$ —	\$2.3	\$ —	
Alent	23.7		38.8	_	
OMG	4.2		4.5		
Arysta	(8.9)	(34.8)	(174.1)	(100.6)	
Total	\$20.2	\$(34.8)	\$(128.5)	\$(100.6)	

As the integration continues for (1) the OMG Malaysia, Alent and OMG Acquisitions within the Company's Performance Solutions business segment and (2) the Arysta Acquisition within the Agricultural Solutions segment,

discrete results reported by these existing businesses are being effected by the integration process and are becoming less comparable to prior periods.

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)

Purchase Price Allocation

The following table summarizes the consideration transferred and transaction costs incurred to acquire OMG Malaysia, Alent and the OMG Businesses, as well as the applicable amounts of identified assets acquired and liabilities assumed at the applicable acquisition date:

(amounts in millions)	OMG Malaysia	Alent	OMG
Consideration			
Cash, net	\$(1.3)	\$1,507.0	\$239.1
Equity instruments	_	231.4	_
Note receivable settlement	125.0	_	_
Total consideration	\$ 123.7	\$1,738.4	\$239.1
Acquisition costs	\$ 0.5	\$29.2	\$7.4
Identifiable assets acquired and liabilities assumed			
Accounts receivable	\$ 4.3	\$177.4	\$33.1
- less uncollectible		(1.8)	(1.6)
Accounts receivable - fair value	4.3	175.6	31.5
Inventories	6.4	116.1	13.2
Other current assets	0.2	29.3	1.6
Property, plant and equipment	4.7	192.2	35.1
Identifiable intangible assets	38.3	682.9	77.9
Other assets		38.3	0.2
Current liabilities	(3.5)	(181.8)	(21.5)
Non-current deferred tax liability	(10.0)	(139.6)	(13.6)
Other long term liabilities		(345.2)	(2.9)
Total identifiable net assets	40.4	567.8	121.5
Goodwill	83.3	1,170.6	117.6
Total purchase price	\$ 123.7	\$1,738.4	\$239.1
m			03.50

The purchase accounting and purchase price allocation is complete for the OMG Acquisition. During the nine months ended September 30, 2016, the Company increased the environmental reserves by \$1.5 million and reduced non-current accrued tax liability by \$2.6 million. The collective impact of these adjustments resulted in a decrease of \$1.1 million in goodwill.

The purchase accounting and purchase price allocation is substantially complete for the Alent Acquisition with the exception of intangible assets, income taxes, environmental reserves and AROs. The Company is still gathering information to finalize purchase accounting for the Alent Acquisition. During the nine months ended September 30, 2016, the Company updated the environmental reserves, non-current other liabilities and non-current deferred tax assets. The updates resulted in increases in environmental reserves of \$25.6 million and non-current other liabilities of \$2.8 million. The collective impact of these adjustments resulted in an increase of \$0.7 million in non-current deferred tax asset along with corresponding adjustments reflected in goodwill.

The purchase accounting and purchase price allocation is substantially complete for the OMG Malaysia Acquisition with the exception of intangible assets. Subsequent to this acquisition, the Company updated the valuation of inventories, identifiable intangible assets and non-current deferred tax liability. The updated valuations resulted in decreases in inventories of \$0.8 million and identifiable intangible assets of \$20.7 million. The collective impact of the adjustments noted above resulted in a decrease of \$5.1 million in non-current deferred tax liability, with

corresponding adjustments reflected in goodwill.

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)

All the measurement period adjustments noted above had an immaterial impact on Condensed Consolidated Statement of Operations for the nine months ended September 30, 2016. There were no measurement period adjustments made for the three months ended September 30, 2016.

The excess of the respective cost of the OMG Malaysia, Alent and OMG Acquisitions over the net of amounts assigned to the fair values of the assets acquired and the liabilities assumed in connection with these acquisitions is recorded as goodwill and represents the value of estimated synergies and the assembled workforces resulting from these acquisitions. Of the \$1.37 billion of goodwill recorded in connection with the OMG Malaysia, Alent and OMG Acquisitions, \$113 million is expected to be deductible for tax purposes as a result of the OMG Malaysia and OMG Acquisitions.

Identifiable intangible assets recorded in conjunction with the OMG Malaysia, Alent and OMG Acquisitions were as follows:

	OMG	Malaysia	Alent		OMG		Total	
		Weighted		Weighted		Weighted		Weighted
(amounts in millions)	Fair Value	average useful life	Fair Value	average useful life	Fair Value	average useful life	Fair Value	average useful life
		(years)		(years)		(years)		(years)
Customer lists	\$35.0	25.0	\$391.4	14.7	\$49.0	24.3	\$475.4	16.5
Developed technology	3.3	5.0	203.3	10.0	28.0	10.0	234.6	9.9
Tradenames	_		85.8 (1)	20.0	0.9	10.0	86.7	18.3
In process - R&D		_	2.4 (2)	_		_	2.4	_
Total	\$38.3	23.3	\$682.9	13.2	\$77.9	19.0	\$799.1	14.3

⁽¹⁾ Includes \$81.4 million of indefinite-lived tradenames which have been excluded from the calculation of weighted average useful life.

Pro Forma Revenue and Earnings

The following unaudited pro forma summary presents consolidated information of the Company for the three and nine months ended September 30, 2016 and 2015 as if the OMG Malaysia, Alent and OMG Acquisitions had each occurred on January 1, 2015, and as if the Arysta Acquisition had occurred on January 1, 2014:

	Three Months Ended September 30,		Nine Mon September	
(amounts in millions)	2016	2015	2016	2015
Pro forma revenue	\$890.5	\$865.5	\$2,638.8	\$2,713.9
Pro forma net income (loss) attributable to stockholders	105.5	(151.8)	(21.8)	(198.5)

For the three and nine months ended September 30, 2016, the Company incurred \$1.3 million and \$14.3 million of acquisition and integration expenses, respectively, related to the OMG Malaysia, Alent, OMG and Arysta Acquisitions, which have been reflected in the pro forma earnings above as if each of these Acquisitions had occurred in 2015. In addition, for the three and nine months ended September 30, 2015, the Company incurred acquisition and integration expenses of \$4.4 million and \$32.2 million, respectively, related to the Arysta Acquisition, which have been excluded from the September 30, 2015 pro forma earnings above. These pro forma amounts have been prepared to reflect fair value adjustments to intangible assets and the related amortization expense, net of tax, from January 1, 2015, as well as the effect of the debt instruments used to fund the Arysta and Alent Acquisitions.

⁽²⁾ Excluded from the calculation of weighted average useful life.

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)

3. INVENTORIES

The major components of inventory were as follows:

(amounts in millions)	September 30,	December 31,			
(amounts in millions)	2016	2015			
Finished goods	\$ 355.9	\$ 340.1			
Work in process	44.2	28.5			
Raw materials and supplies	164.2	148.9			
Total inventory, net	\$ 564.3	\$ 517.5			

In connection with Platform's various business acquisitions, the value of inventory was increased at the respective dates of acquisition to reflect fair value. For the three months ended September 30, 2016 and 2015, zero and \$1.3 million, respectively, was recorded to "Cost of sales" in the Condensed Consolidated Statements of Operations based on inventory turnover of such acquisitions and purchase price adjustments. For the nine months ended September 30, 2016 and 2015, \$11.7 million and \$58.0 million, respectively, was charged to "Cost of sales" in the Condensed Consolidated Statements of Operations based on inventory turnover of such acquisitions and purchase price adjustments.

4. PROPERTY, PLANT AND EQUIPMENT

The major components of property, plant and equipment, including equipment under capital leases, were as follows:

	A A	0 1 1		
(amounts in millions)	September 30,	December 31,		
(amounts in inimons)	2016	2015		
Land and leasehold improvements	\$ 109.2	\$ 107.9		
Buildings and improvements	138.1	143.8		
Machinery, equipment, fixtures and software	302.4	276.8		
Construction in process	27.4	21.4		
Assets under capital lease:				
Land and buildings	8.2	6.4		
Machinery and equipment	5.3	5.1		
Total property, plant and equipment	590.6	561.4		
Accumulated depreciation	(111.1)	(64.3)		
Accumulated amortization of capital leases	(6.8)	(5.5)		
Property, plant and equipment, net	\$ 472.7	\$ 491.6		

For the three months ended September 30, 2016 and 2015, the Company recorded depreciation expense of \$18.9 million and \$11.6 million, respectively. For the nine months ended September 30, 2016 and 2015, the Company recorded depreciation expense of \$55.8 million and \$33.7 million, respectively.

In March 2016, the Company entered into a sale agreement for a long-lived asset with a net book value of \$12.1 million in exchange for a cash payment of \$9.3 million, net of estimated selling costs of \$0.2 million. As a result, the Company reduced the net book value of the asset by \$2.8 million, which was recorded in "Selling, technical, general and administrative expense" in the Condensed Consolidated Statements of Operations during the first quarter of 2016. The asset was subsequently sold during the second quarter of 2016.

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)

5. GOODWILL AND INTANGIBLE ASSETS

The changes in the carrying amount of goodwill by segment were as follows:

(amounts in millions)	Performance	Agricultural	Total	
(amounts in initions)	Solutions	Solutions		
December 31, 2015	\$ 2,147.2	\$ 1,874.7	\$4,021.9	
Addition from acquisitions	66.9	_	66.9	
Purchase accounting adjustments	46.3	_	46.3	
Foreign currency translation and other	4.6	226.6	231.2	
September 30, 2016	\$ 2,265.0	\$ 2,101.3	\$4,366.3	

The carrying value of indefinite-lived intangible assets other than goodwill, which consist solely of tradenames, was \$391 million and \$360 million at September 30, 2016 and December 31, 2015, respectively.

During the nine months ended September 30, 2016, the Company found no indications of impairment related to its goodwill and indefinite-lived intangible assets.

Intangible assets subject to amortization were as follows:

		September 30, 2016		December 31, 2015					
(amounts in millions)	Weighted Average Useful Life (years)	Gross Carrying Amount and Foreign Exchange	and Foreign Exchange	ior		Gross Carrying Amount and Foreign Exchange	and Foreign Exchange		
Customer lists	18.3	\$1,240.5	\$ (117.9)	\$1,122.6	\$1,297.2	\$ (184.0)	\$1,113.2
Developed technology	11.7	2,009.4	(146.7)	1,862.7	2,260.9	(440.4)	1,820.5
Tradenames	8.0	22.2	(5.9)	16.3	24.2	(5.4)	18.8
Non-compete agreements	5.0	1.9	(0.9)	1.0	1.9	(0.5)	1.4
Total	14.1	\$3,274.0	\$ (271.4)	\$3,002.6	\$3,584.2	\$ (630.3)	\$2,953.9

For the three months ended September 30, 2016 and 2015, the Company recorded amortization expense on intangible assets of \$68.0 million and \$50.4 million, respectively. For the nine months ended September 30, 2016 and 2015, the Company recorded amortization expense on intangible assets of \$199 million and \$143 million, respectively.

6. LONG-TERM COMPENSATION PLANS

In June 2014, the Company's stockholders approved the 2013 Plan, which is administered by the compensation committee of the Board, except as otherwise expressly provided in the 2013 Plan. The Board approved a maximum of 15,500,000 shares of common stock (subject to increase in accordance with the terms of the 2013 Plan), which were reserved and made available for issuance under the 2013 Plan.

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)

As of September 30, 2016, a total of 373,434 shares of common stock had been issued and 2,824,164 awarded RSUs and stock options were outstanding under the 2013 Plan.

	Time Training Ended September 60, 2010			
	RSUs			Stock
	Total	Equity	Liability	Options
		Classified	Classified	Options
Outstanding at December 31, 2015	1,006,436	501,634	329,802	175,000
Granted	2,110,173	1,719,975	_	390,198
Exercised/Issued	(7,642)	(7,642)	_	_
Forfeited	(109,803)	(100,313)	(9,490)	_
Outstanding at September 30, 2016	2,999,164	2,113,654	320,312	565,198
~				

Equity Classified RSUs

During the nine months ended September 30, 2016, the Company issued the following RSU grants following their approval by the Board:

Weighted
average

RSUs grant Weighted average vesting period (months)
date fair
value

RSUs issued 1,719,975 \$ 10.86 34.1

In addition to RSUs containing only service vesting conditions, the Company has issued RSUs for which vesting is also tied to performance or market conditions. Certain of these RSUs with performance or market vesting conditions also contain provisions for additional share awards in the event certain performance or market conditions are met at the end of certain applicable measurement periods. These conditions are generally based on ROIC or TSR targets. As of September 30, 2016, the following equity classified RSUs were outstanding:

September 30, 2016

Vesting Conditions:	Outstandir	ngWeighted average service period (years)	Potential additional awards
Service-based	772,835	2.8	_
Performance-based	713,830	3.3	433,780
Market-based	626,989	3.5	1,202,067
Total	2,113,654	3.2	1,635,847

In addition, the Board had approved 166,667 RSUs under the 2013 Plan subject to EBITDA performance conditions that must be achieved in the applicable vesting year which have yet to be set. These awards also include a multiplier of zero to 100% based upon adjusted EBITDA target benchmarks. As the target adjusted EBITDA benchmarks have not yet been established, these RSUs have been excluded from the above grant activity. The adjusted EBITDA target benchmarks are expected to be established in 2017 and 2018.

For the three months ended September 30, 2016 and 2015, total compensation expense associated with RSUs classified as equity totaled \$2.0 million and \$0.2, respectively. For the nine months ended September 30, 2016 and 2015, total compensation expense associated with RSUs classified as equity totaled \$4.6 million and \$0.6 million, respectively.

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)

Liability Classified RSUs

In March 2014, the Company granted to certain employees 329,823 RSUs that cliff vest on December 31, 2020. These RSUs are subject to an adjusted EBITDA performance condition and a share price market condition. Additionally, the number of shares of common stock to be issued is limited to a maximum cash value, requiring these awards to be classified as liabilities. There were 320,312 RSUs associated with these grants outstanding as of September 30, 2016. The combined undiscounted maximum cash value of all liability-classified RSUs issued is approximately \$6.9 million, which is being recognized as compensation expense over the period from grant to the vesting date. For the three months ended September 30, 2016 and 2015, compensation expense (income) associated with these awards totaled zero and \$(0.6) million, respectively. For the nine months ended September 30, 2016 and 2015, compensation expense associated with these awards totaled zero and \$0.8 million, respectively.

Stock Options

During the nine months ended September 30, 2016, the Company granted non-qualified stock options under the 2013 Plan as follows:

		Weighted	Weighted
		C	average
	Stock	average strike	grant
	Options		date fair
		price per	value per
		share	share
Stock options granted	390,198	\$ 8.05	\$ 4.35

All options granted during 2016 are subject to graded vesting over a three-year period and have contractual lives of ten years from the grant date. Fair value of the grants is calculated using the Black-Scholes option pricing model at the grant date.

The following table provides the range of assumptions used in valuing the option grants using the Black-Scholes option pricing method:

Black-Scholes Input Assumptions

Weighted average expected term (years) 6.0 Expected volatility 53.0%

Risk-free rate 1.52% to 1.56%

Expected dividend rate —%

Fair value price per share \$4.32 to \$4.81

Weighted average expected term is calculated based on the simplified method for plain vanilla options as the Company has concluded that its historical share option exercise experience does not provide a reasonable basis upon which to estimate expected term and certain alternative information to assist with estimating it is not easily obtainable. Expected volatility is calculated based on a blend of the implied and historical equity volatility of an index of comparable companies. Risk-free rate of return is based on an interpolation of U.S. Treasury rates to reflect an expected term of six years at the date of grant.

For the three and nine months ended September 30, 2016, the Company recognized compensation expense associated with stock options of \$0.1 million and \$0.3 million, respectively.

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)

Long Term Cash Bonus Plan

The Company established the LTCB during the first quarter of 2015. As of September 30, 2016, the LTCB provides participants with the right to receive long-term cash bonuses totaling in the aggregate \$10.5 million, a decrease of \$4.8 million from December 31, 2015 due to forfeitures. Benefits under the plan vest over periods ranging from 36 to 62.5 months and include adjusted EBITDA performance targets, which are subject to appropriate and equitable adjustments by the compensation committee of the Board in order to reflect any subsequent acquisition, divestiture or other corporate reorganizations, as necessary. For the three months ended September 30, 2016 and 2015, compensation expense (income) associated with the LTCB totaled \$0.1 million and \$(0.6) million, respectively. For the nine months ended September 30, 2016 and 2015, compensation expense associated with the LTCB totaled \$0.2 million and \$0.2 million, respectively.

Employee Stock Purchase Plan

The Company adopted the ESPP in 2014. The Board approved a maximum of 5,178,815 shares of common stock, which were reserved and made available for issuance under the plan. As of September 30, 2016, a total of 152,665 shares had been issued under the ESPP, and approximately 1,200 persons were eligible to participate in the ESPP. For the three months ended September 30, 2016 and 2015, compensation expense associated with the ESPP totaled \$0.2 million and zero, respectively. For the nine months ended September 30, 2016 and 2015, compensation expense associated with the ESPP totaled \$0.3 million and \$0.1 million, respectively.

7. PENSION AND POST-RETIREMENT PLANS

The components of net periodic pension and post-retirement benefit costs for the three and nine months ended September 30, 2016 and 2015 were as follows:

	Three Months	s Ended	Nine Months E	Ended September
	September 30	,	30,	
(amounts in millions)	2016	2015	2016	2015
Pension & SERP Benefits	DomestForeig	n DomestForeign	DomestForeign	DomestForeign
Net periodic (benefit) cost				
Service cost	\$ \$ 0.4	\$— \$ 0.2	\$— \$ 1.3	\$— \$ 0.6
Interest cost on the projected benefit obligation	2.5 0.8	1.6 0.5	7.6 2.3	4.8 1.5
Expected return on plan assets	(2.9) (0.6)) (2.4) (0.5)	(8.7) (1.9)	(7.2) (1.5)
Amortization of prior service cost	— 0.1		— 0.4	
Net periodic (benefit) cost	\$(0.4) \$ 0.7	\$(0.8) \$ 0.2	\$(1.1) \$ 2.1	\$(2.4) \$ 0.6
	Three Months	Ended 1	Nine Months End	ded
	September 30	,	September 30,	
(amounts in millions)	2016	2015	2016 20	15
Post-retirement Benefits	DomeStireign	DomestForeign I	DomeStireign Do	omest F oreign
Net periodic cost				
Interest cost on the projected benefit obligation	\$0.1 \$ 0.1	\$ 0.1 \$ -5	\$0.3 \$ 0.2 \$ 0	0.3 \$ —
Net periodic cost	\$0.1 \$ 0.1	\$ 0.1 \$	\$0.3 \$ 0.2 \$ 0	0.3 \$ —

No pension service costs were recognized during the three and nine months ended September 30, 2016 and 2015 under the domestic pension plans, nor will there be in future periods, as benefits in the plans were frozen. The Company expects to make contributions totaling \$6.9 million to its pension and other post-retirement benefit plans during 2016, of which \$6.6 million was contributed as of September 30, 2016.

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)

8. DEBT, CAPITAL LEASES, FINANCIAL GUARANTEES AND FACTORING ARRANGEMENTS

Excluding the "Preferred stock redemption liability," the Company's debt and capital lease obligations consisted of the following:

Tollowing.	a . 1 20	D 1 01
(amounts in millions)		, December 31,
	2016	2015
Debt and Capital Lease Obligations		
USD Senior Notes due 2022,		
interest at 6.5%, net of unamortized premium and debt issuance costs of \$17.5 million	\$ 1,082.5	\$ 1,081.1
and \$18.9 million at September 30, 2016 and December 31, 2015, respectively		
EUR Senior Notes due 2023,		
interest at 6.00%, net of debt issuance costs of \$5.8 million and \$6.1 million at Septembe	r387.6	374.0
30, 2016 and December 31, 2015, respectively		
USD Senior Notes due 2021,		
interest at 10.375%, net of debt issuance costs of \$11.5 million and \$12.5 million at	488.5	487.5
September 30, 2016 and December 31, 2015, respectively		
First Lien Credit Facility - U.S. Dollar Term Loans due 2020,		
interest at the greater of 5.50% or LIBOR plus 4.50%, net of unamortized discount and	2 (20 0	2 (21 2
debt issuance costs of \$57.4 million and \$66.8 million at September 30, 2016 and	2,620.0	2,631.3
December 31, 2015, respectively		
First Lien Credit Facility - Euro Term Loans due 2020,		
interest at the greater of 5.50% or LIBOR plus 4.50%, net of unamortized discount and		
debt issuance costs of \$13.2 million and \$14.9 million at September 30, 2016 and	638.0	619.2
December 31, 2015, respectively		
Borrowings under the Revolving Credit Facility,		
interest at LIBOR plus 3.00% at September 30, 2016	_	_
Borrowings under lines of credit,		
weighted average interest rate of 3.52% and 4.28% at September 30, 2016 and December	42.8	16.7
31, 2015, respectively		1017
Other	18.9	18.5
Total debt and capital lease obligations	5,278.3	5,228.3
Less: current portion debt and capital lease obligations	•	(54.7)
Total long-term debt and capital lease obligations	\$ 5,196.9	\$ 5,173.6
The role of the dest and capital lease obligations	Ψ 3,170.7	Ψ 2,172.0

The weighted average effective interest rate associated with debt outstanding at September 30, 2016, based on currently applicable interest rates, was 6.99%. This rate includes the effects of interest rate swaps, as well as the impact of deferred financing fees and original issue discount and premium amortization calculated using the effective interest method.

In August 2015, the Company entered into a series of pay fixed, receive floating interest rate swaps with respect to a portion of its indebtedness. The swaps effectively fix the floating base rate portion of the interest payments on approximately \$1.15 billion of the Company's USD denominated debt and €282 million of its Euro denominated debt at 1.96% and 1.20%, respectively, from September 2015 through June 2020.

On September 9, 2016, the Company entered into a settlement agreement with the Arysta Seller with respect to certain obligations relating to the Company's shares of Series B Convertible Preferred Stock. As a result of the settlement agreement, for accounting purposes, the Series B Convertible Preferred Stock was deemed extinguished in exchange for the issuance of another financial instrument that is recognized as a "Preferred stock redemption liability" in the current liability section of the Condensed Consolidated Balance Sheet, which totaled \$504 million as of September 30,

2016. See Note 11, Stockholders' Equity, under the heading "Preferred Stock - Series B Convertible Preferred Stock" for further information.

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)

Minimum principal payments on long-term debt and capital leases were as follows:

(amounts in millions)	Principal
Year ending December 31,	Payments
2016 - remaining	\$8.9
2017	34.9
2018	34.8
2019	34.6
2020	3,218.8
2021	500.7
Thereafter	1,494.4
Total	\$5,327.1

In order to fund its acquisition activity, the Company has \$5.28 billion of debt as of September 30, 2016, with expected interest payments in excess of \$300 million per year. The first significant principal debt payments, totaling \$3.22 billion, are due in 2020 and represent maturities of outstanding term loans under the Amended and Restated Credit Agreement. On October 14, 2016, the Company created new tranches of term loans, the proceeds of which were used to prepay, in full, more than half of the Company's previously existing term loans, having the effect of reducing future interest payments and extending maturity dates. See "Amended and Restated Agreement - Subsequent Events" below. In addition, to the extent the Company does not settle its preferred stock redemption liability as described below, on April 20, 2017, it will be required to repurchase, in consideration and exchange for shares of its common stock, each share of Series B Convertible Preferred Stock that has not been previously converted into shares of the Company's common stock or automatically redeemed for cash. Upon such repurchase, the Company would also pay to holders of Series B Convertible Preferred Stock in cash a make whole payment, which corresponds to any deficit between (i) the 10-day volume weighted price of Platform's common stock prior to such repurchase and (ii) \$27.14 per share. Based on Platform's common stock price of \$8.11 as of September 30, 2016, the maximum potential make whole payment would total approximately \$421 million. Under the terms of a recent settlement agreement with the Arysta Seller, from October 20, 2016 until the close of business on December 15, 2016, the Company may however settle (i) all of its obligations with respect to the Series B Convertible Preferred Stock in exchange for a cash payment of \$1.00 and the issuance of 5,500,000 shares of its common stock upon simultaneous conversion of the Series B Convertible Preferred Stock by the Arysta Seller, and (ii) for a payment of \$460 million, its obligation to pay the make whole payment mentioned above to the Arysta Seller.

The Company anticipates sufficient cash from operations to fund interest, working capital and other capital expenditures for the foreseeable future and has access to a \$500 million line of credit under the Revolving Credit Facility, with current availability of \$500 million, as well as availability under various lines of credit and overdraft facilities of \$118 million. In addition, during the third quarter of 2016, the Company completed the September 2016 Equity Offering of 48,787,878 shares of common stock. This offering resulted in gross proceeds of approximately \$402.5 million. Despite the above, a combination of the settlement of the preferred stock redemption liability, working capital shortfalls and future acquisitions may require utilization of the Revolving Credit Facility as well as proceeds from future debt and/or equity offerings. The Company's long-term liquidity may also be impacted by its ability to borrow additional funds, renegotiate existing debt and/or raise equity or debt under favorable terms.

Amended and Restated Credit Agreement

The Company is party to the Amended and Restated Credit Agreement, which governs the First Lien Credit Facility and the Revolving Credit Facility (in U.S. Dollar or multicurrency). A portion of the Revolving Credit Facility not in excess of \$30.0 million is available for the issuance of letters of credit. As of September 30, 2016, the maximum borrowing capacity under the Amended and Restated Credit Agreement consisted (i) an aggregate principal amount of up to \$250 million under the Revolving Credit Facility to be denominated in U.S. Dollars, and (ii) an aggregate

principal amount of up to \$250 million under the Revolving Credit Facility to be denominated in multicurrency. Pursuant to the terms of the Amended and Restated Credit Agreement, each of the First Lien Credit Facility term loans bear interest at a rate per annum equal to the greater of 5.50% or LIBOR plus an adjusted eurocurrency rate, or 4.50% plus an adjusted base rate, calculated as set forth in the Amended and Restated Credit Agreement. Each tranche of term loans will mature on June 7, 2020.

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)

Pursuant to the terms of the Amended and Restated Credit Agreement, loans under the Revolving Credit Facility bear interest at a rate per annum equal to 3.00% plus an adjusted eurocurrency rate, or 2.00% plus an adjusted base rate, each as calculated as set forth in the Amended and Restated Credit Agreement. The Revolving Credit Facility will mature on June 7, 2019. Revolving loans and commitments held by revolving facility lenders who did not consent to any extension, will mature on June 7, 2018.

Certain domestic and foreign subsidiaries of the Company, including certain subsidiaries acquired in the Alent, Arysta and OMG Acquisitions, are guarantors under the Amended and Restated Credit Agreement, with certain of these subsidiaries having pledged collateral to secure the obligations incurred thereunder.

Covenants and Events of Default

The Amended and Restated Credit Agreement contains customary covenants including limitations on additional indebtedness, dividends and other distributions, entry into new lines of business, use of loan proceeds, capital expenditures, restricted payments, restrictions on liens, transactions with affiliates, amendments to organizational documents, accounting changes, sale and leaseback transactions and dispositions. The Revolving Credit Facility also imposes a financial covenant to maintain a first lien net leverage ratio of 6.25 to 1.0 of (x) consolidated indebtedness secured by a first lien minus unrestricted cash and cash equivalents of the borrowers and guarantors under the Amended and Restated Credit Agreement to (y) consolidated EBITDA for the four most recent fiscal quarters, subject to a right to cure. A violation of this financial covenant can become an event of default under the Credit Facilities and result in the acceleration of all of the Company's indebtedness. As of September 30, 2016, the Company was in compliance with the debt covenants contained in the Credit Facilities and, in accordance with such debt covenants, had full availability of its unused borrowing capacity of \$500 million under the Revolving Credit Facility. The Amended and Restated Credit Agreement also contains customary events of default that include, among others, non-payment of principal, interest or fees, violation of certain covenants, inaccuracy of representations and warranties, failure to make payment on certain other material indebtedness, bankruptcy and insolvency events, material judgments and change of control provisions. Upon the occurrence of an event of default, payment of any outstanding loans under the Amended and Restated Credit Agreement may be accelerated. Borrowings under the Amended and Restated Credit Agreement are also subject to mandatory prepayment from the proceeds of certain dispositions of assets and from certain insurance and condemnation proceeds, excess cash flow and debt incurrences, in each case, subject to customary carve-outs and exceptions.

The Amended and Restated Credit Agreement also contains a yield protection provision wherein the yield on any current indebtedness issued under the Amended and Restated Credit Agreement would be increased to within 50 basis points of the yield on any additional incremental term loan(s), in the event the incremental term loan(s) provided an initial yield, including original issue discount (OID), subject to the yield calculation provisions, as defined, is in excess of 50 basis points of the yield on existing term loan indebtedness.

Subsequent Event

On October 14, 2016, the Company entered into and closed the transactions contemplated by Amendment No. 5 to the Second Amended and Restated Credit Agreement. Amendment No. 5, among other things, provided for the prepayment in full of previously existing tranche B and tranche B-2 term loans denominated in U.S. dollars and tranche C-1 term loans denominated in Euros with the aggregate proceeds of newly created tranche B-4 term loans denominated in U.S. dollars in an aggregate principal amount of \$1.48 billion (less original issue discount of 0.5%) and tranche C-3 term loans denominated in Euros in an aggregate principal amount of €433 million (or \$487 million based on the Euro/USD exchange rate of 1.124 on September 30, 2016)(less original issue discount of 0.25%). The amendment effectively reduced interest rates by 50 basis points for the new U.S. Dollar denominated term loans and by 75 basis points for the new Euro denominated term loans. The new tranche B-4 term loans bear interest at 4.0% per annum, plus an applicable eurocurrency rate and the new Euro tranche C-3 term loans bear interest at 3.75% per annum, plus an applicable eurocurrency rate, in each case as calculated in the Credit Agreement. The maturity date of

the new term loans is June 7, 2023; provided that if, on or prior to November 2, 2021, the Company has not prepaid, redeemed or otherwise retired and/or refinanced in full its 6.50% USD Notes due 2022, as permitted under the Amended and Restated Credit Agreement, the maturity date of the new term loans will be November 2, 2021. Amendment No. 5 also (i) amended the Restricted Payments basket, as defined in the Amended and Restated Credit Agreement, to limit select forms of restricted payments if such payments would cause the total net leverage ratio, calculated as set forth in the Amended and Restated Credit Agreement, to exceed 6.00 to 1.00, and (ii) requires a prepayment percentage in the case of excess cash flow, both calculated as set forth in the Amended and Restated Credit Agreement, of 75% with step-downs to 50%, 25% and 0% based on the applicable first lien net leverage ratio on the prepayment date.

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)

Except as set forth in Amendment No. 5 and above, the new USD tranche B-4 term loans have identical terms as the existing U.S. dollar denominated tranche B-3 term loans and the new Euro tranche C-3 term loans have identical terms as the existing Euro denominated tranche C-2 term loans and, in each case, are otherwise subject to the provisions of the Amended and Restated Credit Agreement.

Guarantees

The obligations of Platform and MacDermid, as borrowers, under the Amended and Restated Credit Agreement are guaranteed by current and future direct and indirect domestic subsidiaries. Certain of Platform's foreign subsidiaries also guarantee the obligations of MAS Holdings, NAIP, MacDermid Europe and MacDermid Funding with respect to the Euro tranche C term loans. Pursuant to the Security Agreement, the Company's obligations under the Amended and Restated Credit Agreement are secured by a security interest in substantially all of the personal property, whether owned on the date of the Security Agreement, or entered into or acquired in the future, of Platform and MacDermid, as borrowers, and the guarantors listed in the Security Agreement, including the pledge by Platform, MacDermid and guarantors generally of 100% of the voting common stock and other equity interests in all of their respective domestic subsidiaries and 65% of the voting common stock and other equity interests in all of their respective directly owned non-domestic subsidiaries (in each case, whether existing on the date of the Security Agreement or entered into or acquired thereafter), subject to certain exceptions contained in the Amended and Restated Credit Agreement and the Security Agreement.

Lines of Credit and Other Debt Facilities

The Company carries a Revolving Credit Facility and various lines of credit, short-term debt facilities and overdraft facilities worldwide which are used to fund short-term cash needs. As of September 30, 2016 and December 31, 2015, the aggregate principal amount outstanding under such facilities totaled \$42.8 million and \$16.7 million, respectively. The Company also had letters of credit outstanding of \$32.9 million and \$40.0 million as of September 30, 2016 and December 31, 2015, respectively, of which \$11.2 million and \$11.0 million as of September 30, 2016 and December 31, 2015, respectively, reduce the borrowings available under the Revolving Credit Facility. As of September 30, 2016 and December 31, 2015, the availability under these facilities was approximately \$618 million, net of outstanding letters of credit.

Financial Guarantees and Factoring Arrangements

The Company periodically enters into certain arrangements with vendors and customers under which it provides guarantees to financial institutions for loans entered into between its vendors and customers and the financial institutions, the proceeds of which are used to settle outstanding accounts receivables. The terms of the guarantees are equivalent to the terms of the customer loans. Liabilities for the guarantees are recorded at amounts that approximate fair value, based on the Company's historical collection experience with vendors and customers that participate in the program and a current assessment of credit exposure. Such liabilities are included in "Accrued expenses and other current liabilities" in the Company's Condensed Consolidated Balance Sheets, and totaled \$6.7 million and \$46.3 million as of September 30, 2016 and December 31, 2015, respectively. Program income and expenses are recorded in "Interest expense, net" in the Condensed Consolidated Statements of Operations. For the three months ended September 30, 2016 and 2015, program income (expenses) totaled \$0.1 million and \$(0.5) million, respectively. For the nine months ended September 30, 2016 and 2015, program income (expenses) totaled \$0.3 million and \$(1.5) million, respectively.

The Company also utilizes accounts receivable factoring arrangements as a part of its working capital management strategies. Total current capacity under such programs is approximately \$287 million as of September 30, 2016. Under these arrangements, factored accounts receivable may be transferred with or without recourse. Factoring transactions qualifying for sales treatment, where the derecognition criteria have been met, totaled \$33.1 million as of September 30, 2016. As of December 31, 2015, such transactions totaled \$189 million. Accounts receivable balances related to arrangements not having met the derecognition criteria, where the risks and rewards of ownership have not

been transferred, remain recorded in "Accounts receivable" and the related liabilities are included in "Accrued expenses and other current liabilities" in the Company's Condensed Consolidated Balance Sheets, and totaled \$31.0 million and \$24.8 million as of September 30, 2016 and December 31, 2015, respectively. Factoring fees are recorded in "Interest expense, net" in the Condensed Consolidated Statements of Operations and totaled \$0.7 million and \$0.1 million for the three months ended September 30, 2016 and 2015, respectively. For the nine months ended September 30, 2016 and 2015, factoring fees totaled \$1.4 million and \$0.1 million, respectively. As of September 30, 2016, the Company had additional capacity under its factoring arrangements of approximately \$96.8 million, subject to the limitations outlined in its Credit Facilities and other agreements governing outstanding debt.

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)

Some of the Company's subsidiaries in the United States and the Netherlands periodically enter into arrangements with financial institutions for consignment and/or purchase of precious metals. The present and future indebtedness and liability relating to such arrangements are guaranteed by the Company. The Company's maximum guarantee liability under these arrangements is limited to an aggregate of \$18.0 million.

9. DERIVATIVE INSTRUMENTS

In the normal course of business, the Company is exposed to risks relating to changes in foreign currency exchange rates, interest rates and commodity prices. Derivative financial instruments, such as foreign currency exchange forward contracts, interest rate swaps and commodities futures contracts are used to manage the risks associated with changes in the conditions of those markets. All derivatives are recognized in the Condensed Consolidated Balance Sheets at fair value at the end of each period. The counterparties to the Company's derivative agreements are primarily major international financial institutions. The Company continually monitors its positions and the credit ratings of its counterparties and does not anticipate nonperformance by the counterparties.

Foreign Currency

The Company conducts a significant portion of its business in currencies other than the U.S. Dollar and in currencies other than the functional currencies of its subsidiaries. As a result, the Company's operating results are affected by foreign currency exchange rate volatility.

As of September 30, 2016, the Company held foreign currency forward contracts to purchase and sell various currencies primarily with U.S. Dollars and Euro, with less significant amounts traded with Japanese Yen. The Company has not designated any foreign currency exchange forward contracts as eligible for hedge accounting. The total U.S. Dollar equivalent of foreign currency exchange forward contracts held at September 30, 2016 was approximately \$264 million, all of which have settlement dates within one year. The following table details the Company's significant outstanding foreign exchange derivative contracts as of September 30, 2016:

			Tradeo	1	
(in millions)	Tradeo	d	against EUR		
(III IIIIIIIOIIS)	agains	against USD		(USD	
			equiva	lent)	
Currency	Purcha	a Siell ing	Purcha	a Siel ging	
Euro (EUR)	\$41.4	\$36.9	\$ —	\$ —	
Brazilian Real (BRL)	13.8	66.1			
Japanese Yen (JPY)	12.3	18.7	9.5	1.6	
South African Rand (ZAR)		22.3		1.4	
Taiwan Dollar (TWD)	10.6	_			
Other	15.4	2.9	9.1	0.3	
Total	\$93.5	\$146.9	\$18.6	\$ 3.3	

The change in the net fair value of the foreign currency forward contracts is recorded in "Loss on derivative contracts" in the Condensed Consolidated Statements of Operations.

Interest Rates

In August 2015, the Company entered into a series of pay fixed, receive floating interest rate swaps with respect to a portion of its indebtedness. The swaps effectively fix the floating base rate portion of the interest payments on approximately \$1.15 billion of the Company's USD denominated debt and £282 million of its Euro denominated debt at 1.96% and 1.20%, respectively, from September 2015 through June 2020.

Changes in the fair value of a derivative that is designated as, and meets all the required criteria of, a cash flow hedge are recorded in "Accumulated other comprehensive income (loss)" and reclassified into earnings as the underlying hedged item affects earnings. Amounts reclassified into earnings related to the interest rate swaps are included in interest expense.

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)

Commodities

As part of its risk management policy, the Company enters into commodities futures contracts on an ongoing basis for the purpose of mitigating its exposure to fluctuations in prices of certain metals it uses in the production of its finished goods. The Company held futures contracts to purchase and sell various metals, primarily silver and tin, for a notional amount of \$38.7 million and \$16.5 million as of September 30, 2016 and December 31, 2015, respectively. All contracts outstanding at September 30, 2016 have delivery dates within the next twelve months. The change in the net fair value of the commodities futures contracts is recorded in "Loss on derivative contracts" in the Condensed Consolidated Statements of Operations.

Certain subsidiaries of the Company have entered into supply agreements with a third party that have been deemed to constitute financing agreements with an embedded derivative feature whose fair value is determined by the change in the market value of the underlying metals between delivery date and measurement date. Amounts associated with these supply agreements, which serve as the notional value of the embedded derivative, have been recorded in "Inventory" and "Current installments of long-term debt and revolving credit facilities" in the Condensed Consolidated Balance Sheets and totaled \$13.7 million and \$13.0 million at September 30, 2016 and December 31, 2015, respectively, and primarily relate to gold purchases. The fair value of these contracts has been bifurcated and recorded as a derivative liability in "Accrued expenses and other current liabilities" in the Condensed Consolidated Balance Sheets and totaled \$0.4 million and zero at September 30, 2016 and December 31, 2015, respectively. Fair Value of Derivative Instruments

The following table summarizes the fair value of derivative instruments reported in the Condensed Consolidated Balance Sheets:

(amounts in millions)		September 2016	: 30	, Decemb 31, 201	
Derivatives designated as hedging instruments	Liabilities Balance Sheet location				
Interest rate swaps	Accrued expenses and other current liabilities	\$ (10.5)	\$ <i>—</i>	
Interest rate swaps	Other long-term liabilities	(17.5)	(12.5)
Derivatives not designated as hedging instruments:	Assets Balance Sheet location				
Foreign exchange and metals contracts	Prepaid expenses and other current assets	2.6		1.1	
Foreign exchange contracts	Other assets	_		1.0	
	Liabilities Balance Sheet location				
Foreign exchange and metals contracts	Accrued expenses and other current liabilities	(5.5)	(1.0)
Net derivative contract liability		\$ (30.9)	\$ (11.4)

The Company recorded unrealized losses of \$1.6 million and \$24.3 million for the three and nine months ended September 30, 2016, respectively, in "Other comprehensive income (loss)" related to interest rate swaps. For the three and nine months ended September 30, 2015, such losses totaled \$18.1 million. The interest rate swaps were deemed highly effective with no ineffective portions for cash flow hedge accounting purposes during the nine months ended September 30, 2016. For the three and nine months ended September 30, 2016, the Company reclassified \$3.0 million and \$8.9 million, respectively, of unrealized losses associated with the interest rate swaps from "Accumulated other comprehensive income" to "Interest expense, net." During the next twelve months, the Company expects to reclassify \$10.5 million from "Accumulated other comprehensive income" to "Interest expense, net" in the Condensed Consolidated Statements of Operations.

For the three months ended September 30, 2016 and 2015, the Company recorded realized and unrealized losses of \$1.4 million and \$47.3 million in "Loss on derivative contracts" in the Condensed Consolidated Statements of Operations related to foreign exchange and metals derivative contracts. For the nine months ended September 30, 2016 and 2015, such losses totaled \$12.1 million and \$49.9 million, respectively.

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)

Master Netting Arrangements

In the normal course of business, the Company enters into contracts with certain counterparties to purchase and sell foreign currency exchange forwards and metal futures that contain master netting arrangements, typically in the form of an International Swaps and Derivatives Association (ISDA) or similar agreements. The right to set-off within these agreements is limited to certain termination events, such as bankruptcy or default of either party to the agreement. The Company has made an accounting policy decision not to offset and reports gross derivative asset and liability balances in the Condensed Consolidated Balance Sheets.

The following table presents recognized foreign currency exchange forward and metal future derivative contracts that are subject to master netting arrangements but not offset, as of September 30, 2016 and December 31, 2015, and shows in the "Net" column what the net impact would be on the Company's Condensed Consolidated Balance Sheets if all set-off rights were exercised:

α		1	20	20	
V @1	otem	her	411	711	l h
\mathcal{L}		ω_{CI}	50,	40.	L O

(amounts in millions)	Amounts offset		Amounts not offset	Net
Financial assets	Gross liabilities assets offset	Net amounts presented	Cash Financial collateral instruments paid	
Derivative assets	\$2.1 \$ -	\$ 2.1	\$(0.4) \$ —	\$1.7
	September 30, 2	2016		
	Amounts offset		Amounts not offset	Net
Financial liabilities	Gross Gross liabilities offset	Net amounts presented	Financial Cash collateral instruments paid	
Derivative liabilities	\$4.8 \$	\$ 4.8	\$(1.0) \$ (1.0)	\$2.8
	December 31, 2	015		
(amounts in millions)	Amounts offset		Amounts not offset	Net
Financial assets	Gross liabilities assets	Net amounts	Financial Collateral	
	offset	presented	instruments paid	
Derivative assets	offset	presented -\$ 3.1	s(0.3) \$ —	\$2.8
Derivative assets	offset	presented -\$ 3.1	•	\$2.8
Derivative assets	\$3.1 \$ -	presented -\$ 3.1	•	\$2.8 Net
Derivative assets Financial liabilities	soffset \$3.1 \$ — December 31, 2	presented \$_\$ 3.1 015 Net amounts presented	\$(0.3) \$ — Amounts not offset Cash Financial collateral instruments paid	
	\$3.1 \$ — December 31, 2 Amounts offset Gross Gross	presented \$_\$ 3.1 015 Net amounts	\$(0.3) \$ — Amounts not offset Cash Financial collateral instruments paid	

Collateral paid to counterparties is recorded in "Prepaid expenses and other current assets" in the Condensed Consolidated Balance Sheets.

10. FAIR VALUE MEASUREMENTS

The Company determines fair value measurements used in its unaudited interim Condensed Consolidated Financial Statements based upon the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants exclusive of any transaction costs, as determined by either the principal

market or the most advantageous market. The principal market is the market with the greatest level of activity and volume for the asset or liability. Absent a principal market to measure fair value, the Company uses the most advantageous market, which is the market in which the Company would receive the highest selling price for the asset or pay the lowest price to settle the liability, after considering transaction costs. However, when using the most advantageous market, transaction costs are only considered to determine which market is the most advantageous and these costs are then excluded when applying a fair value measurement.

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)

Inputs used in the valuation techniques to derive fair values are classified based on a three-level hierarchy. The basis for fair value measurements for each level within the hierarchy is described below, with Level 1 having the highest priority, and Level 3 having the lowest.

The three levels of the fair value hierarchy are as follows:

Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.

Level 2 – quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in non-active markets; and model-derived valuations whose inputs are observable or whose significant valuation drivers are observable.

Level 3 – significant inputs to the valuation model are unobservable and/or reflect the Company's market assumptions. Recurring Fair Value Measurements

The following tables present the Company's financial instruments, assets and liabilities that are measured at fair value on a recurring basis:

(amounts in millions)	September 30, 2016	Fair Value Meas Quoted pricesSignificant in other activeobservable markatsputs (Leve(Level 2) 1)	C
Asset Category Cash equivalents Available for sale equity securities Derivatives Total	\$ 23.2 2.5 2.6 \$ 28.3	\$— \$ 23.2 1.9 0.6 — 2.6 \$1.9 \$ 26.4	\$ — — — \$ —
Liability Category Derivatives Long-term contingent consideration Preferred stock redemption liability Total		\$— \$ 33.5 — — \$— \$ 33.5 Fair Value Measu	\$ — 75.0 504.0 \$ 579.0 arement Using
(amounts in millions)	December 31, 2015	Quoted pricesSignificant in other activeobservable marketsputs (Level 2) 1)	Significant unobservable inputs (Level 3)
Asset Category Cash equivalents Available for sale equity securities Derivatives Total	\$ 59.4 6.6 2.1 \$ 68.1	\$2.9 \$ 56.5 5.8 0.8 — 2.1 \$8.7 \$ 59.4	\$ — — — \$ —

Liability Category

Derivatives	\$ 13.5	\$— \$ 13.5	\$ —
Long-term contingent consider	ration 70.7		70.7
Total	\$ 84.2	\$— \$ 13.5	\$ 70.7

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)

The following methods and assumptions were used to estimate the fair value of each class of the Company's financial instruments, assets and liabilities:

Cash equivalents - Cash equivalents primarily comprise certificates of deposits issued by financial institutions. These funds are not publicly traded, but historically have been highly liquid. The Company records certificates of deposit at amortized cost in the Condensed Consolidated Balance Sheets. Given the relatively short maturities of these instruments, the Company believes amortized cost approximates fair value. The Company classifies these instruments as Level 2.

Available for sale equity securities - Equity securities classified as available for sale are measured using quoted market prices at the reporting date multiplied by the quantity held and, accordingly, are classified as Level 1 assets. Level 2 equity securities are measured using quoted prices for similar instruments in active markets. Available for sale securities are included in "Other assets" in the Condensed Consolidated Balance Sheets.

Derivatives - Derivative assets and liabilities include foreign currency, metals and interest rate derivatives. The values were determined using pricing models based upon observable market inputs, such as market spot and futures prices on over-the-counter derivative instruments, market interest rates and consideration of counterparty credit risk. Long-term contingent consideration - The long-term contingent consideration represents a potential liability of up to \$100 million tied to achievement of EBITDA and common stock trading price performance metrics over a seven-year period ending December 2020 in connection with the MacDermid Acquisition. The common stock performance metric has been satisfied. The fair value of the EBITDA performance metric is derived using the income approach with unobservable inputs, based on future forecasts and present value assumptions which include a discount rate of approximately 1.06% and expected future value of payments of \$60.0 million calculated using a probability weighted EBITDA assessment with higher probability associated with the Company achieving the maximum EBITDA targets. Changes in the fair value of the long-term contingent consideration are recorded in "Selling, technical, general and administrative expenses" in the Condensed Consolidated Statements of Operations. Relative to the share price metric, an increase or decrease in the discount rate of 1% changes the fair value measure of the metric by approximately \$1.7 million. Relative to the EBITDA metric, an increase or a decrease in the discount rate of 1%, within a range of probability between 80% and 100%, changes the fair value measure of the metric by approximately \$3.0 million. Preferred stock redemption liability - The preferred stock redemption liability represents a potential liability of up to \$600 million related to the issuance of 600,000 shares of Series B Convertible Preferred Stock in connection with the Arysta Acquisition. The Company and the Arysta Seller entered into a settlement agreement in September 2016 with respect to certain obligations related to the Company's shares of Series B Convertible Preferred Stock. See Note 11, Stockholders' Equity, under the heading "Series B Convertible Preferred Stock." The fair value of the preferred stock redemption liability is computed as the sum of the \$460 million cash consideration, which is discounted at an interpolated, risk-free rate, the September 30, 2016 market value of the 5,500,000 shares of common stock of the Company and accounts for settlement option assumptions. Accordingly, this liability is measured using Level 3 inputs. For the three and nine months ended September 30, 2016, the Company recorded a \$6.0 million gain associated with the change in fair value of the preferred stock redemption liability, which was recorded to "Other income, net" in the Condensed Consolidated Statement of Operations.

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)

The following table provides a reconciliation of the beginning and ending balances for the nine months ended September 30, 2016 for instruments measured at fair value on a recurring basis using significant unobservable inputs (Level 3):

(amounts in millions)	Septemb 30, 2016	
Fair value measurements using significant unobservable inputs (Level 3)		
Balance at December 31, 2015	\$ 70.7	
Changes in fair value	(1.7)
Purchases, sales and settlements (1)		
Additions	510.0	
Transfers into Level 3		
Transfers out of Level 3		
Balance at September 30, 2016	\$ 579.0	

⁽¹⁾ There were no purchases, sales or settlements during the nine months ended September 30, 2016.

The Company consistently applies its policy for transfers between fair value hierarchy levels as disclosed in the Company's Annual Report. There were no significant transfers between the fair value hierarchy levels for the nine months ended September 30, 2016.

Nonrecurring Fair Value Measurements

The following table presents the carrying value and estimated fair value of the Company's long-term debt and capital lease obligations:

(amounts in millions)	September 30,		December 31,		
(amounts in immons)		2016		2015	
	Carrying Fair		Carrying Fair		
	Value	Value	Value	Value	
USD Senior Notes due 2022	\$1,082.5	\$1,071.6	\$1,081.1	\$946.3	
EUR Senior Notes due 2023	387.6	371.6	374.0	326.7	
USD Senior Notes due 2021	488.5	539.9	487.5	500.0	
First Lien Credit Facility - U.S. Dollar Term Loans	2,620.0	2,685.7	2,631.3	2,603.6	
First Lien Credit Facility - Euro Term Loans	638.0	657.8	619.2	624.3	
Capital lease obligations	5.1	5.2	5.5	5.3	
Total	\$5,221.7	\$5,331.8	\$5,198.6	\$5,006.2	

Carrying values presented above include unamortized premiums, discounts and debt issuance costs.

The following methods and assumptions were used to estimate the fair value of the Company's liabilities:

Long-term Debt and Capital Lease Instruments - These financial instruments are measured using quoted market prices at the reporting date multiplied by the gross carrying amount of the related debt, which excludes unamortized premiums, discounts and debt issuance costs. Such instruments are valued using Level 2 inputs.

11. STOCKHOLDERS' EQUITY

Underwritten Public Offering

On September 21, 2016, the Company completed the September 2016 Equity Offering of 48,787,878 shares of its common stock at a public offering price of \$8.25 per share. This number of shares includes 6,363,636 shares sold to the underwriters upon exercise in full of their option to purchase additional shares. The September 2016 Equity Offering was registered with the SEC pursuant

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)

to Platform's shelf registration statement on Form S-3 declared effective by the SEC on July 26, 2016. The September 2016 Equity Offering resulted in gross proceeds to Platform of approximately \$402.5 million, before underwriting discounts and commissions and offering expenses of \$11.6 million.

Preferred Stock

The Company is authorized to issue 5,000,000 shares of preferred stock. The Board has designated 2,000,000 of those shares as "Series A Preferred Stock." As of September 30, 2016 and December 31, 2015, a total of 2,000,000 shares of Series A Preferred Stock were issued and outstanding. The Board has also designated 600,000 of the authorized shares as "Series B Convertible Preferred Stock," which are redeemable and were presented in the mezzanine section of the Company's Condensed Consolidated Balance Sheet as of December 31, 2015. As further described below under the heading "Series B Convertible Preferred Stock", the Series B Convertible Preferred Stock was, for accounting purposes, deemed extinguished. As of September 30, 2016 and December 31, 2015, a total of 600,000 shares of Series B Convertible Preferred Stock were issued and outstanding. Shares of preferred stock have no voting rights, except in respect of any amendment to the Company's Certificate of Incorporation, as amended, that would alter or change their rights or privileges.

Series A Preferred Stock

The Founder Entities are the current holders of Platform's outstanding 2,000,000 shares of Series A Preferred Stock. Each share of Series A Preferred Stock is convertible into one share of common stock at the option of the holders until December 31, 2020. All outstanding shares of Series A Preferred Stock will be automatically converted into shares of common stock on a one for one basis (i) in the event of a change of control of the Company following an acquisition or (ii) upon the last day of the seventh full financial year following the MacDermid Acquisition, being December 31, 2020 (which may be extended by the Board for three additional years).

Holders of Series A Preferred Stock are entitled to receive dividends in the form of shares of common stock. The dividend amount is calculated based on the appreciated stock price compared to the highest dividend price previously used in calculating the Series A Preferred Stock dividends, which is currently \$22.85.

Series B Convertible Preferred Stock

In connection with the Arysta Acquisition, the Company issued to the Arysta Seller 600,000 shares of Series B Convertible Preferred Stock, which have a \$1,000 per share liquidation preference. The fair value of these shares at the time of the Arysta Acquisition of \$646 million was recognized as "Redeemable preferred stock – Series B" in the Condensed Consolidated Balance Sheets. To the extent the Company does not settle all of its obligations pursuant to the settlement agreement mentioned below, at any time after December 15, 2016, the Arysta Seller has the ability to convert these shares into common stock of Platform at a conversion price of \$27.14 per share. Additionally, any shares that have not previously been converted will be automatically redeemed at a \$1,000 redemption price in the event of certain mergers or consolidations, the sale of all or substantially all of the Company's assets or subsidiaries, the sale of certain subsidiaries of the Company or the approval of any plan for the dissolution, liquidation or termination of the Company by its stockholders.

Under the terms of a settlement agreement with the Arysta Seller, from October 20, 2016 until the close of business on December 15, 2016, the Company may settle (i) all of its obligations with respect to the Series B Convertible Preferred Stock in exchange for a cash payment of \$1.00 and the issuance of 5,500,000 shares of its common stock upon simultaneous conversion of the Series B Convertible Preferred Stock by the Arysta Seller, and (ii) for a payment of \$460 million, its obligation to pay the make whole payment mentioned below to the Arysta Seller. To the extent the Company does not settle all of its obligations by December 15, 2016, it will be required, on April 20, 2017, pursuant to a share purchase agreement among the Company, the Arysta Seller and certain other parties thereto, dated as of October 20, 2014, as amended, to repurchase each share of Series B Convertible Preferred Stock that has not been converted into shares of common stock of Platform, or automatically redeemed as described above at the \$1,000 redemption price payable in shares of the Company's common stock (22,107,590 shares of common stock valued at

\$27.14 per share). Upon such repurchase, the Company shall also pay to holders of Series B Convertible Preferred Stock in cash a make whole payment, which corresponds to any deficit between (i) the 10-day volume weighted price of Platform's common stock prior to such repurchase and (ii) \$27.14 per share. Based on Platform's common stock price of \$8.11 as of September 30, 2016, the maximum potential make whole payment would total approximately \$421 million. To the extent the Company does not settle all of its obligations by December 15, 2016, the holders of Series B Convertible Preferred Stock are also entitled to an incremental payment equal to \$4.0 million per month from October 20, 2016 to April 20, 2017, or such earlier date after October 20, 2016 that

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)

the then outstanding shares of Series B Convertible Preferred Stock are converted into shares of common stock of Platform or automatically redeemed for cash by Platform.

As a result of the settlement agreement, for accounting purposes, the Series B Convertible Preferred Stock was deemed an extinguishment in exchange for the issuance of another financial instrument that is recognized as a "Preferred stock redemption liability" in the Condensed Consolidated Balance Sheets. The Company recognized a gain of \$103 million in "Other income, net" in the accompanying Condensed Consolidated Statement of Operations and a gain of \$32.9 million in "Net income (loss) attributable to common stockholders." The Company also elected the fair value option to measure the liability as it most accurately reflects the economics of the transaction and the value of the liability. For the three and nine months ended September 30, 2016, the Company recorded a \$6.0 million gain associated with the remeasurement of the liability, which was recorded to "Other income, net" in the Condensed Consolidated Statement of Operations.

Non-Controlling Interest

In connection with the MacDermid Acquisition, approximately \$97.5 million was raised in new equity consisting of shares of PDH Common Stock. Since October 31, 2014, all shares of PDH common stock are convertible, at the option of the holder, into a like number of shares of the Company's common stock, the sale of which is subject to a contractual lock-up of 25% per year over a four-year period, which started on October 31, 2013.

The PDH Common Stock is classified as a non-controlling interest on the Condensed Consolidated Balance Sheets at September 30, 2016 and December 31, 2015 and will continue to be until such time as it is fully converted into shares of the Company's common stock. The total number of shares of common stock originally issuable upon the exchange of PDH Common Stock pursuant to the RHSA was approximately 8.8 million, against which 776,862 shares have been issued as of September 30, 2016.

For the three months ended September 30, 2016 and 2015, approximately \$1.5 million and \$1.1 million, respectively, of net loss has been allocated to the Retaining Holders, as included in the Condensed Consolidated Statements of Operations, representing non-controlling interest of 6.20% and 6.35% at September 30, 2016 and 2015, respectively. For the nine months ended September 30, 2016 and 2015, approximately \$(4.2) million and \$0.1 million, respectively, of net (loss) income has been allocated to the Retaining Holders, as included in the Condensed Consolidated Statements of Operations.

12. ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME

Changes in each component of accumulated other comprehensive (loss) income, net of tax, for the three and nine months ended September 30, 2016 and 2015 were as follows:

	Three Months Ended September 30, 2016				
(amounts in millions)	Foreign Currency Post-retirement Translation Plans Adjustments	Unrealized Loss on Financial Non-Control for Sale Securities Revaluation	Accumulated Other ling Comprehensive (Loss) Income		
Balance at June 30, 2016	\$(446.8) \$ (26.3)	\$ (0.4) \$ (24.9) \$ 24.7	\$ (473.7)		
Other comprehensive (loss) income before reclassifications, net	(0.7) —	(0.1) (1.6) 9.0	6.6		
Reclassifications, pretax Balance at September 30, 2016			3.0 \$ (464.1)		

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)

	Nine Months Ended September 30, 2016				
(amounts in millions)	Foreign Currency Post-retirement Translation Plans Adjustments	Unrealized Derivative Gain on Available for Sale Securities Derivative Financial Instrument Revaluatio		Accumulate Other ling Compreher (loss) Income	ed nsive
Balance at December 31, 2015	\$(899.3) \$ (26.3)	\$ 1.2 \$ (8.1)	\$ 46.4	\$ (886.1)
Other comprehensive income (loss) before reclassifications, net	451.8 —	(1.7) (24.3)	(12.7)	413.1	
Reclassifications, pretax		— 8.9		8.9	
Balance at September 30, 2016	\$(447.5) \$ (26.3) Three Months Ended S	September 30, 2015	\$ 33.7	\$ (464.1)
(amounts in millions)	Foreign Currency Post-retirem Translation Plans Adjustments	Unrealized Gain on Financial enavailable for Sale Securities For Sale Revaluatio	Non-Control Interests	Accumulate lOther Comprehen Loss	
Balance at June 30, 2015	\$(386.0) \$ (15.4)	\$ 0.3 \$—	\$ 13.5	\$ (387.6)
Other comprehensive (loss) income before reclassifications, net	(350.2) —	1.0 (11.8)	7.2	(353.8)
Balance at September 30, 2015	\$(736.2) \$ (15.4)	\$ 1.3 \$ (11.8)	\$ 20.7	\$ (741.4)
	Nine Months Ended So	eptember 30, 2015			
(amounts in millions)	Foreign Pension and Currency Post-retirem Translation Plans Adjustments	Unrealized Gain on Financial enavailable for Sale Securities For Sale Revaluatio	Non-Control Interests	Accumulate lMther Compreher Loss	
Balance at December 31, 2014	\$(122.2) \$ (14.9)	\$ 0.1 \$—	\$ 6.4	\$ (130.6)
Other comprehensive (loss) income before reclassifications, net	(614.0) —	1.2 (11.8)	14.3	(610.3)
Tax expense reclassified	— (0.5)		_	(0.5)
Balance at September 30, 2015	\$(736.2) \$ (15.4)	\$ 1.3 \$ (11.8)	\$ 20.7	\$ (741.4)

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)

13. EARNINGS (LOSS) PER SHARE

A computation of earnings (loss) per share and weighted average shares of common stock outstanding for the three and nine months ended September 30, 2016 and 2015 follows:

•	Three Months Ended September 30,		Nine Months Ended September 30,		
(amounts in millions, except per share amounts)	2016	2015	2016	2015	
		(as		(as	
	* · · · · =	restated)	****	restated)	
Net income (loss) attributable to common stockholders for basic EPS Adjustments to the numerator for diluted earnings per share:	\$104.7	\$(140.1)	\$(39.0)	\$(178.9)	
Gain on settlement agreement related to Series B Convertible Preferred Stock	(103.0)		(103.0) —	
Gain on amendment of Series B Convertible Preferred Stock	(32.9)		(32.9) —	
Remeasurement adjustment associated with the Preferred Series B redemption liability	(6.0)		(6.0) —	
Income allocated to PDH non-controlling interest	(1.5)	_		_	
Net loss attributable to common stockholders for diluted EPS	\$(38.7)	\$(140.1)	\$(180.9)	\$(178.9)	
Basic weighted average common stock outstanding	234.4	210.9	231.2	198.6	
Assumed conversion related to the amendment of Series B preferred shares	17.1	_	20.4	_	
Assumed settlement of preferred stock redemption liability	5.0		1.7		
Issuable upon conversion of the PDH non-controlling interest	8.0		_	_	
Share adjustments (1)	30.1		22.1	_	
Dilutive weighted average common stock outstanding	264.5	210.9	253.3	198.6	
Income (loss) per share attributable to common stockholders:					
Basic	\$0.45			\$(0.89)	
Diluted	\$(0.15)	\$(0.66)	\$(0.71)	\$(0.89)	
Dividends per share paid to common stockholders	\$ —	\$ —	\$—	\$ —	

⁽¹⁾ For the three and nine months ended September 30, 2015, no share adjustments are included in the dilutive weighted average shares outstanding computation as their effect would have been anti-dilutive. For more information about such dilutive shares outstanding, refer to the table below.

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)

For the three and nine months ended September 30, 2016 and 2015, the following securities were not included in the computation of diluted shares outstanding because the effect would be anti-dilutive or because performance targets were not yet achieved for awards contingent upon performance. These securities may become dilutive in future periods.

	Timee	vionuis	INTITE IV	onuis
	Ended September 30,		Ended	
			September 30,	
(amounts in thousands)	2016	2015	2016	2015
Shares contingently issuable to Founder Entities as stock dividend on Series A Preferred Stock	_	_	_	1,652
Shares issuable upon conversion of PDH Common Stock	_	8,207	8,023	8,207
Shares issuable upon conversion of Series A Preferred Stock	2,000	2,000	2,000	2,000
Shares issuable upon conversion of Series B Convertible Preferred Stock	_	22,108	_	18,544
Shares contingently issuable for the contingent consideration	9,262	2,496	8,820	1,719
Stock options	_	55		70
RSUs	186	60	110	94
Shares issuable under the ESPP	1	2	3	1
	11,449	34,928	18,956	32,287

14. OPERATING LEASE COMMITMENTS

The Company leases certain land, office space, warehouse space and equipment under agreements which are classified as operating leases for financial statement purposes. Certain of these leases provide for payment of real estate taxes, common area maintenance, insurance and certain other expenses. Lease terms may have escalating rent provisions and rent holidays which are recognized on a straight-line basis over the term of the lease. The leases expire at various dates through 2055.

Total rent expense for operating leases was as follows:

Three Nine
Months Months
Ended Ended
September September
30. 30.

(amounts in millions) 2016 2015 2016 2015 Rent expense \$8.9 \$6.0 \$28.0 \$16.4

Minimum non-cancelable operating lease commitments were as follows:

(amounts in millions)	Operating
As of September 30, 2016	
2017	26.0
2018	17.7
2019	12.0
2020	9.8
2021	8.7
Thereafter	26.8
Total minimum non-cancelable operating lease commitments	\$ 111.2

Three Months Nine Months

The fixed operating lease commitments detailed above assume that the Company continues the leases through their initial lease terms.

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)

15. CONTINGENCIES, ENVIRONMENTAL AND LEGAL MATTERS

Asset Retirement Obligations

The Company has recognized AROs for properties where it can make a reasonable estimate of the future expenditures necessary to satisfy the related obligations. The Company considers identified legally enforceable obligations, estimated settlement dates and appropriate discount and inflation rates in calculating the fair value of its AROs. As of September 30, 2016 and December 31, 2015, the Company's ARO reserves, included in other short and long-term liabilities in the Condensed Consolidated Balance Sheets, totaled \$21.2 million and \$17.5 million, respectively.

Changes in the Company's AROs were as follows:

	Three				
	Months		Nine Months		
	Ended September		Ended September 30,		
	30,		-		
(amounts in millions)	2016	2015	2016	2015	
AROs, beginning of period	\$20.9	\$17.7	\$17.5	\$18.5	
Acquisitions		_	2.8	0.4	
Accretion expense	0.3	0.2	0.9	0.7	
Remeasurements		0.5	0.1	(0.2)	
Payments		(0.4)	(0.5)	(0.4)	
Foreign currency adjustments		(0.2)	0.4	(1.2)	
AROs, end of period	\$21.2	\$17.8	\$21.2	\$17.8	
Environmental					

The Company formulates and distributes specialty chemical products and is therefore subject to extensive domestic and foreign environmental protection laws and regulations, including those governing the management, discharge and disposal of hazardous materials and pollutants into the soil, air and water, as well as laws and regulations governing workers' health and safety. As a result, the Company is exposed to risks of liability or claims with respect to environmental clean-up of contaminated facilities or other matters, including those in connection with the disposal or releases of, or exposure to, hazardous materials. The Company has incurred, and will continue to incur, costs and capital expenditures in complying with these laws and regulations. Additional costs could be incurred, including clean-up costs, fines, sanctions, and third-party claims, as a result of violations of or liabilities under environmental laws.

Among other environmental laws, the Company is subject to the Comprehensive Environmental Response, Compensation and Liability Act of 1980 (commonly known as Superfund), under which the Company may be designated as a "potentially responsible party," or PRP, with respect to clean-up costs associated with sites on the U.S. Environmental Protection Agency National Priority List. The Company conducts studies, individually or jointly with other PRPs, to determine the feasibility of various remedial techniques. It is the Company's policy to record appropriate liabilities for environmental matters when remedial efforts or damage claim payments are probable and the costs can be reasonably estimated. Such liabilities are based on the Company's best estimate of the undiscounted future costs required to complete the remedial work. The recorded liabilities are adjusted periodically as remediation efforts are determined.

Remediation activities vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, diverse regulatory agencies and enforcement policies, as well as the presence or absence of PRPs.

In particular, the Company has reserved approximately \$44.7 million primarily related to potential liability in connection with environmental remediation, clean-up costs, and monitoring of sites that were either closed or disposed of in prior years by Alent, which the Company acquired in December 2015. These sites are in various stages of environmental management: at some sites, the work is in the early stages of assessment and investigation, while at others, the clean-up remedies have been implemented and the remaining work consists of monitoring the integrity of those remedies. These sites include, but are not limited to, federal or state Superfund sites. Because the laws pertaining to Superfund sites generally impose retroactive, strict, joint and several liability,

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)

a governmental plaintiff could seek to recover all remediation costs at any such site from any of the PRPs for such site, including the Company, despite the involvement of other PRPs. The Company is one of several identified PRPs in the aforementioned Superfund sites. The Company believes that the liability associated with these sites has been apportioned based on the type and amount of waste disposed by each PRP at such disposal site and the number of financially solvent PRPs. In many cases, the nature of future environmental expenditures cannot be quantified with accuracy.

The Company does not currently anticipate any material losses in excess of the reserve amount recorded. However, it is possible that new information about these sites, such as results of investigations, could make it necessary for the Company to reassess its potential exposure related to these environmental matters. As the settlement of many of the obligations for which provision is made is subject to legal or other regulatory process, the timing of the associated cash outflows is subject to some uncertainty, but the majority of the amounts provided are expected to be utilized over the next five to ten years.

As of September 30, 2016 and December 31, 2015, the Company's environmental reserves totaled \$47.9 million and \$25.7 million, respectively. As of the date hereof, management does not believe it is possible to develop an estimate of the range of reasonably possible environmental loss in excess of the Company's recorded liabilities, and is unable to ascertain the ultimate aggregate amount of monetary liability or financial impact with respect to these matters. Legal Proceedings

From time to time, the Company is involved in various legal proceedings in the normal course of its business. The Company believes that the resolution of these claims, to the extent not covered by insurance, will not, individually or in the aggregate, have a material adverse effect on the Company's business, financial condition, results of operations or cash flows. As of September 30, 2016 and December 31, 2015, the Company has reserved approximately \$8.8 million and \$6.5 million, respectively, for its outstanding legal proceedings. The following is a description of certain litigation matters.

Product liability and/or personal injury claims for, or relating to, products the Company sells under its Agricultural Solutions segment are complex in nature and have outcomes that are difficult to predict. Since these products are used in the food chain on a global basis, any such product liability or personal injury claim could lead to litigation in multiple jurisdictions. In September 2014, Agricola Colonet, SA de CV filed a complaint with the 1st Civil Court in San Quintin (Baja California) where it alleged that certain Arysta products purchased from a retail distributor in Mexico were contaminated, requiring treated crops to be destroyed. Agricola Colonet, SA de CV is seeking compensation of approximately MXN 191 million (\$9.8 million, based on the MXN/ USD exchange rate of 0.0516 on September 30, 2016). A related complaint was filed in June 2016 in the U.S. District Court for the Southern District of California by Fresh Pac International, Inc., naming the Company as a defendant. In the complaint, Fresh Pac International Inc. claims to be a distributor of produce for Agricola Colonet, SA de CV and seeks in excess of \$6.0 million in damages allegedly sustained in connection with the events that appear to form the basis of the claim by Agricola Colonet SA de CV. The Company believes that it has adequate defenses and intends to vigorously defend against these claims. Under its risk management policies, the Company maintains certain insurance policies under which such claims may be covered.

In March 2013, a claim was filed against Arysta LifeScience Corporation, a subsidiary of the Company, relating to a purchasing optimization agreement entered into in 2011 between Arysta LifeScience Corporation and a consulting firm. The agreement provided for an incentive fee to be paid to the plaintiff based upon savings to Arysta resulting from the plaintiff's work. In addition to fees already received, the plaintiff claims damages, which the Company considered to be immaterial. The Company believes this claim was without merit and that the fees already paid under the agreement exceeded or were equal to the fees owed to the plaintiff. An arbitration hearing was conducted in May 2014, and in May 2015 the tribunal published a partial award, ruling on various issues of principle, but declining to calculate an award amount, rather asking the parties to attempt to agree upon a calculation reflecting the decisions of

the tribunal set out in the award. In April 2016, the tribunal awarded the plaintiff \$0.1 million pursuant to the agreement. In addition, the tribunal ordered the plaintiff to pay to Arysta LifeScience Corporation the amount of \$0.6 million, which represents a portion of Arysta LifeScience Corporation's total legal costs, with each party bearing 50% of the arbitration costs. Finally, the tribunal dismissed any and all other claims in this arbitration. The time period available to the plaintiff under the arbitration rules to seek to "correct" the award has expired, with no such attempt by the plaintiff. The plaintiff may seek to vacate the award in a judicial proceeding, but the Company believes there are no grounds for any such action.

The \$600 million of Series B Convertible Preferred Stock issued in connection with the Arysta Acquisition may be converted into a maximum of 22,107,590 shares of Platform common stock. Under the terms of a settlement agreement with the Arysta Seller, from October 20, 2016 until the close of business on December 15, 2016, the Company may settle all of its obligations with respect to the Series B Convertible Preferred Stock as described in Note 11, Stockholders' Equity, to the Company's unaudited interim

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)

Condensed Consolidated Financial Statements included in this Quarterly Report. To the extent the Company does not settle all of its obligations by December 15, 2016, it will be required, on April 20, 2017, to repurchase each outstanding share of Series B Convertible Preferred Stock. To the extent that the aggregate value of the shares of common stock which the shares of Series B Convertible Preferred Stock are converted into is less than \$600 million (based on a 10-day volume weighted average price), then such shortfall would be payable in cash by Platform. As previously disclosed, such shortfall would be reduced by a portion, or all, of the amount for which the March 2013 arbitration matter described in the preceding paragraph may be resolved. In light of the resolution of this matter as described above, such shortfall reduction is expected to be immaterial.

In June 2009, a lawsuit was filed in the District Court for the City of Ulianópolis in the State of Pará, Brazil by a private individual against Arysta LifeScience do Brasil Industria Química e Agropecuária Ltda, or Arysta Brazil, and 25 other defendants, and in November 2011, a claim was filed, also in the District Court for the City of Ulianópolis in the State of Pará, Brazil, against Arysta Brazil and five other defendants by the city of Ulianópolis, in each case in connection with materials sent by Arysta Brazil and others to an incineration site owned and operated by an unaffiliated third party in the state of Pará, Brazil. Arysta Brazil was summoned and has filed its answer in connection with both cases. Proceedings have been suspended indefinitely in order to allow the Pará State Attorney to conduct civil inquiries to determine the extent of contamination and the appropriate remediation, and to identify potentially responsible parties. Damages sought in the private lawsuit include a penalty of BRL 50.0 million (\$15.3 million, based on the BRL/USD exchange rate of 0.3065 on September 30, 2016), plus interest and the cost of remediation. The cost of remediation in the case brought by the city of Ulianopolis was previously estimated by the city to be BRL 70.9 million (\$21.7 million, based on the BRL/USD exchange rate of 0.3065 on September 30, 2016). In addition, 29 former employees of the incineration facility have brought actions in the Labor Court of Paragominas in the State of Pará, Brazil naming 80 defendants, including Arysta Brazil, seeking compensation in an aggregate amount of BRL 387 million (\$118 million, based on the BRL/USD exchange rate of 0.3065 on September 30, 2016) for health problems allegedly contracted as a result of their employment at the incineration site.

From time to time, in the ordinary course of our business, we contest tax assessments received by our subsidiaries in various jurisdictions. Our contested tax assessments have been most prevalent in Brazil, where the tax regime is complex, and the administrative and judicial procedures for resolving disputed tax assessments are expensive and time-consuming. In addition, short of simply paying the entire amount demanded, including penalties, interest, and attorney's fees, it is not possible to settle disputed tax assessments other than by submission for inclusion in formal tax amnesty programs announced by the Brazilian federal or state governments from time to time at irregular intervals. The terms of such amnesty programs vary, but generally offer the possibility of reduced interest and penalties. Historically, Arysta has submitted selected contested tax matters for inclusion in such amnesty programs in Brazil, when it appeared prudent to management to do so. The Company is currently contesting several tax assessments at various stages of the applicable administrative and judicial processes, with a combined amount at issue, including interest and penalties, of approximately BRL 81.1 million (\$24.9 million, based on the BRL/USD exchange rate of 0.3065 on September 30, 2016). Because tax matters in Brazil historically take many years to resolve, it is very difficult to estimate when these matters will be finally resolved. Based on management's judgments, the Company does not expect it will incur a material loss in excess of accrued liabilities.

In July 2014, a federal court jury in the U.S. District Court for the District of Connecticut found in favor of MacDermid Printing Solutions LLC in litigation against Cortron, Inc. The court entered a judgment in the amount of approximately \$64.7 million. Cortron, Inc. appealed the verdict, and in August 2016 the United States Court of Appeals for the Second Circuit issued a decision in which it reversed the District Court's verdict with respect to certain claims, affirmed with respect to other claims, and remanded to the District Court to recalculate the damages payable to MacDermid Printing Solutions LLC. Accordingly, the amount of the ultimate judgment is subject to further

proceedings in the District Court and is, therefore, uncertain. All proceeds from this litigation are subject to the pending litigation provisions of the Business Combination Agreement and Plan of Merger dated as of October 10, 2013.

In September 2014, the U.S. District Court for the District of New Jersey rendered a summary judgment in favor of MacDermid related to a patent litigation with E.I. du Pont de Nemours and Company. The Court issued summary judgment rulings in favor of MacDermid finding certain E.I. du Pont de Nemours and Company's patents invalid and not infringed. These rulings summarily found against E.I. du Pont de Nemours and Company on all of the patent claims asserted by E.I. du Pont de Nemours and Company in this lawsuit. The ruling, however, leaves the counterclaims made by MacDermid against E.I. du Pont de Nemours and Company in place. E.I. du Pont de Nemours and Company appealed the summary judgment, and in August 2016 the United States Court of Appeals for the Federal Circuit affirmed the District Court's summary judgment rulings. E.I. du Pont de Nemours and Company petitioned the Court of Appeals for a review of the decision en banc, which petition was denied. A trial date for MacDermid's

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)

counterclaims against E.I. du Pont de Nemours and Company has not yet been set. All proceeds from this litigation are subject to the pending litigation provisions of the Business Combination Agreement and Plan of Merger dated as of October 10, 2013.

In February 2015, MacDermid, as plaintiff, settled a litigation with Cookson Group plc, Enthone Inc., Cookson Electronics and David North, as defendants, for \$25.0 million. The litigation related to certain corporate activities that occurred between MacDermid and the defendants in 2006 and 2007. On April 3, 2015, the Company received part of the settlement in the amount of \$16.0 million, and placed the remainder, net of legal costs, into escrow for future distribution in accordance with the pending litigation provisions of our Business Combination Agreement and Plan of Merger dated as of October 10, 2013.

In March and April 2016, a class action lawsuit entitled Dillard v. Platform Specialty Products Corporation, et al. and a shareholder derivative action entitled Tuttelman v. Platform Specialty Products Corporation, et al., respectively, were filed against Platform, certain of its former and current executive officers and, in the case of the derivative action, its directors in the U.S. District Court for the Southern District of Florida alleging that the defendants made material false and misleading statements relating to the Company's business, operational and compliance policies in light of certain matters discovered and reported by the Company itself in connection with a Company internal investigation into certain past business practices of the Company's Arysta West Africa business, as disclosed herein and in the Annual Report. In June 2016, the shareholder derivative action was dismissed by the Court. In June 2016, the Court appointed joint lead plaintiffs in the class action lawsuit, and in July 2016, the lead plaintiffs filed an amended complaint with an expanded class period but stating substantially similar claims to those contained in the original complaint. The amended complaint seeks unspecified damages. In September 2016, Platform filed a motion to dismiss this complaint, which is fully briefed and currently pending before the Court. The Company believes this proceeding is without merit and intends to defend it vigorously.

16. INCOME TAXES

For the three months ended September 30, 2016 and 2015, income tax expense totaled \$20.4 million and \$35.4 million, respectively. The Company's effective tax rate in the third quarter of 2016 was 23.6% on pre-tax income of \$86.3 million, compared to an effective tax rate of (34.0)% on pre-tax losses of \$104 million in the third quarter of 2015. The difference between the statutory and effective tax rates for the three months ended September 30, 2016 primarily relates to the recognition of a \$38.2 million benefit for a nontaxable purchase price adjustment related to the Arysta Acquisition, a \$25.6 million benefit for deductions associated with the Alent Acquisition, and a \$15.3 million benefit related to the recognition of tax deductible goodwill. Partially offsetting these items was a \$21.9 million valuation allowance on current quarter losses that may not be recoverable for U.S. and foreign companies, a \$26.0 million increase in tax reserves primarily for deductions related to the Alent Acquisition, and a \$14.7 million charge related to tax on foreign operations.

For the nine months ended September 30, 2016 and 2015, income tax expense totaled \$65.7 million and \$59.8 million, respectively. The Company's effective tax rate for the nine months ended September 30, 2016 was (602.8)% on pre-tax losses of \$10.9 million, compared to an effective tax rate of (52.0)% on pre-tax losses of \$115 million for the nine months ended September 30, 2015. The difference between the statutory and effective tax rates for the nine months ended September 30, 2016 primarily relates to the recognition of a \$103 million valuation allowance on current period losses that may not be recoverable for U.S. and foreign companies, a \$27.9 million increase in tax reserves primarily for deductions related to the Alent Acquisition, and a \$10.0 million charge related to tax on foreign operations. Partially offsetting these items was a \$38.2 million benefit for a nontaxable purchase price adjustment related to the Arysta Acquisition, a \$25.6 million benefit for deductions associated with the Alent Acquisition, and a \$15.3 million benefit related to the recognition of tax deductible goodwill.

The amount of unrecognized tax benefits was \$188 million and \$112 million at September 30, 2016 and December 31, 2015, respectively, of which \$94.0 million and \$92.0 million, respectively, if recognized, would reduce the Company's

effective tax rate. The increase of unrecognized tax benefits during the period is in part attributable to the Alent Acquisition. Based on an analysis of the information that existed as of the acquisition date, the Company recorded an unrecognized tax benefit of \$44.5 million in purchase accounting related to certain acquired net operating losses. In addition, the Company also increased its unrecognized tax benefits by \$25.6 million for deductions related to the Alent Acquisition. Accrued interest and penalties related to unrecognized tax benefits were \$19.7 million and \$17.5 million at September 30, 2016 and December 31, 2015, respectively. The Company recognized interest and penalties of \$3.5 million and \$0.4 million related to unrecognized tax benefits in the income tax provision for the nine months ended September 30, 2016 and 2015, respectively. The unrecognized tax benefits could be reduced by \$7.8 million over the next 12 months as a result of the lapse of statutes of limitations in various jurisdictions.

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)

17. RELATED PARTY TRANSACTIONS

Series B Convertible Preferred Stock

On September 9, 2016, the Company entered into a settlement agreement with the Arysta Seller with respect to certain of its obligations relating to the Company's shares of Series B Convertible Preferred Stock. See Note 11, Stockholders' Equity, under the heading "Series B Convertible Preferred Stock."

RHSA

Immediately prior to the closing of the MacDermid Acquisition, each Retaining Holder entered into a RHSA pursuant to which they agreed to exchange their respective interests in MacDermid Holdings for shares of PDH Common Stock, at an exchange rate of \$11.00 per share plus, with respect to the common, class A and class B unit equity interests of MacDermid Holdings held by the Retaining Holder, (i) a proportionate share of a contingent interest in certain pending litigation, and (ii) a proportionate share of up to \$100 million of contingent purchase price payable upon the attainment of certain EBITDA and stock trading price performance metrics during the seven-year period following the closing of the MacDermid Acquisition. The resulting non-controlling interest percentage for the Retaining Holders was 6.20% at September 30, 2016 and 6.25% at December 31, 2015.

Advisory Services Agreement

The Company is party to an Advisory Services Agreement with Mariposa Capital, LLC, an affiliate of one of our founder directors, whereby Mariposa Capital, LLC is entitled to receive an annual fee equal to \$2.0 million, payable in quarterly installments. This agreement is automatically renewed for successive one-year terms unless either party notifies the other party in writing of its intention not to renew no later than 90 days prior to the expiration of the term. For each of the three month periods ended September 30, 2016 and 2015, the Company incurred advisory fees under the agreement totaling \$0.5 million. For each of the nine month periods ended September 30, 2016 and 2015, the Company incurred advisory fees under the agreement totaling \$1.5 million.

18. RESTRUCTURING

The Company continuously evaluates all operations to identify opportunities to improve profitability by leveraging existing infrastructure to reduce operating costs and respond to overall economic conditions.

Restructuring expenses were recorded as follows in each of the Company's segments:

Three Nine
Months Months
Ended Ended
September September

30, 30,

(amounts in millions) 2016 2015 2016 2015 Performance Solutions \$6.4 \$2.9 \$16.8 \$5.8

Agricultural Solutions 0.9 1.6 2.7 12.4

Total restructuring \$7.3 \$4.5 \$19.5 \$18.2

The restructuring plans initiated within the Performance Solutions segment primarily relate to headcount reductions associated with the integration of the Alent, OMG and OMG Malaysia Acquisitions. The restructuring plans initiated within the Agricultural Solutions segment primarily relate to cost saving opportunities associated with the integration of the Arysta, CAS and Agriphar Acquisitions. There are no material additional costs expected to be incurred related to these discrete restructuring plans.

As of September 30, 2016 and December 31, 2015, restructuring liabilities totaled \$0.4 million and \$1.1 million, respectively, and were included in "Accrued expenses and other current liabilities" in the Condensed Consolidated Balance Sheets.

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)

Restructuring expenses were recorded as follows in the Condensed Consolidated Statements of Operations:

restructuring expenses were recorded as rone	J *	tile C	on acrise.	a Const
	Three	•	Nine M	onths
	Mont	hs	Ended	iontiis
	Ende	d		h a m
	September		r September	
	30,		30,	
(amounts in millions)	2016	2015	2016	2015
Cost of sales	\$ —	\$2.4	\$(0.4)	\$3.6
Selling, technical, general and administrative	7.3	2.1	19.9	14.6
Total restructuring	\$7.3	\$4.5	\$19.5	\$18.2

19. SEGMENT INFORMATION

The Company's operations are organized into two reportable segments: Performance Solutions and Agricultural Solutions. The reporting segments represent businesses for which separate financial information is utilized by the chief operating decision maker, or CODM, for purpose of allocating resources and evaluating performance. Each of the reportable segments has its own president, who reports to the CODM.

Performance Solutions - The Performance Solutions segment formulates and markets dynamic chemistry solutions that are used in automotive production, commercial packaging and printing, electronics, and oil and gas production and drilling. Its products include surface and coating materials, functional conversion coatings, electronics assembly materials, water-based hydraulic control fluids and photopolymers. Performance Solutions products are sold worldwide. In conjunction with the sale of its products, extensive technical service and support is provided to ensure superior performance. Within this segment, the Company provides specialty chemicals to the following industries: Electronics, Electronics Assembly Materials, Commercial Packing and Printing, Industrial, and Offshore. For the Electronics industry, the segment designs and formulates a complete line of proprietary "wet" dynamic chemistries used by customers to process the surface of the printed circuit boards and other electronic components they manufacture. For the Electronics Assembly Materials industry, the segment develops, manufactures and sells innovative interconnected materials, primarily in the electronics market, used to assemble printed circuit boards and advanced semiconductor packaging. For the Commercial Packaging and Printing industries, the segment produces photopolymers, through an extensive line of flexographic plates, which are used to produce printing plates for transferring images onto commercial packaging, including packaging for consumer food products, pet food bags, corrugated boxes, labels and beverage containers. In addition, the segment also produces photopolymer printing plates for the flexographic and letterpress newspaper and publications markets. For the Industrials, the segment's dynamic chemistries are used for finishing, cleaning and providing surface coatings for a broad range of metal and non-metal surfaces which improve the performance or look of a component of an industrial part or process. For the Offshore industry, the segment produces water-based hydraulic control fluids for major oil and gas companies and drilling contractors for offshore deep water production and drilling applications.

Agricultural Solutions - The Agricultural Solutions segment is based on a solutions-oriented business model that focuses on product innovation to address an ever-increasing need for higher crop yield and quality. It offers to growers diverse crop-protection solutions from weeds (herbicides), insects (insecticides) and diseases (fungicides), in foliar and seed treatment applications. The segment also offers a wide variety of proven biosolutions, including biostimulants, innovative nutrition and biocontrol products. It emphasizes farmer economics and food safety by combining, when possible, biosolutions with crop protection and seed treatment agrochemicals. Its Global Value Added Portfolio, or GVAP, consists of agrochemicals in the fungicides, herbicides, insecticides and seed treatment categories, based on patented or proprietary off-patent AIs. Its Global BioSolutions Portfolio, or GBP, includes biostimulants, innovative nutrition and biocontrol products. The segment considers its GVAP and GBP offerings to be key pillars for sustainable growth. In addition, the segment offers regional off-patent AIs and certain non-crop

products, including animal health products, such as honey bee protective miticides and certain veterinary vaccines. The Company evaluates the performance of its operating segments based on net sales and adjusted EBITDA. Adjusted EBITDA for each segment is defined as earnings before interest, taxes, depreciation and amortization, as further adjusted for additional items included in earnings that are not representative or indicative of each segment's ongoing business. Adjusted EBITDA for each segment also includes an allocation of corporate costs such as corporate salaries, wages, equity compensation expenses and legal costs.

PLATFORM SPECIALTY PRODUCTS CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)

The following table summarizes financial information regarding each reportable segment's results of operations for the periods presented.

	Three Months		Nine Moi	nths	
	Ended		Ended Se	eptember	
	Septem	ber 30,	30,		
(amounts in millions)	2016	2015	2016	2015	
Net Sales (from external customers):					
Performance Solutions	\$454.9	\$179.7	\$1,312.9	\$541.6	
Agricultural Solutions	435.6	417.6	1,323.0	1,265.7	
Consolidated net sales	\$890.5	\$597.3	\$2,635.9	\$1,807.3	
Adjusted EBITDA:					
Performance Solutions	\$109.9	\$54.1	\$290.7	\$156.9	
Agricultural Solutions	80.2	59.5	260.7	256.5	
Adjusted EBITDA	\$190.1	\$113.6	\$551.4	\$413.4	

The following table reconciles Net income (loss) attributable to common stockholders to Adjusted EBITDA:

(coss) and coss coss coss coss	Three month	s Nine months
	ended Septer	nber ended September
	30,	30,
(amounts in millions)	2016 201	5 2016 2015
Net income (loss) attributable to common stockholders	\$104.7 \$(1	40.1) \$(39.0) \$(178.9)
Gain on amendment of Series B Convertible Preferred Stock	(32.9) —	(32.9) —
Net (loss) income attributable to the non-controlling interests	(5.9) 0.5	(4.7) 4.0
Income tax expense	20.4 35.4	4 65.7 59.8
Income (loss) before income taxes and non-controlling interests	86.3 (10-	4.2) (10.9) (115.1)
Adjustments to reconcile to Adjusted EBITDA:		
Interest expense, net	98.5 52.7	7 289.7 143.2
Depreciation expense	18.9 11.6	5 55.8 33.7
Amortization expense	68.0 50.4	199.1 142.6
Long-term compensation issued in connection with acquisitions	0.2 (1.5	0.6
Restructuring expenses	7.3 4.5	19.5 18.2
Manufacturer's profit in inventory purchase accounting adjustments	1.3	11.7 58.0
Acquisition and integration costs	3.2 15.0	27.4 70.4
Non-cash change in fair value of contingent consideration	0.2 2.7	4.3 6.3
Legal settlements		(2.8) (16.0)
Foreign exchange loss on foreign denominated external and internal debt	12.0 33.0	58.7 26.8
Fair value loss on foreign exchange forward contract	— 48.1	48.1
Gain on settlement agreement related to Series B Convertible Preferred Stock	(103.0) —	(103.0) —
Non-cash change in fair value of preferred stock redemption liability	(6.0) —	(6.0) —
Other income (expense), net	4.5 —	7.3 (3.0)
Adjusted EBITDA	\$190.1 \$11	3.6 \$551.4 \$413.4

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Forward-Looking Information

From time to time, Platform may make or publish forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect Platform's current views with respect to, among other things, future events and performance. These statements may discuss, among other things, Platform's financial or operational results including earnings guidance, future capital expenditures, expenses, revenues, earnings, synergies, economic performance, indebtedness, financial condition, dividend policy, losses and future prospects; business and management strategies; and the effects of global economic conditions on Platform's business. Platform generally identifies forward-looking statements by words such as "plans," "expects," "is expected," "is subject to," "budget," "scheduled," "estimates," "forecasts," "intends," "anticipates," "believes," "targets," "aims," "projects" or words or terms of si substance or the negative thereof, as well as variations of such words and phrases or statements that certain actions, events or results "may," "could," "should," "would," "might" or "will" be taken, occur or be achieved. Forward-looking statem are based on beliefs and assumptions made by management using currently available information. These statements are only predictions and are not guarantees of future performance, actions or events. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying beliefs and assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Factors that can cause actual results to differ materially from those reflected in the forward-looking statements include, among others, those discussed in Part I, Item 1A of Platform's Annual Report, Part II, Item 1A of Platform's quarterly reports on Form 10-O for the three months ended March 31, 2016 and June 30, 2016, and this Quarterly Report, in each case under the heading "Risk Factors." You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider any such list to be a complete set of all potential risks or uncertainties, and we urge you not to place undue reliance on any forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. Also, historical results are not necessarily indicative of the results expected for any future period. You are advised to consult any further disclosures we make on related subjects in the Company's Form 10-K, 10-O and 8-K reports filed with the SEC.

The following "Executive Overview" section is a brief summary of our recent developments, business, past acquisitions and certain significant items addressed in this Management's Discussion and Analysis of Financial Condition and Results of Operations. Investors should read the relevant portions of this section for a complete discussion of the events and items summarized below.

Executive Overview

We are a global, diversified producer of high-technology specialty chemical products. Our business involves the formulation of a broad range of solutions-oriented specialty chemicals, which are sold into multiple industries, including agricultural, animal health, electronics, graphic arts, plating, and offshore oil and gas production and drilling. We refer to our products as "dynamic chemistries" due to their intricate chemical compositions. Our dynamic chemistries are used in a wide variety of attractive niche markets and we believe that the majority of our operations hold strong positions in the product markets they serve.

Our strategy is to acquire and maintain leading positions in niche sectors of high-growth markets. As our name "Platform Specialty Products Corporation" implies, we continually seek opportunities to act as an acquirer and consolidator of specialty chemical businesses on a global basis, particularly those meeting our "Asset-Lite, High-Touch" philosophy, which involves prioritizing extensive resources to research and development and highly technical customer service, while managing conservatively our investments in fixed assets and capital expenditures. We regularly review acquisition opportunities and may acquire businesses that meet our acquisition criteria when we deem it to be financially prudent. To date, we have completed seven acquisitions: the MacDermid Acquisition on October 31, 2013; the Agriphar Acquisition on October 1, 2014; the CAS Acquisition on November 3, 2014; the Arysta Acquisition on February 13, 2015; the OMG Acquisition on October 28, 2015; the Alent Acquisition on December 1, 2015 and the OMG Malaysia Acquisition on January 31, 2016.

We generate revenue through the formulation and sale of our dynamic chemistries and by providing highly-technical services to our customers through our extensive global network of specially trained service personnel. Our personnel work closely with our customers to ensure that the intricate chemical composition and function of our products are

maintained as intended while ensuring that these products are applied safely and effectively by users globally. We believe that the fragmented nature of the specialty chemical products market will continue to provide significant opportunities for growth. We also believe that our combined company provides a strong platform on which to grow our business and expand our market shares in key geographic markets, particularly in emerging markets. We expect that the Acquisitions will enhance our

growth by extending our products' breadth, developing higher-margin products and growing internationally. We intend to extend many of our product offerings through the development of new applications for our existing products or through synergistic combinations. Our goal is to target those geographies with attractive market fundamentals where our strengths in marketing, portfolio development, registration and customer education can add value for our customers.

On September 9, 2016, we agreed with the Arysta Seller that from October 20, 2016 until the close of business on December 15, 2016, we may settle (i) all of our obligations with respect to our shares of Series B Convertible Preferred Stock in exchange for a cash payment of \$1.00 and the issuance of 5,500,000 shares of our common stock upon simultaneous conversion of the Series B Convertible Preferred Stock by the Arysta Seller, and (ii) for a payment of \$460 million, our obligation to pay a "make whole payment" to the Arysta Seller pursuant to a share purchase agreement among us, the Arysta Seller and certain other parties thereto, dated as of October 20, 2014, as amended. On September 21, 2016, we completed the September 2016 Equity Offering of 48,787,878 shares of our common stock at a public offering price of \$8.25 per share. This number of shares includes 6,363,636 shares sold to the underwriters upon exercise in full of their option to purchase additional shares. The September 2016 Equity Offering was registered with the SEC pursuant to Platform's shelf registration statement on Form S-3 declared effective by the SEC on July 26, 2016. The September 2016 Equity Offering resulted in gross proceeds to Platform of approximately \$402.5 million, before underwriting discounts and commissions and offering expenses of \$11.6 million. On October 14, 2016, we entered into and closed the transactions contemplated by Amendment No. 5 to the Second Amended and Restated Credit Agreement which, among other things, provided for the prepayment in full of previously existing term loans denominated in U.S. dollars and in Euros with the aggregate proceeds of newly created term loans denominated in U.S. dollars in an aggregate principal amount of \$1.48 billion and term loans denominated in Euros in an aggregate principal amount of €433 million. The amendment effectively reduced interests rates by 50 basis points for the new U.S. Dollar denominated term loans and by 75 basis points for the new Euro denominated term loans, reducing annual interest payments by approximately \$11.0 million. Amendment No. 5 also extended maturity from June 7, 2020 to June 7, 2023; provided that if, on or prior to November 2, 2021, we have not prepaid, redeemed or otherwise retired and/or refinanced in full the 6.50% USD Notes due 2022, as permitted under the Amended and Restated Credit Agreement, the maturity date of the new term loans will be November 2, 2021. See Note 8, Debt, Capital Leases, Financial Guarantees and Factoring Arrangements, to our unaudited interim Condensed Consolidated Financial Statements included in this Quarterly Report, under the heading "Amended and Restated Credit Agreement - Subsequent Events."

John E. Capps joined Platform on May 31, 2016 as Executive Vice President, General Counsel and Secretary. Before joining Platform, Mr. Capps was Executive Vice President - Administration, General Counsel and Secretary of Jarden Corporation, a Fortune 500 broad-based consumer products company, where he served until April 2016 when Jarden Corporation merged with Newell Brands Inc. Previously, Mr. Capps worked with American Household, Inc., which was acquired by Jarden Corporation in January 2005, and as a private lawyer with the firm Sullivan & Cromwell LLP. As previously disclosed in our Annual Report, in connection with the implementation of our internal controls, policies and procedures at Arysta, a newly acquired subsidiary, following our acquisition of that business we discovered certain payments made to third-party agents in connection with Arysta's government tender business in West Africa which may be illegal or otherwise inappropriate. We have engaged outside counsel and an outside accounting firm to conduct an internal investigation to review the legality of these and other payments made in Arysta's West Africa tender business, including Arysta's compliance with the FCPA. We contacted the SEC and the U.S. Department of Justice to voluntarily inform them of this matter and we are fully cooperating with these governmental authorities as the investigation continues and as they review the matter. Although the internal investigation is still ongoing at the time of this Quarterly Report, based on the results to date, management does not currently believe that the amount of the payments in question, or any revenue or operating income related to those payments, are material to our business, results of operations, financial condition or liquidity.

Acquisitions

OMG Malaysia Acquisition

On January 31, 2016, we completed the OMG Malaysia Acquisition for approximately \$124 million, net of acquired cash and closing working capital adjustments.

We financed the OMG Malaysia Acquisition with the proceeds from the June 2015 Equity Offering.

Alent Acquisition

On December 1, 2015, we completed the Alent Acquisition by acquiring all the issued shares of Alent for approximately \$1.74 billion in cash, net of acquired cash, and 18,419,738 shares of our common stock issued to Alent shareholders, including Cevian Capital II Master Fund LP, the then largest shareholder of Alent.

We financed the Alent Acquisition with (i) available cash on hand, (ii) the proceeds from the November 2015 Notes Offering of \$500 million aggregate principal amount of 10.375% USD Notes due 2021, and (iii) additional borrowings of \$1.05 billion (less original issue discount of 2%) and approximately €300 million (less original discount of 2%) under our First Lien Credit Facility, and \$115 million under our U.S. Dollar Revolving Credit Facility. OMG Acquisition

On October 28, 2015, we completed the OMG Acquisition for a total purchase price of approximately \$239 million in cash, net of acquired cash, and purchase price adjustments.

We financed the OMG Acquisition with the proceeds from the June 2015 Equity Offering.

Arysta Acquisition

On February 13, 2015, we completed the Arysta Acquisition for approximately \$3.50 billion. The purchase price consisted of \$2.86 billion in cash (net of acquired cash, closing adjustments and including Arysta Seller transaction expenses paid by Platform) and \$600 million of Platform's Series B Convertible Preferred Stock issued to the Arysta Seller with a fair market value at the time of the Arysta Acquisition of \$646 million. On September 9, 2016, we entered into a settlement agreement with the Arysta Seller with respect to certain of our obligations relating to the shares of Series B Convertible Preferred Stock. See Note 11, Stockholders' Equity, to our unaudited interim Condensed Consolidated Financial Statements, under the heading "Series B Convertible Preferred Stock."

We financed the Arysta Acquisition with the proceeds from (i) available cash on hand, (ii) the offering of \$1.10 billion aggregate principal amount of 6.50% USD Notes due 2022 denominated in U.S. Dollars and €350 million aggregate principal amount of 6.00% EUR Notes due 2023 denominated in Euros (plus original issue premium of \$1.0 million), and (iii) additional borrowings of \$500 million (less original issue discount of 1%) and €83 million (less original discount of 2%) under our First Lien Credit Facility, and an additional \$160 million under our U.S. Dollar Revolving Credit Facility.

Our Business

We generate revenue through the formulation and sale of our dynamic chemistries to our customers through our extensive global network of specially trained service personnel. Our personnel work closely with our customers to ensure that the chemical composition and function of our dynamic chemistries are maintained as intended. While our dynamic chemistries typically represent only a small portion of our customers' costs, we believe that they are critical to our customers' manufacturing processes and overall product performance. Further, operational risks and switching costs make it difficult for our customers to change suppliers, which grants us an advantage in retaining customers and maintaining our market positions.

Business Segments

Our operations are organized into two reportable segments: Performance Solutions and Agricultural Solutions. The reporting segments represent businesses for which separate financial information is utilized by the chief operating decision maker, or CODM, for the purpose of allocating resources and evaluating performance. Each of the reportable segments has its own president, who reports to the CODM.

Performance Solutions

Our Performance Solutions segment formulates and markets dynamic chemistry solutions that are used in electronics, automotive production, oil and gas production, drilling, and commercial packaging and printing. Our products include surface and coating materials, functional convention coatings, electronic assembly materials, water-based hydraulic control fluids and photopolymers. In conjunction with the sale of these products, we provide extensive technical service and support when necessary to ensure superior performance of their application. Within this segment, we provide specialty chemicals to the following industries: Electronics, Electronics Assembly Materials, Industrial, Offshore and Commercial Packing and Printing. For the Electronics industry, we design and formulate a complete line of proprietary "wet" dynamic chemistries that our customers use to process the surface of printed circuit boards and other electronic components they manufacture. For the Electronics Assembly Materials industry, we develop, manufacture and sell innovative interconnected materials, primarily in the electronics market, used to assemble printed circuit boards and advanced semiconductor packaging. We also offer a small water treatment product line. For the Industrial industry, our dynamic chemistries are used for finishing, cleaning and providing surface coatings for a broad range of metal and non-metal surfaces which improve the performance or look of a component of an industrial part or process. For the Offshore industry, we produce water-based hydraulic control fluids for major oil and gas companies and drilling contractors for offshore deep water production and drilling applications. For the Commercial Packaging and Printing industries, we produce photopolymers through an extensive line of flexographic plates, used to produce printing plates for transferring images onto commercial packaging, including packaging for consumer food products, pet food bags, corrugated boxes, labels and beverage containers. In addition, we also produce photopolymer printing plates for the flexographic and letterpress newspaper and publications markets. **Agricultural Solutions**

Our Agricultural Solutions segment is based on a solutions-oriented business model that focuses on product innovation to address an ever-increasing need for higher crop yield and quality. We offer to growers diverse crop protection solutions from weeds (herbicides), insects (insecticides) and diseases (fungicides), in foliar and seed treatment applications. We also offer a wide variety of proven biosolutions, including biostimulants, which stimulate plant growth and reproductive development, innovative nutrition, which optimizes the nutrition of plants, and biocontrol products, such as bioinsecticides and biofungicides, which perform the same task as conventional crop protection products without chemical residues. We emphasize farmer economics and food safety by combining, when possible, biosolutions with crop protection and seed treatment agrochemicals. Our Global Value Added Portfolio, or GVAP, consists of agrochemicals in the herbicides, insecticides, fungicides and seed treatment categories, based on patented or proprietary off-patent AIs. Our Global BioSolutions Portfolio, or GBP, includes biostimulants, innovative nutrition and biocontrol products. In addition, we offer regional off-patent AIs and certain non-crop products, including animal health products, such as honey bee protective miticides and certain veterinary vaccines. Our business segments include significant foreign operations. There are certain risks associated with our foreign operations. See Part II, Item 1A Risk Factors – "Our substantial international operations subject us to risks not faced by domestic competitors" included in this Ouarterly Report.

We sell our products worldwide. Because our segments may utilize shared facilities and administrative resources and offer products that are distinct from one another, we make decisions about how to manage our operations by reference to each segment and not with respect to the underlying products or geographic regions that comprise each segment.

Results of Operations

The following table summarizes the results of operations for the three and nine months ended September 30, 2016 and 2015:

	Ended September		Nine Months Ended		
			September	f 30,	
(amounts in millions)	2016	2015	2016	2015	
Net sales	\$890.5	\$597.3	\$2,635.9	\$1,807.3	
Cost of sales	515.4	354.6	1,524.1	1,088.8	
Gross profit	375.1	242.7	1,111.8	718.5	
Selling, technical, general and administrative	274.3	194.8	823.5	593.2	
Research and development	20.9	16.6	61.3	47.8	
Operating profit	79.9	31.3	227.0	77.5	
Interest expense, net	(98.5)	(52.7)	(289.7)	(143.2)	
Other income (expense), net	104.9	(82.8)	51.8	(49.4)	
Income tax expense	(20.4)	(35.4)	(65.7)	(59.8)	
Net income (loss)	\$65.9	\$(139.6)	\$(76.6)	\$(174.9)	

In addition, our other comprehensive income increased by \$363 million and \$1.03 billion for the three and nine months ended September 30, 2016 and 2015, driven primarily by changes in foreign currency translation gains associated with the Brazilian Real on a quarterly basis and the Brazilian Real, British Pound, Euro and Japanese Yen on a year-to-date basis.

The following table summarizes the results of operations for the three and nine months ended September 30, 2016 and 2015 by reportable segment:

	Three Months		Nine Months	
(amounts in millions)	in millions) Ended		Ended Se	ptember
	Septem	ber 30,	30,	
Performance Solutions	2016	2015	2016	2015
Net sales	\$454.9	\$179.7	\$1,312.9	\$541.6
Cost of sales	251.8	86.5	736.7	259.1
Gross profit	203.1	93.2	576.2	282.5
Selling, technical, general and administrative	120.9	50.5	372.5	159.0
Research and development	10.6	5.4	34.1	16.9
Operating profit	\$71.6	\$37.3	\$169.6	\$106.6
A ani aultural Calutiana				
Agricultural Solutions	Φ 425 C	¢ 417 6	Ф1 202 О	Φ1 265 7
Net sales			\$1,323.0	
Cost of sales	263.6	268.1	787.9	828.9
Gross profit	172.0	149.5	535.1	436.8
Selling, technical, general and administrative	135.0	113.7	370.8	349.5
Research and development	10.3	11.2	27.2	30.9
Operating profit	\$26.7	\$24.6	\$137.1	\$56.4
Non-GAAP Financial Measures				

In this Management's Discussion and Analysis of Financial Condition and Results of Operations section, we present certain financial measures related to our business that are "non-GAAP financial measures" within the meaning of Item 10 of Regulation S-K. Such non-GAAP financial measures include adjusted net sales change, adjusted cost of sales change, adjusted gross profit change, adjusted selling, technical, general and administrative expense change, adjusted research and development expense change and adjusted operating profit change, in each case adjusted for the OMG Malaysia, Alent and OMG Acquisitions for all periods presented and changes in foreign currency translations. We believe these non-GAAP financial measures provide useful information about our operating performance by excluding certain items that we believe are not representative of our business and including other items that we believe are useful

in evaluating our business. We also believe that these financial measures provide investors

with measures that allow them to more readily assess our performance, including, among other things, giving investors additional information regarding our organic performance without giving effect to the OMG Malaysia, Alent and OMG Acquisitions and the impact of translating foreign currencies into U.S. Dollars and the impact of currency rate changes on certain foreign currency denominated transactions. However, these non-GAAP financial measures should be considered in addition to, and not a substitute for, the financial information that we report in accordance with GAAP.

The adjustments for the OMG Malaysia, Alent and OMG Acquisitions were as follows:

	Three	Nine
	Months	Months
	Ended	Ended
	September	September
	30,	30,
(amounts in millions)	2016	2016
Net sales	\$ 280.2	\$ 795.3
Cost of sales	171.0	494.1
Gross profit	109.2	301.2
Selling, technical, general and administrative	62.1	202.4
Research and development	5.8	19.3
Operating profit	41.3	79.5

The adjustments for changes in foreign currency translations consisted of converting our current-period local currency financial results into U.S. Dollars using the prior period's exchange rates and comparing these adjusted amounts to our prior period reported results. The weakening Brazilian Real, British Pound and Mexican Peso most notably contributed to the nine month year-over-year results, offset in part by the strengthening Japanese Yen. The same currencies had similar effects on a quarterly year-over-year basis, with the exception of the Brazilian Real, which significantly appreciated during the third quarter of 2016 compared to 2015.

We believe that these adjustments provide a more meaningful basis of comparison of our results on a year-over-year basis, consistent with how we evaluate our performance.

Three and nine months ended September 30, 2016 versus the three and nine months ended September 30, 2015. Net Sales

Three Months Nine Months
Ended Ended September
September 30, 30,
(amounts in millions) 2016 2015 2016 2015
Net sales \$890.5 \$597.3 \$2,635.9 \$1,807.3

For the three months ended September 30, 2016, net sales totaled \$891 million, representing an increase of \$293 million, or 49.1%, as compared to the same period in 2015. For the nine months ended September 30, 2016, net sales totaled \$2.64 billion, representing an increase of \$829 million, or 45.8%, as compared to the same period in 2015.

	Three Months		Nine Months	
	Ended September		Ended S	eptember
	30, 2016		30, 2016	
(amounts in millions)	\$	%	\$	%
(amounts in inimons)	Change	Change	Change	Change
Total change	\$293.2	49.1 %	\$828.6	45.8 %
- acquisitions	(280.2)	(46.9)%	(795.3)	(44.0)%
- foreign currency translation	(6.7)	(1.1)%	60.7	3.4 %
Change, adjusted for acquisitions and foreign currency translation	\$6.3	1.1 %	\$94.0	5.2 %

For the three months ended September 30, 2016, adjusted for acquisitions and foreign currency translation, net sales increased by \$6.3 million, or 1.1%. For the nine months ended September 30, 2016, adjusted for acquisitions and foreign currency translation, net sales increased by \$94.0 million, or 5.2%.

	Ended		Nine Mon September		
(amounts in millions)	2016	2015	2016	2015	
Performance Solutions					
Net sales	\$454.9	\$179.7	\$1,312.9	\$541.6	
- acquisitions	(280.2)	_	(795.3)	_	
- foreign currency translation	3.0	_	13.8		
Net sales, adjusted for acquisitions and foreign exchange	\$177.7	\$179.7	\$531.4	\$541.6	

Agricultural Solutions

Net sales	\$435.6	\$417.6	\$1,323.0	\$1,265.7
- foreign currency translation	(9.7)		46.9	_
Net sales, adjusted for foreign exchange	\$425.9	\$417.6	\$1,369.9	\$1,265.7

Performance Solutions' net sales in the third quarter of 2016, adjusted for acquisitions and foreign currency translation, totaled \$178 million, representing a decrease of \$2.0 million, or 1.1%, as compared to the third quarter of 2015. The decrease in net sales was driven predominantly by general softness in the offshore business primarily in the U.S. and European regions due to decreases in the price of oil, which resulted in delays of project startups. The impact of oil prices was twofold: (1) reduced demand for offshore production control and drilling fluids, and (2) reduced demand for plating chemistry sold into the supply chain for onshore oil production rigs and stripping/cleaning chemistry utilized in polyethylene terephthalate recycling.

Performance Solutions' net sales for the nine months ended September 30, 2016, adjusted for acquisitions and foreign currency translation, totaled \$531 million, representing a decrease of \$10.2 million, or 1.9%, as compared to the nine months ended September 30, 2015. The decrease in net sales was driven by softness in the offshore U.S. and European markets, due to lower fills and maintenance product activity.

Agricultural Solutions' net sales in the third quarter of 2016, adjusted for foreign currency translation, totaled \$426 million, representing an increase of \$8.3 million, or 2.0%, as compared to the third quarter of 2015. The increase is primarily related to increased volumes of herbicides and fungicides in Europe, gains in Asia that coincided with a strategic shift to increase sales of proprietary brands over generic alternatives, growth in sales for insecticides suited for specialty crops in the United States, and continued growth in anti-malarial insecticides in Africa. These effects were partially offset by our continued integration efforts to reduce volumes related to low-margin products across geographic markets.

Agricultural Solutions' net sales for the nine months ended September 30, 2016, adjusted for foreign currency translation, totaled \$1.37 billion, representing an increase of \$104 million, or 8.2%, as compared to the nine months ended September 30, 2015. The increase in net sales on a comparable basis was primarily driven by volume and pricing growth in our insecticide and herbicide businesses in Latin America and Europe, our anti-malarial insecticides in Africa, and our biosolutions business, along with management's focus on price growth via an increase in sales of proprietary brands. These effects were partially offset by lower volumes in North America, mainly due to falling farmer incomes and soft demand, as well as our continued integration efforts to reduce volumes related to low-margin products across geographic markets.

Cost of Sales

Three Months Nine Months
Ended Ended September
September 30, 30,

(amounts in millions) 2016 2015 2016 2015 Cost of sales \$515.4 \$354.6 \$1,524.1 \$1,088.8

For the three months ended September 30, 2016, cost of sales totaled \$515 million, or 57.9% of net sales, as compared to \$355 million, or 59.4% of net sales, during the same period in 2015, representing an increase of \$161 million. For the nine months ended September 30, 2016, cost of sales totaled \$1.52 billion, or 57.8% of net sales, as compared to \$1.09 billion, or 60.2% of net sales, during the same period in 2015, representing an increase of \$435 million.

	Three Months		Nine Months	
	Ended September		r Ended September	
	30, 2016		30, 2016	
(amounts in millions)	\$	%	\$	%
mounts in mimons)	Change	Change	Change	Change
Total change	\$160.8	45.3 %	\$435.3	40.0 %
- acquisitions	(171.0)	(48.2)%	(494.1)	(45.4)%
- foreign currency translation	(4.9)	(1.4)%	33.7	3.1 %
Change, adjusted for acquisitions and foreign currency translation	\$(15.1)	(4.3)%	\$(25.1)	(2.3)%

For the three months ended September 30, 2016, adjusted for acquisitions and foreign currency translation, cost of sales decreased by \$15.1 million, or 4.3%. For the nine months ended September 30, 2016, adjusted for acquisitions and foreign currency translation, cost of sales decreased by \$25.1 million, or 2.3%.

	Three Months		Nine Months		
	Ended		Ended		
	September 30,		September 30,		
(amounts in millions)	2016	2015	2016	2015	
Performance Solutions					
Cost of sales	\$251.8	\$86.5	\$736.7	\$259.1	
- acquisitions	(171.0)	_	(494.1)		
- foreign currency translation	1.0		5.7		
Cost of sales, adjusted for acquisitions and foreign exchange	\$81.8	\$86.5	\$248.3	\$259.1	
Agricultural Solutions					
Cost of sales	\$263.6	\$268.1	\$787.9	\$828.9	
- foreign currency translation	(5.9)	_	28.0	_	
Cost of salas, adjusted for foreign avalance	¢2577	\$268 1	¢ 215 0	0.969	

management's integration efforts.

Cost of sales, adjusted for foreign exchange \$257.7 \$268.1 \$815.9 \$828.9 Performance Solutions' cost of sales in the third quarter of 2016, adjusted for acquisitions and foreign currency translation, totaled \$81.8 million, as compared to \$86.5 million in the third quarter of 2015, representing a decrease of \$4.7 million, or 5.4%. The decrease in cost of sales related primarily to lower adjusted sales volume in the third quarter of 2016 associated with our Offshore business and lower procurement costs for raw materials resulting from

Performance Solutions' cost of sales for the nine months ended September 30, 2016, adjusted for acquisitions and foreign currency translation, totaled \$248 million, as compared to \$259 million for the nine months ended September 30, 2015, representing a decrease of \$10.8 million, or 4.2%, due primarily to the aforementioned lower adjusted sales volume, lower material costs from achieved synergies and favorable product mix.

Agricultural Solutions' cost of sales in the third quarter of 2016, adjusted for foreign currency translation, totaled \$258 million, as compared to \$268 million in the third quarter of 2015, representing a decrease of \$10.4 million, or 3.9%. The decrease included the impact of purchase accounting related to the step-up of inventory that was sold during the third quarter of 2015, which totaled \$1.3 million. Excluding the effect of purchase accounting, cost of sales decreased by \$9.1 million. The decrease was driven primarily by continued integration efforts and cost management strategies that produced more favorable procurement pricing from vendors, especially in Latin America, production process efficiencies derived from infrastructure improvements in Europe, and the reduction of certain low-margin product volumes across geographic markets.

Agricultural Solutions' cost of sales for the nine months ended September 30, 2016, adjusted for foreign currency translation, totaled \$816 million, as compared to \$829 million for the nine months ended September 30, 2015, representing a decrease of \$13.0 million, or 1.6%. The decrease included the impact of purchase accounting related to the step-up of inventory that was sold during the nine months of 2015, which totaled \$58.0 million. Excluding the effect of purchase accounting, cost of sales increased by \$45.0 million. The increase was primarily driven by higher overall sales volume and the exclusion of costs of sales incurred prior to the Arysta Acquisition in February 2015. On a comparable basis, cost of sales declined for the nine months ended September 30, 2016, primarily due to the third

quarter activity discussed in the preceding paragraph, as cost of sales for the first six months of 2016 was relatively flat compared to the same period of 2015.

Gross Profit

Three Months
Ended
September 30, September 30,

(amounts in millions) 2016 2015 2016 2015 Gross profit \$375.1 \$242.7 \$1,111.8 \$718.5

For the three months ended September 30, 2016, gross profit totaled \$375 million, or 42.1% of net sales, as compared to \$243 million, or 40.6% of net sales, during the same period in 2015, representing an increase of \$132 million. For the nine months ended September 30, 2016, gross profit totaled \$1.11 billion, or 42.2% of net sales, as compared to \$719 million, or 39.8% of net sales, during the same period in 2015, representing an increase of \$393 million.

Three Months Nine Months Ended September Ended September 30, 2016 30, 2016 \$ % (amounts in millions) Change Change Change \$132.4 54.6 % \$393.3 54.7 % Total change - acquisitions (109.2) (45.0)% (301.2) (41.9)% - foreign currency translation) (0.7)% 27.0 (1.8)3.8 % Change, adjusted for acquisitions and foreign currency translation \$21.4 8.8 % \$119.1 16.6 %

For the three months ended September 30, 2016, adjusted for acquisitions and foreign currency translation, gross profit increased \$21.4 million, or 8.8%. For the nine months ended September 30, 2016, adjusted for acquisitions and foreign currency translation, gross profit increased \$119 million, or 16.6%.

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
(amounts in millions)	2016	2015	2016	2015
Performance Solutions				
Gross profit	\$203.1	\$93.2	\$576.2	\$282.5
- acquisitions	(109.2)		(301.2)	_
- foreign currency translation	2.0	_	8.1	
Gross profit, adjusted for acquisitions and foreign exchange	\$95.9	\$93.2	\$283.1	\$282.5

Agricultural Solutions

Gross profit	\$172.0 \$149.5 \$535.1	\$436.8
- foreign currency translation	(3.8) - 18.9	
Gross profit, adjusted for foreign exchange	\$168.2 \$149.5 \$554.0	\$436.8

Performance Solutions' gross profit in the third quarter of 2016, adjusted for acquisitions and foreign currency translation, totaled \$95.9 million, as compared to \$93.2 million in the third quarter of 2015, representing an increase of \$2.7 million, or 2.9%. The increase in gross profit primarily related to a shift in product mix, as management focuses on continued cost savings realized from integration efforts, which were partially offset by a decrease of \$2.0 million in net sales.

Performance Solutions' gross profit for the nine months ended September 30, 2016, adjusted for acquisitions and foreign currency translation, totaled \$283 million, and was essentially flat when compared to the nine months ended September 30, 2015. The lower sales volume when compared to the first nine months of 2015 was partially offset by gross margin expansion from lower raw material purchases through synergies and favorable product mix. Agricultural Solutions' gross profit in the third quarter of 2016, adjusted for foreign currency translation, totaled \$168 million, as compared to \$150 million in the third quarter of 2015, representing an increase of \$18.7 million, or 12.5%. The increase is primarily driven by an overall increase in sales volume coupled with a more favorable product mix and continued reduction in procurement costs due to integration efforts and cost management.

Agricultural Solutions' gross profit for the nine months ended September 30, 2016, adjusted for foreign currency translation, totaled \$554 million, as compared to \$437 million for the nine months ended September 30, 2015, representing an increase of \$117 million,

or 26.8%. The increase is largely a result of the exclusion of gross profit earned in 2015 prior to the Arysta Acquisition on February 13, 2015. On a comparable basis, gross profit increased primarily due to a broad increase in sales volumes and pricing. These increases are partially offset by soft demand in North America, where volumes fell as a result of declining farmer incomes and lower demand. We continue to see favorable effects from improved procurement trends, product mix and our focus on proprietary products and more profitable growing niche markets. Selling, Technical, General and Administrative Expense

Three Months
Ended
September 30, September 30, 2016 2015

Nine Months
Ended
September 30, 2016 2015

(amounts in millions)

Selling, technical, general and administrative \$274.3 \$194.8 \$823.5 \$593.2

For the three months ended September 30, 2016, selling, technical, general and administrative expense totaled \$274 million, or 30.8% of net sales, as compared to \$195 million, or 32.6% of net sales, during the same period in 2015, representing an increase of \$79.5 million. For the nine months ended September 30, 2016, selling, technical, general and administrative expense totaled \$824 million, or 31.2% of net sales, as compared to \$593 million, or 32.8% of net sales, during the same period in 2015, representing an increase of \$230 million.

	Ended Ended			e Months ed September 2016		
(amounts in millions)	\$	%		\$	%	
(amounts in millions)	Change	Chan	ge	Change	Chan	ige
Total change	\$79.5	40.8	%	\$230.3	38.8	%
- acquisitions	(62.1)	(31.9)%	(202.4)	(34.1	.)%
- foreign currency translation	3.0	1.5	%	23.4	3.9	%
Change, adjusted for acquisitions and foreign currency translation	\$20.4	10.5	%	\$51.3	8.6	%

For the three months ended September 30, 2016, adjusted for acquisitions and foreign currency translation, selling, technical, general and administrative expense increased by \$20.4 million, or 10.5%. The increase is due to increased segment level costs, partially offset by a reduction in corporate spending related to acquisition and integration activities.

For the nine months ended September 30, 2016, adjusted for acquisitions and foreign currency translation, selling, technical, general and administrative expense increased by \$51.3 million, or 8.6%. The increase was due in part to additional investments made in our corporate infrastructure, especially related to acquisition and integration activities during the first quarter of 2016, aimed at supporting increased demands driven by our substantial growth, including increases in headcount and professional fees, and higher segment-level costs, as discussed below. These increases were partially offset by lower acquisition and integration-related costs incurred at the corporate level.

were partially offset by lower acquisition and integration-related costs incurred at th	e corpora	de level.		
	Three M	onths	Nine Mo	onths
	Ended		Ended	
	September 30,		September 30,	
(amounts in millions)	2016	2015	2016	2015
Performance Solutions				
Selling, technical, general and administrative expense	\$120.9	\$50.5	\$372.5	\$159.0
- acquisitions	(62.1)	_	(202.4)	
- foreign currency translation	0.8		3.9	_
Selling, technical, general and administrative expense, adjusted for acquisitions and foreign exchange	\$59.6	\$50.5	\$174.0	\$159.0
Torcign exchange				
Agricultural Solutions				
Selling, technical, general and administrative expense	\$135.0	\$113.7	\$370.8	\$349.5
- foreign currency translation	2.2		19.5	

Selling, technical, general and administrative expense, adjusted for foreign exchange\$137.2 \$113.7 \$390.3 \$349.5

Performance Solutions' selling, technical, general and administrative expense in the third quarter of 2016, adjusted for acquisitions and foreign currency translation, totaled \$59.6 million as compared to \$50.5 million in the third quarter of 2015, representing an increase of \$9.1 million, or 18.0%. The increase is primarily due to additional third-party professional fees, restructuring costs and administrative expenses in connection with integrating and managing the acquired businesses. These increases are partially offset by reductions in overhead and headcount associated with management's integration efforts.

Performance Solutions' selling, technical, general and administrative expense for the nine months ended September 30, 2016, adjusted for acquisitions and foreign currency translation, totaled \$174 million, as compared to \$159 million for the nine months ended September 30, 2015, representing an increase of \$15.0 million, or 9.4%. The increase is due primarily to the integration-related activity discussed in the preceding paragraph.

Agricultural Solutions' selling, technical, general and administrative expense in the third quarter of 2016, adjusted for foreign currency translation, totaled \$137 million, as compared to \$114 million in the third quarter of 2015, representing an increase of \$23.5 million, or 20.7%. The increase was due primarily to expenses related the expansion of our businesses, such as sales bonuses, commissions and product promotion expenses. We also incurred additional overhead as we continue to integrate our businesses and develop the appropriate operational infrastructure to support further growth.

Agricultural Solutions' selling, technical, general and administrative expense for the nine months ended September 30, 2016, adjusted for foreign currency translation, totaled \$390 million, as compared to \$350 million for the nine months ended September 30, 2015, representing an increase of \$40.8 million, or 11.7%. The increase is largely a result of the exclusion of 2015 selling, technical, general and administrative expenses prior to the Arysta Acquisition on February 13, 2015. On a comparable basis, related expenses declined for the first nine months of 2016 compared to the same period in 2015. The decline is largely the result of management's realization of synergies associated with acquisitions and focus to control spending. These activities have offset the increase in growth-related and infrastructural expenditures.

Research and Development Expense

Three Nine
Months Months
Ended Ended
September September
30, 30,

(amounts in millions)

2016 2015 2016 2015

Research and development expense \$20.9 \$16.6 \$61.3 \$47.8

For the three months ended September 30, 2016, research and development expense totaled \$20.9 million, or 2.3% of net sales, as compared to \$16.6 million, or 2.8% of net sales, during the same period in 2015, representing an increase of \$4.3 million. For the nine months ended September 30, 2016, research and development expense totaled \$61.3 million, or 2.3% of net sales, as compared to \$47.8 million, or 2.6% of net sales, during the same period in 2015, representing an increase of \$13.5 million.

Three Months Nine Months Ended Ended September 30, September 30, 2016 2016 % \$ % (amounts in millions) Change Change Change \$4.3 25.9 % \$13.5 28.2 % Total change - acquisitions (5.8) (34.9)% (19.3) (40.4)% - foreign currency translation 0.2 1.2 % 1.6 3.3 Change, adjusted for acquisitions and foreign currency translation \$(1.3) (7.8)% \$(4.2) (8.8)%

For the three months ended September 30, 2016, adjusted for acquisitions and foreign currency translation, research and development expense decreased by \$1.3 million, or 7.8%. For the nine months ended September 30, 2016, adjusted for acquisitions and foreign currency translation, research and development expense decreased by \$4.2

million, or 8.8%.

	Three Month Ended Septem 30,	_	Nine M Ended Septen 30,	
(amounts in millions)	2016	2015	2016	2015
Performance Solutions				
Research and development expense	\$10.6	\$5.4	\$34.1	\$16.9
- acquisitions	(5.8)		(19.3)	
- foreign currency translation			0.1	
Research and development expense, adjusted for acquisitions and foreign exchange	\$4.8	\$5.4	\$14.9	\$16.9
Agricultural Solutions				
Research and development expense	\$10.3	\$11.2	\$27.2	\$30.9
- foreign currency translation	0.2		1.5	
	¢ 10.5	0110	Φ 20 7	# 20 0

Research and development expense, adjusted for foreign exchange \$10.5 \$11.2 \$28.7 \$30.9

Performance Solutions' research and development expense in the third quarter of 2016, adjusted for acquisitions, totaled \$4.8 million, as compared to \$5.4 million in the third guarter of 2015, representing a decrease of \$0.6 million, or 11.1%. For the nine months ended September 30, 2016, research and development expense, adjusted for acquisitions and foreign currency translation, totaled \$14.9 million, as compared to \$16.9 million for the nine months ended September 30, 2015, representing a decrease of \$2.0 million, or 11.8%. The decrease in both periods is driven by integration activities that have reduced research and innovation-related operating costs.

Agricultural Solutions' research and development expense in the third quarter of 2016, adjusted for foreign currency translation, totaled \$10.5 million, as compared to \$11.2 million in the third quarter of 2015, representing a decrease of \$0.7 million, or 6.3%. For the nine months ended September 30, 2016, adjusted for foreign currency translation, research and development expense totaled \$28.7 million, as compared to \$30.9 million for the nine months ended September 30, 2015, representing a decrease of \$2.2 million, or 7.1%. The decrease in research and development expense in both periods is largely due to the integration of research and development functions of the acquisitions into the legacy business and management's continued focus on cost controls.

Operating Profit

Three Nine Months Months Ended Ended September September 30. 30.

(amounts in millions) 2016 2015 2016 2015 \$79.9 \$31.3 \$227.0 \$77.5 Operating profit

For the three months ended September 30, 2016, operating profit totaled \$79.9 million, or 9.0% of net sales, as compared to \$31.3 million, or 5.2% of net sales, during the same period in 2015, representing an increase of \$48.6 million. For the nine months ended September 30, 2016, operating profit totaled \$227 million, or 8.6% of net sales, as compared to \$77.5 million, or 4.3% of net sales, during the same period in 2015, representing an increase of \$150 million.

(amounts in millions)

Total Change

- acquisitions

- foreign currency translation

Nine Months Three Months Ended September Ended September 30, 2016 30, 2016 \$ % Change Change Change \$48.6 155.3 % \$149.5 192.9 % (41.3) (131.9)% (79.5) (102.6)% (5.0) (16.0)% 2.1 2.7

Change, adjusted for acquisitions and foreign currency translation \$2.3 7.3 % \$72.1 93.0 % For the three months ended September 30, 2016, adjusted for acquisitions and foreign currency translation, operating profit increased by \$2.3 million. For the nine months ended September 30, 2016, adjusted for acquisitions and foreign currency translation, operating profit increased by \$72.1 million.

	Three			
	Months	3	Nine Mo	onths
	Ended En		Ended	
	September		September 30,	
	30,			
(amounts in millions)	2016	2015	2016	2015
Performance Solutions				
Operating profit	\$71.6	\$37.3	\$169.6	\$106.6
- acquisitions	(41.3)		(79.5)	
- foreign currency translation	1.2		4.1	
Operating Profit, adjusted for acquisitions and foreign exchange	\$31.5	\$37.3	\$94.2	\$106.6

Agricultural Solutions

Operating profit	\$26.7 \$24.6 \$137.1 \$56.4
- foreign currency translation	(6.2) — (2.0) —
Operating profit, adjusted for foreign exchange	\$20.5 \$24.6 \$135.1 \$56.4

Performance Solutions' operating profit in the third quarter of 2016, adjusted for acquisitions and foreign currency translation, totaled \$31.5 million, as compared to \$37.3 million in the third quarter of 2015, representing a decrease of \$5.8 million, or 15.5%. Performance Solutions' operating profit for the nine months ended September 30, 2016, adjusted for acquisitions and foreign currency translation, totaled \$94.2 million, as compared to \$106.6 million for the nine months ended September 30, 2015, representing a decrease of \$12.4 million, or 11.6%. The decrease for both periods was due primarily to higher selling, general, technical and administrative expenses related to integration activities, partially offset by modest increases in gross profit during both periods.

Agricultural Solutions' operating profit in the third quarter of 2016, adjusted for foreign currency translation, totaled \$20.5 million, as compared to \$24.6 million in the third quarter of 2015, representing an increase of \$4.1 million, or 16.7%. The increase was driven primarily by the increase in gross profit, partially offset by increases in selling, technical, general and administrative expenditures tied to costs associated with the expansion of our businesses. Agricultural Solutions' operating profit for the nine months ended September 30, 2016, adjusted for foreign currency translation, totaled \$135 million, as compared to \$56.4 million for the nine months ended September 30, 2015, representing an increase of \$78.7 million. The increase is due in part to the exclusion of 2015 operating results prior to the Arysta Acquisition on February 13, 2015, as well as the impact of inventory purchase accounting in 2015 of \$58.0 million. On a comparable basis, operating profit improvements were driven primarily by the increase in gross profits, complemented by reductions in selling, technical, general and administrative expenditures and research and development costs, resulting from integration efforts and management oversight.

Other (Expense) Income

_	Three Months		Nine Months		
	Ended September		Ended September		
	30,		30,		
(amounts in millions)	2016	2015	2016	2015	
Interest expense, net	\$(98.5)	\$(52.7)	\$(289.7)	\$(143.2)	
Loss on derivative contracts	(1.4)	(47.3)	(12.1)	(49.9)	
Foreign exchange loss	(10.3)	(36.9)	(56.5)	(19.3)	
Other income, net	116.6	1.4	120.4	19.8	
Total other expense	\$6.4	\$(135.5)	\$(237.9)	\$(192.6)	
Interest Expense Net					

Interest Expense, Net

For the three months ended September 30, 2016 and 2015, net interest expense totaled \$98.5 million and \$52.7 million, respectively, representing an increase of \$45.8 million. For the nine months ended September 30, 2016 and 2015, net interest expense totaled \$290 million and \$143 million, respectively, representing an increase of \$147 million. The increase in both periods relates primarily to interest charges resulting from incremental debt facilities used to fund the Alent Acquisition, including the November 2015 Notes Offering of \$500 million, borrowings of

\$1.05 billion (less original issue discount of 2%) and approximately €300 million (less original discount of 2%) under our First Lien Credit Facility. In addition, the year-to-date increase also includes a full first quarter's impact in 2016 of the interest expense related to the incremental debt facilities used to fund the Arysta Acquisition.

Loss on Derivative Contracts

For the three months ended September 30, 2016 and 2015, loss on derivative contracts totaled \$1.4 million and \$47.3 million, respectively, representing a decrease in loss of \$45.9 million. The decrease in loss is mainly due to the settlement in prior year's fourth quarter of a deal contingent foreign exchange contract associated with the Alent Acquisition, which had a balance of \$48.1 million at September 30, 2015. The remaining change is due to normal volatility of the underlying currency exchange rates and commodities prices being hedged. For the nine months ended September 30, 2016 and 2015, loss on derivative contracts totaled \$12.1 million and \$49.9 million, respectively, representing a decrease in loss of \$37.8 million. The decrease in loss is due mainly to the aforementioned \$48.1 million unrealized loss on a deal contingent forward contract settled in prior year, partially offset by our increased use of foreign exchange and commodities derivative contracts to better manage our market risks coupled with an increase in the volatility of certain foreign exchange rates, particularly the Brazilian Real, and of prices of certain commodities, particularly silver.

Foreign Exchange Gain (Loss)

For the three months ended September 30, 2016 and 2015, foreign exchange loss totaled \$10.3 million and \$36.9 million, respectively, representing a decrease of \$26.6 million. The third quarter of 2016 includes \$12.0 million of foreign exchange loss associated with the remeasurement of foreign denominated external and intercompany debt related to the Acquisitions, compared to a loss of \$33.0 million in the third quarter 2015.

For the nine months ended September 30, 2016 and 2015, foreign exchange loss totaled \$56.5 million and \$19.3 million, respectively, representing an increase of \$37.2 million. The nine months of 2016 include \$58.7 million of foreign exchange losses associated with the remeasurement of foreign denominated external and intercompany debt related to the Acquisitions, compared to a loss of \$26.8 million for the same period in 2015.

Other Income, Net

For the three months ended September 30, 2016 and 2015, other income, net totaled \$117 million and \$1.4 million, respectively, representing an increase of \$115 million. The increase related primarily to a gain of \$103 million from the settlement agreement related to our Series B Convertible Preferred Stock, a \$6.0 million gain associated with the remeasurement of the Preferred Series B redemption liability recorded during the third quarter of 2016, as well as a \$3.5 million gain on the sale of our 15% equity interest in Certis Europe B.V.

For the nine months ended September 30, 2016 and 2015, other income, net totaled \$120 million and \$19.8 million, respectively, representing an increase of \$101 million. The increase was primarily driven by a legal settlement gain totaling \$16.0 million and the expiration of an acquisition-related put option on our common stock in connection with the Agriphar Acquisition totaling \$3.0 million in the first nine months of 2015 as compared to a gain of \$103 million from the settlement agreement with the Arysta seller, a \$6.0 million gain associated with the remeasurement of the Series B Convertible Preferred Stock redemption liability recorded, a \$2.8 million legal settlement, and a \$3.5 million gain on the sale of our 15% equity interest in Certis Europe B.V. recorded during the first nine months of 2016. Income Tax

	Three Mo Ended Se 30,		Nine Mon September	
(amounts in millions)	2016	2015	2016	2015
Income tax expense	\$(20.4)	\$(35.4)	\$(65.7)	\$(59.8)
Effective tax rate	23.6 %	(34.0)%	(602.8)%	(52.0)%

For the three months ended September 30, 2016, income tax expense totaled \$20.4 million, compared to an income tax expense of \$35.4 million for the three months ended September 30, 2015. Our effective tax rate for the three months ended September 30, 2016 was 23.6% on pre-tax income of \$86.3 million, compared to an effective tax rate of (34.0)% on pre-tax loss of \$104 million for the three months ended September 30, 2015. The difference between the statutory and effective tax rates for the three months ended September 30, 2016 primarily related to the recognition of a \$38.2 million benefit for a nontaxable purchase price adjustment related to the Arysta acquisition, a \$25.6 million benefit for deductions related to the Alent Acquisition, and a \$15.3 million benefit related to the recognition of tax deductible goodwill. Partially offsetting these items was a \$21.9 million valuation allowance on current quarter losses that may not be recoverable for U.S. and foreign companies, a \$26.0 million increase in tax reserves primarily

for deductions related to the Alent Acquisition, and a \$14.7 million charge related to tax on foreign operations. The difference from the statutory to effective tax rates for the three months ended September 30, 2015 primarily relates to a tax expense of \$33.9 million for U.S. tax on foreign operations and \$33.9 million related to non-deductible transactional costs.

The change in the effective tax rate from (34.0)% for the three months ended September 30, 2015 to 23.6% for the three months ended September 30, 2016 is attributable to a disproportionate change in pre-tax income, primarily the gain from the settlement agreement related to the Series B Convertible Preferred Stock in 2016.

For the nine months ended September 30, 2016 and 2015, income tax expense totaled \$65.7 million and \$59.8 million, respectively. Our effective tax rate for the nine months ended September 30, 2016 was (602.8)% on pre-tax loss of \$10.9 million, compared to an effective tax rate of (52.0)% on pre-tax loss of \$115 million for the nine months ended September 30, 2015. The difference between the statutory and effective tax rates for the nine months ended September 30, 2016 primarily related to the recognition of a \$103 million valuation allowance on current period losses that may not be recoverable for U.S. and foreign companies, a \$27.9 million increase in tax reserves primarily for deductions related to the Alent Acquisition, and a \$10.0 million charge related to tax on foreign operations. Partially offsetting these items was a \$38.2 million benefit for a nontaxable purchase price adjustment related to the Arysta Acquisition, a \$25.6 million benefit for deductions associated with the Alent Acquisition, and a \$15.3 million benefit related to the recognition of tax deductible goodwill. The difference from the statutory to effective tax rates for the nine months ended September 30, 2015 primarily relates to a tax expense for the establishment of a \$21.5 million valuation allowance on foreign tax credit carryovers as a result of the impact of the Arysta Acquisition, \$28.0 million for U.S. tax on foreign operations, a \$11.0 million foreign rate differential and losses that did not produce tax benefits and \$34.9 million related to non-deductible transactional costs.

The change in the effective tax rate from (52.0)% for the nine months ended September 30, 2015 to (602.8)% for the nine months ended September 30, 2016 is attributable to a disproportionate change in pre-tax income, primarily the gain from the settlement agreement related to the Series B Convertible Preferred Stock in 2016.

Liquidity and Capital Resources

In order to fund our acquisition activity, we have \$5.28 billion of debt as of September 30, 2016, with expected interest payments in excess of \$300 million per year. Our first significant principal debt payments, totaling \$3.22 billion, are due in 2020 and represent maturities of our outstanding term loans under our Amended and Restated Credit Agreement. In October 2016, we entered into and closed the transactions contemplated by Amendment No. 5 to the Second Amended and Restated Credit Agreement which, among other things, provided for the prepayment in full of previously existing term loans denominated in U.S. dollars and in Euros with the aggregate proceeds of newly created term loans denominated in U.S. dollars in an aggregate principal amount of \$1.48 billion and term loans denominated in Euros in an aggregate principal amount of £433 million. The amendment effectively reduced interest rates by 50 basis points for the new U.S. Dollar denominated term loans and by 75 basis points for the new Euro denominated term loans, while extending maturity by three years to June 7, 2023; provided that if, on or prior to November 2, 2021, we have not prepaid, redeemed or otherwise retired and/or refinanced in full the 6.50% USD Notes due 2022 as permitted under the Amended and Restated Credit Agreement, the maturity date of the new term loans will be November 2, 2021. See Note 8, Debt, Capital Leases, Financial Guarantees and Factoring Arrangements, to our unaudited interim Condensed Consolidated Financial Statements included in this Quarterly Report, under the heading "Amended and Restated Credit Agreement - Subsequent Events."

In addition, under the terms of a settlement agreement with the Arysta Seller, from October 20, 2016 until the close of business on December 15, 2016, we may settle (i) all of our obligations with respect to the Series B Convertible Preferred Stock in exchange for a cash payment of \$1.00 and the issuance of 5,500,000 shares of our common stock upon simultaneous conversion of the Series B Convertible Preferred Stock by the Arysta Seller, and (ii) for a payment of \$460 million, our obligation to pay the make whole payment mentioned below to the Arysta Seller. To the extent we do not settle all of our obligations by December 15, 2016, we will be required, on April 20, 2017, to repurchase, in consideration and exchange for shares of our common stock, each share of Series B Convertible Preferred Stock that has not been previously converted into shares of our common stock or automatically redeemed for cash. Upon such repurchase, we may also pay to holders of Series B Convertible Preferred Stock in cash a make-whole payment, which corresponds to any deficit between (i) the 10-day volume weighted price of Platform's common stock prior to such repurchase and (ii) \$27.14 per share. This make-whole payment, which varies based on our stock price, corresponds to a maximum amount of \$600 million. As of September 30, 2016, this maximum make-whole payment was approximately \$421 million.

We anticipate sufficient cash from operations to fund interest, working capital and other capital expenditures for the foreseeable future and have access to a \$500 million line of credit under our Revolving Credit Facility, with current availability of \$500 million, as well as availability under various lines of credit and overdraft facilities of \$118 million. In addition, during the third quarter of 2016, we completed the September 2016 Equity Offering of 48,787,878 shares of common stock. This offering resulted in gross proceeds of approximately \$402.5 million. Despite the above, a combination of the settlement of the preferred stock redemption liability, working capital shortfalls and future acquisitions may require utilization of our Revolving Credit Facility as well as proceeds from future debt and/or equity offerings. Our long-term liquidity may be impacted by our ability to borrow additional funds, renegotiate existing debt and/or raise equity or debt under terms that are favorable to us. Our long-term liquidity may also be impacted by the pending withdrawal of the United Kingdom (U.K.) from the E.U., commonly referred to as "Brexit." In June 2016, a referendum was held in which voters approved the exit from the E.U. As a result, it is expected that the British government will begin negotiating the terms of the U.K.'s withdrawal from the E.U. A withdrawal could cause disruption and uncertainty surrounding our business, including affecting our relationships with our existing and future customers, suppliers and employees in the U.K. and in other countries in the E.U. The announcement of Brexit also caused significant volatility in global stock markets and fluctuations in currency exchange rates that resulted in the strengthening of the U.S. Dollar against foreign currencies in which we conduct business. The strengthening of the U.S. Dollar relative to other currencies may adversely affect our business, financial conditions or results of operations, and expose us to gains and losses on non-U.S. currency transactions. This volatility in foreign currencies is expected to continue as the U.K. negotiates and executes its exit from the E.U. but it is uncertain over what time period this will occur. Any of these effects of Brexit, among others, could adversely affect our business, financial condition, operating results and cash flows.

Our primary sources of liquidity during the nine months ended September 30, 2016 were proceeds received from the September 2016 Equity Offerings, periodic borrowings under our Revolving Credit Facility and available cash. Our primary uses of cash and cash equivalents were operating expenses, capital expenditures and debt service obligations. We believe that our cash and cash equivalent balance, cash generated from operations and availability under our Revolving Credit Facility will be sufficient to meet our working capital needs, capital expenditures and other business requirements for at least the next twelve months. Pending any future acquisitions, however, we may require additional borrowings against our Revolving Credit Facility, as well as future debt and/or equity offerings. At September 30, 2016, we had \$714 million in cash and cash equivalents in addition to availability under our Revolving Credit Facility and lines of credit of \$618 million.

Of our \$714 million of cash and cash equivalents at September 30, 2016, \$523 million was held by our foreign subsidiaries. The laws of certain countries may limit our ability to utilize cash resources held in those countries for operations in other countries. However, these laws are not likely to impact our liquidity in a material way. The operations of each foreign subsidiary generally fund such subsidiary's capital requirements. In the event that other foreign operations or operations within the United States require additional cash, we may transfer cash between and among subsidiaries as needed so long as such transfers are in accordance with law. As of September 30, 2016, we had the ability to repatriate \$23.1 million at our discretion from the foreign subsidiaries and branches while the remaining balance of \$499 million was held at subsidiaries in which earnings are considered permanently reinvested.

Repatriation of some of these funds could be subject to delays and could have potential tax consequences, principally with respect to withholding taxes paid in foreign jurisdictions. If cash is repatriated from jurisdictions in which earnings are considered permanently reinvested we will be required to accrue and pay U.S. income taxes on such repatriations.

On January 31, 2016, we completed the OMG Malaysia Acquisition for approximately \$124 million, net of acquired cash and closing working capital adjustments, subject to purchase price adjustments. We acquired OMG Malaysia to add-on to the OMG Acquisition and further enhance our Performance Solutions segment. See Note 2, Acquisitions of Businesses, to our interim Condensed Consolidated Financial Statements included in this Quarterly Report for further detail.

We may from time to time seek to retire or purchase our outstanding debt, including, but not limited to, our Senior Notes, through cash purchases, exchanges for equity securities, or refinancing, in open market purchases, privately negotiated transactions or otherwise. Such repurchases or exchanges, if any, will depend on prevailing market conditions, our liquidity requirements, contractual restrictions and other factors.

The following is a summary of our cash flows (used in) provided by operating, investing and financing activities during the periods indicated:

	Nine Months		
	Ended September		
	30,		
(amounts in millions)	2016	2015	
Cash and cash equivalents, beginning of the period	\$432.2	\$397.3	
Cash (used in) provided by operating activities	(24.0)	131.1	
Cash used in investing activities	(37.5)	(2,305.8)	
Cash provided by financing activities	337.4	2,481.0	
Exchange rate impact on cash and cash equivalents	6.0	(21.6)	
Cash and cash equivalents, end of the period	\$714.1	\$682.0	
Key operating metrics			
Days sales outstanding (DSO)	117	121	
Days in Inventory (DII)	100	114	
Operating Activities			

During the nine months ended September 30, 2016, cash used in operating activities totaled \$24.0 million, compared to cash provided by operating activities of \$131 million during the nine months ended September 30, 2015. This year-over-year change was driven by higher cash income which was more than offset by a \$190 million unfavorable change in cash used for assets and liabilities, net of acquisitions. The major drivers of the unfavorable change in assets and liabilities were decreases in our accounts payable and accrued expenses related to timing of payments to suppliers and, to a lesser extent, non-working capital assets and liabilities. Partially offsetting this cash usage was a modest improvement in inventories.

Investing Activities

Cash flows used in investing activities totaled \$37.5 million during the nine months ended September 30, 2016, as compared to \$2.31 billion used during the nine months ended September 30, 2015. The decrease was largely due to \$2.86 billion of net cash outflows related primarily to the Arysta Acquisition on February 13, 2015, which was partially offset by a release of \$600 million in acquisition-related restricted cash. Additionally, during the nine months

ended September 30, 2016, capital expenditures and investments in product registration rights were \$3.1 million lower when compared to the same period in 2015.

Financing Activities

Cash flows provided by financing activities totaled \$337 million during the nine months ended September 30, 2016, as compared to \$2.48 billion during the nine months ended September 30, 2015. The decreased financing activity cash inflows were primarily related to the financing of the Arysta Acquisition, which included proceeds of \$2.09 billion from borrowings and \$470 million from the issuance of common stock. Offsetting these 2015 inflows were payments of debt financing fees associated primarily with the Arysta Acquisition of \$45.5 million. Additionally, on a year-over-year basis, our factored liabilities decreased cash flows by \$28.7 million and we made additional repayments of debt of \$10.5 million. Partially offsetting these year-over-year reduced cash inflows was a stock issuance in the third quarter 2016 that generated net proceeds of \$392 million and \$14.2 million of increased borrowings under our revolving credit facilities during the nine months ended September 30, 2016. Financial Borrowings

Credit Facilities

As of September 30, 2016, we had \$5.28 billion of indebtedness, which included \$1.96 billion of Senior Notes and \$3.26 billion of term debt arrangements outstanding under our First Lien Credit Facility; \$42.8 million under our overdraft lines of credit; and \$11.2 million of stand-by letters of credit, which reduce the borrowings available under our Revolving Credit facility. Availability under our Revolving Credit Facility and various lines of credit and overdraft facilities totaled \$618 million as of September 30, 2016.

Alent Acquisition

In connection with the Alent Acquisition, we completed the November 2015 Notes Offering of \$500 million in aggregate principal amount of 10.375% USD Notes due 2021. The notes are governed by an indenture, dated November 10, 2015, as amended from time to time, bear interest at a rate of 10.375% and mature on May 1, 2021, unless redeemed earlier. In addition, we borrowed \$1.05 billion (less original issue discount of 2%) and €300 million (less original issue discount of 2%) under our First Lien Credit Facility, and \$115 million under our multi-currency Revolving Credit Facility.

Arysta Acquisition

In connection with the Arysta Acquisition, we completed the February 2015 Notes Offering of \$1.10 billion aggregate principal amount of 6.50% USD Notes due 2022, plus original issue premium of \$1.0 million, and €350 million aggregate principal amount of 6.00% EUR Notes due 2023. The notes are governed by an indenture, dated February 2, 2015, as amended from time to time. The 6.50% USD Notes due 2022 and the 6.00% EUR Notes due 2023 mature on February 1, 2022 and February 1, 2023, respectively, unless redeemed earlier. The 6.50% USD Notes due 2022 and the 6.00% EUR Notes due 2023 bear interest at a rate of 6.50% and 6.00% per year, respectively, until maturity. In addition, we borrowed \$500 million (less original issue discount of 1%) and €83.0 million (less original issue discount of 2%) under our First Lien Credit Facility, and \$160 million under our U.S. Dollar Revolving Credit Facility. CAS Acquisition

In connection with the CAS Acquisition, in August 2014, we borrowed \$130 million and €205 million under our First Lien Credit Facility, \$60.0 million under our U.S. Dollar Revolving Credit Facility, and €55.0 million under our multicurrency Revolving Credit Facility.

Agriphar Acquisition

In connection with the Agriphar Acquisition, in October 2014, we borrowed \$300 million under our First Lien Credit Facility.

MacDermid Acquisition

In connection with the MacDermid Acquisition, in October 2013, under its First Lien Credit Agreement, MacDermid, with Platform as co-borrower, borrowed \$373 million in connection with the repayment of the \$360 million in principal on its then second lien credit facility.

Our Credit Facilities contain various covenants, including limitations on additional indebtedness, dividends and other distributions, entry into new lines of business, use of loan proceeds, capital expenditures, restricted payments, restrictions on liens, transactions with affiliates, amendments to organizational documents, accounting changes, sale and leaseback transactions and dispositions. In addition, our Revolving Credit Facility requires compliance with certain financial covenants, including a first lien net leverage ratio of no greater than 6.25 to 1.0 of (x) consolidated indebtedness secured by a first lien minus unrestricted cash and cash equivalents of the borrowers and guarantors under the Amended and Restated Credit Agreement to (y) consolidated EBITDA for the four most recent fiscal quarters, subject to a right to cure. As of September 30, 2016, the Company was in compliance with the debt covenants contained in our Credit Facilities.

Contractual Obligations and Commitments

The contractual obligations and commitments disclosures have not changed materially from those disclosed in our Annual Report, except as indicated below. For a discussion of our contractual obligations and commitments, refer to Part II, Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations," contained in our Annual Report.

The proportion of liabilities measured at fair value using significant level 3 inputs comprised about 94.5% and 84.0% of total liabilities measured at fair value as of September 30, 2016 and December 31, 2015, respectively. See Note 10, Fair Value Measurements, to our unaudited interim Condensed Consolidated Financial Statements included in this Quarterly Report.

Amendment No. 5 to the Second Amended and Restated Credit Agreement

On October 14, 2016, we entered into and closed the transactions contemplated by Amendment No. 5 to the Second Amended and Restated Credit Agreement which, among other things, provided for the prepayment in full of previously existing term loans denominated in U.S. dollars and in Euros with the aggregate proceeds of newly created term loans denominated in U.S. dollars in an aggregate principal amount of \$1.48 billion and term loans denominated in Euros in an aggregate principal amount of €433 million. The amendment effectively reduced interest rates by 50 basis points for the new U.S. Dollar denominated term loans and by 75 basis points for the new Euro denominated term loans, reducing annual interest payments by approximately \$11.0 million. Amendment No. 5 also extended maturity from June 7, 2020 to June 7, 2023; provided that if, on or prior to November 2, 2021, we have not prepaid, redeemed or otherwise retired and/or refinanced in full the 6.50% USD Notes due 2022 as permitted under the Amended and Restated Credit Agreement, the maturity date of the new term loans will be November 2, 2021. See Note 8, Debt, Capital Leases, Financial Guarantees and Factoring Arrangements, to our unaudited interim Condensed Consolidated Financial Statements included in this Quarterly Report, under the heading "Amended and Restated Credit Agreement - Subsequent Events."

Series B Convertible Preferred Stock

In connection with the Arysta Acquisition, we issued to the Arysta Seller 600,000 shares of Series B Convertible Preferred Stock, which have a \$1,000 per share liquidation preference. To the extent we do not settle all of our obligations pursuant to the settlement agreement mentioned below, at any time after December 15, 2016, the Arysta Seller has the ability to convert these shares into shares of common stock of Platform at a conversion price of \$27.14 per share. Additionally, any shares that have not previously been converted will be automatically redeemed at a \$1,000 redemption price in the event of certain mergers or consolidations, the sale of all or substantially all of our assets or subsidiaries, the sale of certain subsidiaries or the approval of any plan for the dissolution, liquidation or termination of Platform by its stockholders. Under the terms of a settlement agreement with the Arysta Seller, from October 20, 2016 until the close of business on December 15, 2016, we may settle (i) all of our obligations with respect to the Series B Convertible Preferred Stock in exchange for a cash payment of \$1.00 and the issuance of 5,500,000 shares of our common stock upon simultaneous conversion of the Series B Convertible Preferred Stock by the Arysta Seller, and (ii) for a payment of \$460 million, our obligation to pay the make whole payment mentioned below to the Arysta Seller. To the extent we do not settle all of our obligations by December 15, 2016, we will be required, on April 20, 2017, to repurchase each share of Series B Convertible Preferred Stock that has not been converted into shares of common stock of Platform, or automatically redeemed, as described above. Upon such repurchase, we would also pay to holders of Series B Convertible Preferred Stock in cash a make whole payment, which corresponds to any deficit between (i) the 10-day volume weighted price of Platform's common stock prior to

such repurchase and (ii) \$27.14 per share. Based on Platform's common stock price of \$8.11 as of September 30, 2016, the maximum potential make whole payment would total approximately \$421 million. To the extent we do not settle all of our obligations by December 15, 2016, the holders of Series B Convertible Preferred Stock are also entitled to an incremental payment equal to \$4.0 million per month from October 20, 2016 to April 20, 2017, or such earlier date after October 20, 2016 that the then outstanding shares of Series B Convertible Preferred Stock are converted into shares of common stock of Platform or automatically redeemed by us for cash.

The contractual obligations and commitments table reported in Part II, Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations," contained in our Annual Report, does not include our Series B Convertible Preferred Stock obligations, including the estimated make whole payment, described above. Off-Balance Sheet Transactions

We use customary off-balance sheet arrangements, such as operating leases and letters of credit, to finance our business. As a result of ASU No. 2016-02, "Leases," for fiscal years and interim periods beginning after December 15, 2018, we will be required to record lease liabilities and right-of-use assets for all of our qualifying operating leases that are currently treated as off-balance sheet transactions.

There are no other arrangements that have, or are reasonably likely to have, a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

Recent Accounting Pronouncements

A summary of recent accounting pronouncements in included in Note 1, Basis of Presentation and Significant Accounting Policies, to our unaudited interim Condensed Consolidated Financial Statements included in this Quarterly Report.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

The quantitative and qualitative disclosures about market risk required by this item have not changed materially from those disclosed in our Annual Report, except as indicated below. For a discussion of our exposure to market risk, refer to Part II, Item 7A, "Quantitative and Qualitative Disclosures about Market Risk," contained in our Annual Report. Foreign Currency Risk

The announcement of the Referendum of the United Kingdom's Membership of the E.U., often referred to as "Brexit," advising for the exit of the United Kingdom from the E.U., caused significant volatility in global stock markets and currency exchange rate fluctuations that resulted in the strengthening of the U.S. Dollar against foreign currencies in which we conduct business. The strengthening of the U.S. Dollar relative to other currencies may adversely affect our business, financial condition, or results of operations, and expose us to gains and losses on non-U.S. currency transactions. In addition, a potential devaluation of the local currencies of our customers relative to the U.S. Dollar may impair the purchasing power of our customers and could cause customers to decrease or cancel orders or default on payments. This volatility in foreign currencies is expected to continue as the United Kingdom negotiates and executes its exit from the E.U., but it is uncertain over what time period this will occur.

Item 4. Controls and Procedures

(a) Evaluation of Disclosure Controls and Procedures

Our management is responsible for establishing and maintaining disclosure controls and procedures as defined in Rules 13a-15 (e) and 15d-15(e) under the Exchange Act. As required by Rule 13a-15(b) of the Exchange Act, management, including our CEO and CFO, has evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report. The term "disclosure controls and procedures," as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company's management, including its CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure. Based on that evaluation, our CEO and CFO have concluded that the Company's disclosure controls and procedures were not effective due to material weaknesses in our internal control over financial reporting previously identified by our management and described more fully under Item 9A of our Annual Report.

The material weaknesses in our internal control relating to insufficient complement of personnel with an appropriate level of accounting knowledge, experience and training commensurate with our financial reporting requirements, as further described in our Annual Report, continued to exist as of the end of the period covered by this Quarterly Report. These material weaknesses resulted to date in the restatement of the unaudited interim financial statements previously issued in our quarterly report on Form 10-Q for the quarter ended March 31, 2015 as a result of an error related to the Arysta Acquisition, as described in the 2016 Q1 Form 10-Q, and the restatement of income taxes in the unaudited interim financial statements previously issued in our quarterly report on Form 10-Q for the quarter ended September 30, 2015, as described in our Annual Report.

Our management is actively engaged in implementing the remediation initiatives described in our Annual Report, 2016 Q1 Form 10-Q and 2016 Q2 Form 10-Q which are designed to address these material weaknesses. Our ongoing remediation efforts include the implementation of the following previously stated initiatives:

implementation of a global consolidation and planning system;

implementation of control processes relating to newly-acquired businesses and non-routine transactions; implementation of enhanced monitoring controls relating to the financial reporting and performance of our newly-acquired businesses;

enhancement of our financial planning and analysis function within our businesses and at the corporate level; addition of further qualified resources to our corporate and segment staff;

enhancement of the controllership function in our newly-acquired businesses; and

continued recruiting efforts to hire qualified personnel.

In addition, as part of our remediation efforts related to the accounting for income taxes, we have completed the implementation of a global tax reporting system during the first quarter of 2016

While significant progress has been made, additional time is necessary to fully implement and demonstrate the effectiveness of these remediation initiatives and until remediated, the material weaknesses described above could result in material misstatements of our annual or interim consolidated financial statements that would not be prevented or detected. We are committed to operating effective controls, and management continues to regularly assess the progress and sufficiency of the ongoing initiatives and make adjustments as and when necessary.

Notwithstanding the aforementioned material weaknesses, our management believes that the unaudited interim Condensed Consolidated Financial Statements included in this Quarterly Report fairly represent, in all material respects, our results of operations, financial position, and cash flows as of and for the periods presented, each in accordance with GAAP. Based in part on our continuing efforts, our CEO and CFO have included their certifications as exhibits to this Quarterly Report.

Our management has excluded from the evaluation of disclosure controls and procedures as of September 30, 2016 the internal control over financial reporting related to Alent, the OMG Businesses and OMG Malaysia because they were acquired by Platform in purchase business combinations consummated during the fourth quarter of 2015 with respect to Alent and the OMG Businesses and the first quarter of 2016 with respect to OMG Malaysia. Alent's, the OMG Businesses' and OMG Malaysia's total assets, excluding goodwill and intangible assets recognized in purchase accounting, and total revenues represent approximately 23% and 31%, respectively, of the related unaudited interim Condensed Consolidated Financial Statement amounts as of and for the quarter ended September 30, 2016. These acquisitions are material to our results of operations, financial condition and cash flows, and the integration following these business combinations is likely to materially impact the Company's internal control over financial reporting. We are in process of evaluating the internal controls over financial reporting for these acquisitions as required by the above stated Rules.

(b) Changes to Internal Control Over Financial Reporting

As required by Rule 13a-15(d) under the Exchange Act, our management, including our CEO and CFO, has evaluated the Company's internal control over financial reporting to determine whether any changes occurred during the quarter covered by this Quarterly Report have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

There have been no changes that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting during the quarter covered by this Quarterly Report.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

In the ordinary course of our business, we are subject to periodic lawsuits, investigations and claims, including, but not limited to, product liability claims, contractual disputes, premises claims, and employment, environmental, health and safety matters. Although we cannot predict with certainty the ultimate resolution of lawsuits, investigations and claims asserted against us, we believe that the resolution of these claims, to the extent not covered by insurance, will not individually or in the aggregate, have a material adverse effect on our consolidated financial position, results of operations or cash flows.

For more information regarding certain proceedings and their possible effects on our business, see Note 15, Contingencies, Environmental and Legal Matters, to our unaudited interim Condensed Consolidated Financial Statements included in this Quarterly Report, under the headings Environmental and Legal Proceedings, which sections are incorporated herein by reference.

Item 1A. Risk Factors

Except as set forth below, there have been no material changes to the risk factors set forth in Part I, Item 1A of our Annual Report under the heading "Risk Factors."

We have numerous equity instruments outstanding that could require us to issue additional shares of common stock. Therefore, you may experience significant dilution of your ownership interests and the future issuance of additional shares of our common stock, or the anticipation of such issuances, could have an adverse effect on our stock price. We have numerous equity instruments outstanding that would require us to issue additional shares of our common stock. Depending on the equity instrument, these additional shares may either be issued for no additional consideration or based on a fixed amount of additional consideration. Specifically, as of September 30, 2016, we had outstanding the following:

2,000,000 shares of Series A Preferred Stock which are convertible into shares of our common stock, on a one-for-one basis, at any time at the option of the holder;

600,000 shares of Series B Convertible Preferred Stock, issued in connection with the Arysta Acquisition which, to the extent we do not settle all of our obligations pursuant to the settlement agreement mentioned below, are convertible into up to 22,107,590 shares of our common stock at any time after December 15, 2016 by the Arysta Seller, Each share of Series B Convertible Preferred Stock will also be automatically redeemed in connection with certain mergers or consolidations, the sale of all or substantially all of the assets of Platform and its subsidiaries, the sale of certain subsidiaries of Platform, or a dissolution, liquidation or termination of Platform. Under the terms of a settlement agreement with the Arysta Seller, from October 20, 2016 until the close of business on December 15, 2016, we may settle (i) all of our obligations with respect to the Series B Convertible Preferred Stock in exchange for a cash payment of \$1.00 and the issuance of 5,500,000 shares of our common stock upon simultaneous conversion of the Series B Convertible Preferred Stock by the Arysta Seller, and (ii) for a payment of \$460 million, our obligation to pay the make whole payment mentioned below to the Arysta Seller. To the extent we do not settle all of our obligations by December 15, 2016, we will be required, on April 20, 2017, pursuant to a share purchase agreement among us, the Arysta Seller and certain other parties thereto, dated as of October 20, 2014, as amended, to repurchase each share of Series B Convertible Preferred Stock that has not been converted into shares of common stock of Platform, or automatically redeemed as described above. Upon such repurchase, we shall also pay to holders of Series B Convertible Preferred Stock in cash a make whole payment corresponding to any deficit between (i) the 10-day volume weighted price of our common stock prior to such repurchase and (ii) \$27.14 per share. The related potential cash obligation, which varies based on our stock price, corresponds to a maximum amount of \$600 million. Based on our common stock price of \$8.11 as of September 30, 2016, the maximum potential make whole payment as of September 30, 2016 would total approximately \$421 million;

7,997,665 exchange rights which require us to issue shares of our common stock in exchange for shares of common stock of our subsidiary, PDH, on a one-for-one basis, at the option of the holder;

approximately 565,198 options which are exercisable to purchase shares of our common stock, on a one-for-one basis, at any time at the option of the holder, of which 390,198 shares were issued under the 2013 Plan; and

approximately 2,433,966 RSUs which were granted to employees under our 2013 Plan. Each RSU represents a contingent right to receive one (1) share of our common stock.

We have approximately 12,302,402 shares of our common stock currently available under our 2013 Plan, net of the outstanding RSUs and options noted above (subject to increase in accordance with the terms of such plan) and 373,434 shares issued under the 2013 Plan, and an additional 5,026,150 shares of our common stock currently available under our 2014 ESPP.

In addition, the holders of our Series A Preferred Stock are entitled to receive an annual dividend on their Series A Preferred Stock in the form of shares of our common stock. For 2015, no stock dividend was declared with respect to their Series A Preferred Stock. Since December 31, 2014, the dividend amount is calculated based on the appreciated stock price compared to the highest dividend price (calculated based upon the average of the last ten trading days of the year's volume weighted average share prices) previously used in calculating the Series A Preferred Stock dividends. In 2014, the dividend price was \$22.85. Such issuance of common stock as stock dividend in the future could have a dilutive impact on, and reduce the value of, our outstanding common stock.

We have restated our unaudited interim condensed consolidated financial statements previously issued in our quarterly report on Form 10-Q for the quarter ended March 31, 2015.

As further described in Note 20, Restatement of Unaudited Interim Condensed Consolidated Financial Statements (Unaudited) to the unaudited interim Condensed Consolidated Financial Statements included in the 2016 Q1 Form 10-Q, we previously disclosed in our quarterly report on Form 10-Q for the quarter ended June 30, 2015 an error to goodwill and foreign currency translation adjustment of \$72.8 million related to the Arysta Acquisition, which was corrected as an out-of-period adjustment in such quarterly report. We subsequently concluded that this previously disclosed error also had the effect of understating cash flows provided by operating activities and cash flows used in investing activities by \$72.8 million and therefore further concluded that the previously reported information should no longer be relied upon. As a result, we restated our unaudited interim financial information for our first quarter ended March 31, 2015 in the aforementioned Note 20. If we are required to restate previously issued financial statements for any additional periods, such restatement could impair our reputation, could cause a loss of investor confidence and adversely materially affect our business, financial condition, or results of operations.

Volatility of the trading prices of our common stock and/or Senior Notes could adversely affect our security holders. The trading prices of our common stock and Senior Notes have been highly volatile and could continue to be subject to wide fluctuations in response to various factors, some of which are beyond our control, including, but not limited to:

quarterly variations in our operating results;

changes in the market's expectations about our operating results;

our operating results failing to meet the expectation of management, securities analysts or investors in a particular period;

the failure to remediate identified material weaknesses;

changes in financial estimates and recommendations by securities analysts concerning our Company or our industry in general;

operating and securities price performance of companies that investors deem comparable to us;

news reports and publication of research reports relating to our business or trends in our markets;

changes in laws and regulations affecting our businesses;

announcements or strategic developments, acquisitions and other material events by us or our competitors;

sales of substantial amounts of common stock by our directors, executive officers or significant stockholders or the perception that such sales could occur;

adverse market reaction to any additional debt we incur in the future;

litigation and class action proceedings;

the failure to identify and complete acquisitions in the future or unexpected difficulties or developments related to the integration of recently completed, pending or future acquisitions;

actions by institutional stockholders;

general economic and political conditions such as business cycles, recessions and acts of war or terrorism; and other matters discussed in this Quarterly Report.

In addition, the stock market in general, and the market for specialty chemicals companies in particular, has experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating

performance of those companies. Broad market and industry factors may seriously affect the market price of companies' stock, including ours, regardless of actual

operating performance. In addition, in the past, following periods of volatility in the overall market and the market price of particular companies' securities, securities litigation and class action proceedings have often been instituted against such companies. A shareholder derivative action and a class action lawsuit of these types were filed against us in April and March 2016, respectively. There can be no assurance that the market price of our common stock and/or Senior Notes will not fall in the future due to any of the aforementioned factors.

Failure to comply with the FCPA and other similar anti-corruption laws could subject us to penalties and damage our reputation.

We are subject to the FCPA, the Bribery Act, and other anti-corruption laws that generally prohibit companies, directors, officers, employees, and their intermediaries from making corrupt payments to foreign officials for the purpose of obtaining or retaining business or securing an improper advantage. Under many of these laws, companies may also be held liable for actions taken by third-parties acting on their behalf, such as strategic or local partners or representatives. Certain anti-corruption laws, including the Bribery Act, also prohibit commercial bribery and the receipt of bribes, while others, such as the FCPA, require companies to maintain accurate books and records and adequate internal controls. Certain of the jurisdictions in which we conduct business are perceived to have a heightened risk for corruption, extortion, bribery, pay-offs, theft and other improper practices. We also count governments among our customers, which increases our risks under the FCPA, the Bribery Act and other laws. Our businesses prohibit bribery and unethical conduct, but these policies may not prevent our employees or agents from violating these laws in contravention of our policies. Failure by us, our employees or our intermediaries to comply with applicable anti-corruption laws, governmental authorities in the United States or elsewhere, as applicable, may result in civil and/or criminal penalties against us, our officers or our employees, or prohibitions on the conduct of our business, all of which could damage our reputation and have a material adverse effect on our business, financial condition and results of operations. Any determination that our operations or activities, including our licenses or permits, importing or exporting, product testing or registrations, or sales and marketing are not in compliance with existing laws or regulations could result in the imposition of substantial fines, civil and criminal penalties, interruptions of business, modification of business practices and compliance programs, loss of supplier, vendor or other third-party relationship, termination of necessary licenses and permits, and other legal or equitable sanctions, including disgorgement, injunctive relief and other sanctions that we may take against our personnel or that may be taken against us or our personnel.

As previously disclosed in our 2015 Annual Report, in connection with the implementation of our internal controls, policies and procedures at Arysta, a newly acquired subsidiary, following our acquisition of that business we discovered certain payments made to third-party agents in connection with Arysta's government tender business in West Africa which may be illegal or otherwise inappropriate. We have engaged outside counsel and an outside accounting firm to conduct an internal investigation to review the legality of these and other payments made in Arysta's West Africa tender business, including Arysta's compliance with the FCPA. We contacted the SEC and the U.S. Department of Justice to voluntarily inform them of this matter and we are fully cooperating with these governmental authorities as the investigation continues and as they review the matter. Because the internal investigation and compliance reviews are ongoing, there can be no assurance as to how the resulting consequences, if any, may impact our internal controls and reputation, as well as our business, financial condition, or results of operations.

We are subject to a shareholder class action lawsuit which may adversely affect our business, financial condition, results of operations and cash flows.

We and certain of our current and former executive officers are defendants in a securities class action lawsuit. This lawsuit, including its current status, is described in Part II, Item 1 "Legal Proceedings" in this Quarterly Report. While we believe this lawsuit to be without merit and intend to vigorously defend it, we are in the early stages of this case and we cannot guarantee any particular outcome. This and any similar future matters may divert our attention from our ordinary business operations, and we may incur significant expenses associated with it (including, without limitation, substantial attorneys' fees and other fees of professional advisors and potential indemnification obligations). Depending on the outcome of such matter, we could be required to pay material damages and/or suffer other penalties, remedies or sanctions. Accordingly, the ultimate resolution of this pending matter or any similar future matters could have a material adverse effect on our business, financial condition, results of operations, cash flows, and/or liquidity

and could negatively impact the trading price of our common stock. Any existing or future shareholder lawsuits could also materially adversely affect our reputation and our business, financial condition, or results of operations.

Our substantial international operations subject us to risks not faced by domestic competitors.

Sales from international markets represent a significant portion of our net sales. Accordingly, our business is subject to increasing risks related to the different legal, political, social and regulatory requirements and economic conditions of many jurisdictions. Risks inherent to our international operations include the following:

increased credit risk and different financial conditions, which may necessitate longer payment cycles of accounts receivable or result in increased bad debt write-offs (including due to bankruptcy) or additions to reserves;

additional withholding taxes or otherwise tax our foreign income, tariffs, duties, export controls, import restrictions or other restrictions on foreign trade or investment, including currency exchange controls;

foreign exchange controls or other currency restrictions and limitation on the movement of funds, including the prohibition of the repatriation of funds, which may result in adverse tax consequences and tax inefficiencies;

export licenses may be difficult to obtain, and the transportation of our products may be delayed or interrupted; general economic and political conditions in the countries in which we operate, including devaluation or fluctuations in the value of currencies, gross domestic product, interest rates, market demand, labor costs and other factors beyond our control;

unexpected adverse changes in foreign laws or in foreign regulatory requirements, including in laws or regulatory requirements pertaining to employee benefits, the environment and health and safety;

protectionist policies, which may restrict or impair the manufacturing, sales or import and export of our products; new restrictions on access to markets, such as adverse trade policies or trade barriers;

a lack of or inadequate infrastructure;

natural disasters or other crises;

reduced protection of intellectual property rights in some countries;

expropriation of assets or forced relocations of operations;

inflation and hyperinflationary economic conditions and adverse economic effects resulting from governmental attempts to control inflation, such as imposition of wage and price controls and higher interest rates;

the requirement to comply with a wide variety of foreign and U.S. laws and regulations that apply to international operations, including, without limitation, economic sanctions regulations, labor laws, import and export regulations, anti-corruption and anti-bribery laws;

challenges in maintaining an effective internal control environment with operations in multiple international locations, including language differences, varying levels of GAAP expertise in international locations and multiple financial information systems; and

labor disruptions, civil unrest, significant social, political or economic instability, wars or other armed conflict or acts of terrorism.

Should any of these risks occur, our ability to manufacture, source, sell or export our products or repatriate profits could be impaired; we could experience a loss of sales and profitability from our international operations; and/or we could experience a substantial impairment or loss of assets, any of which could have a material adverse impact on our business, financial condition, or results of operations.

Furthermore, some of our international operations are conducted in parts of the world that experience corruption to some degree. Although we have policies and procedures in place that are designed to promote legal and regulatory compliance (including with respect to the FCPA and the Bribery Act as further described above), our employees, distributors and wholesalers could take actions in contravention of our policies and procedures that violate applicable anti-corruption laws or regulations. Violations of these laws, or allegations of such violations, could have a material adverse affect on our reputation, our business, financial condition, or results of operations.

We also may face difficulties managing and administering an internationally dispersed business. In particular, the management of our personnel across many countries can present legal, logistical and managerial challenges. Additionally, international operations present challenges related to operating under different business cultures and languages. Our overall success as a global business depends, in part, upon our ability to succeed in different legal, regulatory, economic, social and political conditions.

The results of the United Kingdom's referendum on withdrawal from the E.U. may have a negative effect on global economic conditions, financial markets and our business, which could reduce the price of our shares of common stock

We are a multinational company with worldwide operations, including significant business operations in Europe. In June 2016, a majority of voters in the United Kingdom elected to withdraw from the E.U. in a national referendum, commonly referred to as "Brexit." The referendum was advisory, and the terms of any withdrawal are subject to a negotiation period that could last at least two years after the government of the United Kingdom formally initiates a withdrawal process. Nevertheless, the referendum has created significant uncertainty about the future relationship between the United Kingdom and the E.U., and has given rise to calls for certain regions within the United Kingdom

to preserve their place in the E.U. by separating from the United Kingdom as well as for the governments of other E.U. member states to consider withdrawal.

These developments, or the perception that any of them could occur, have had and may continue to have a material adverse effect on global economic conditions and the stability of global financial markets, and could significantly reduce global market liquidity and restrict the ability of key market participants to operate in certain financial markets. Asset valuations, currency exchange rates and credit ratings may be especially subject to increased market volatility. Lack of clarity about future United Kingdom laws and regulations as the United Kingdom determines which E.U. laws to replace or replicate in the event of a withdrawal, including financial laws and regulations, tax and free trade agreements, intellectual property rights, supply chain logistics, environmental, health and safety laws and regulations, immigration laws and employment laws, could decrease foreign direct investment in the United Kingdom, increase costs, depress economic activity and restrict our access to capital. If the United Kingdom and the E.U. are unable to negotiate acceptable withdrawal terms or if other E.U. member states pursue withdrawal, barrier-free access between the United Kingdom and other E.U. member states or among the European economic area overall could be diminished or eliminated. Any of these factors could have a material adverse effect on our business, financial condition or results of operations and reduce the price of our shares of common stock.

We are exposed to fluctuations in currency exchange rates, which may adversely affect our operating results and may significantly affect the comparability of our results between financial periods.

Our consolidated financial statements are reported in U.S. Dollars while a significant proportion of our assets, liabilities and earnings are denominated in non-U.S. Dollar currencies. As a result, we are exposed to foreign currency exchange rate fluctuations from translating certain of our foreign subsidiaries' financial statements. Fluctuations in the value of local currencies in which we derive significant net sales may also impact the U.S. Dollar amounts reflected in our financial statements. Such U.S. Dollar amounts may obscure underlying financial trends that would be apparent in financial statements prepared on a constant currency basis or affect the comparability of our results between financial periods.

The announcement of Brexit caused significant volatility in global stock markets and currency exchange rate fluctuations that resulted in the strengthening of the U.S. Dollar against foreign currencies in which we conduct business. The strengthening of the U.S. Dollar relative to other currencies may adversely affect our business, financial condition, or results of operations, and expose us to gains and losses on non-U.S. currency transactions. In addition, a potential devaluation of the local currencies of our customers relative to the U.S. Dollar may impair the purchasing power of our customer and could cause customers to decrease or cancel orders or default on payment. This volatility in foreign currencies is expected to continue as the United Kingdom negotiates and executes its exit from the E.U. but it is uncertain over what time period this will occur. Any of these effects of Brexit, among others, could adversely affect our business, financial condition, results of operations and cash flows.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None

Item 3. Defaults Upon Senior Securities

None

Item 4. Mine Safety Disclosures

None

Item 5. Other Information

On November 3, 2016, John E. Capps, Executive Vice President, General Counsel and Secretary of Platform, entered into the Company's standard change of control agreement. According to this agreement, in the event of a "Change in Control" (as defined in the agreement), Mr. Capps would immediately vest in full in outstanding incentive programs and equity awards, and as such would be entitled to receive a lump sum equal to his short- or long-term target cash bonus awards payable under the terms of any existing incentive plan of Platform and all shares underlying any stock rights granted by Platform to Mr. Capps and outstanding on the date of Change of Control. In addition, if a Change in Control occurs and Mr. Capps' employment with Platform is terminated by Platform without cause or by Mr. Capps for good reason, in each case during the six (6) months prior to or within two (2) years

following the Change in Control, Mr. Capps would be entitled to receive, subject to the signing of a general release of claims and compliance with the restrictive covenants, a lump sum termination payment equal to 2 multiplied Mr. Capps' base salary plus target bonus as of the date of termination of Mr. Capps' employment or, if higher, the base salary and/or target bonus in effect immediately prior to the occurrence of the condition giving rise to good reason. A more detailed summary of the change in control agreement is set forth in Platform's Current Report on Form 8-K as filed with the SEC on April 8, 2016, which summary is incorporated herein by reference. The description of the change in control agreement is also qualified in its entirety by reference to the full text of the change in control agreement, a form of which is attached hereto as Exhibit 10.2, and is also incorporated herein by reference.

Item 6. Exhibits

The following exhibits are filed as part of this Quarterly Report:

Exhibit Number	Description	
2.1	Settlement Agreement and Release, dated September 9, 2016, among Platform Specialty Products Corporation and MacDermid Agricultural Solutions, Inc. and Permira Advisers LLC, Nalozo S.à.r.l., and Nalozo L.P. (filed as Exhibit 2.1 of the Current Report on Form 8-K filed on September 12, 2016, and incorporated herein by reference)	
3.1(a)	Certificate of Incorporation (filed as Exhibit 3.1 of Post-Effective Amendment No. 1 to the Registration Statement on Form S-4 (File No. 333-192778) filed on January 24, 2014, and incorporated herein by	
	reference)	
3.1(b)	Certificate of Amendment of Certificate of Incorporation (filed as Exhibit 3.1 of the Current Report on Form 8-K filed on June 13, 2014, and incorporated herein by reference)	
3.1(c)	Certificate of Designation of Series B Convertible Preferred Stock (filed as Exhibit 3.1 of the Current Report on Form 8-K filed on February 17, 2015, and incorporated herein by reference)	
3.2	Amended and Restated By-laws (filed as Exhibit 3.2 of the Annual Report on Form 10-K filed on March 31, 2014, and incorporated herein by reference)	
10.1	Amendment No. 5, dated October 14, 2016, among, inter alios, Platform, MacDermid, the subsidiaries of the borrowers from time to time parties thereto, the lenders from time to time parties thereto, and Barclays Bank PLC, as administrative agent and collateral agent (filed as Exhibit 10.1 of the Current Report on Form 8-K filed on October 17, 2016, and incorporated herein by reference)	
10.2	Form of Change in Control Agreement (filed as Exhibit 10.1 of the Current Report on Form 8-K filed on April 8, 2016, and incorporated herein by reference)	
31.1*	Principal Executive Officer Certification Pursuant to Exchange Act Rules 13a-14 and 15d-14 as adopted pursuant to the Section 302 of the Sarbanes-Oxley Act of 2002	
31.2*	Principal Financial Officer Certification Pursuant to Exchange Act Rules 13a-14 and 15d-14 as adopted pursuant to the Section 302 of the Sarbanes-Oxley Act of 2002	
32.1**	Principal Executive Officer and Principal Financial Officer Certifications Pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	
101. INS* XBRL Instance Document		
101 0011	WANDER E. C. O. D. A.	

- 101.SCH* XBRL Taxonomy Extension Schema Document
- 101.CAL*XBRL Extension Calculation Linkbase Document
- 101.DEF* XBRL Taxonomy Extension Definition Linkbase Document
- 101.LAB*XBRL Taxonomy Extension Label Linkbase Document
- 101.PRE* XBRL Taxonomy Extension Presentation Linkbase Document
- * Filed herewith.
- ** Furnished herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized this November 7, 2016.

PLATFORM SPECIALTY PRODUCTS CORPORATION

By:/s/ John P. Connolly

Name: John P. Connolly

Title: Vice President, Corporate Controller and Chief Accounting Officer (Principal Accounting Officer)

EXHIBIT INDEX

Exhibit Number	Description
2.1	Settlement Agreement and Release, dated September 9, 2016, among Platform Specialty Products Corporation and MacDermid Agricultural Solutions, Inc. and Permira Advisers LLC, Nalozo S.à.r.l., and Nalozo L.P. (filed as Exhibit 2.1 of the Current Report on Form 8-K filed on September 12, 2016, and incorporated herein by reference)
3.1(a)	Certificate of Incorporation (filed as Exhibit 3.1 of Post-Effective Amendment No. 1 to the Registration Statement on Form S-4 (File No. 333-192778) filed on January 24, 2014, and incorporated herein by reference)
3.1(b)	Certificate of Amendment of Certificate of Incorporation (filed as Exhibit 3.1 of the Current Report on Form 8-K filed on June 13, 2014, and incorporated herein by reference)
3.1(c)	Certificate of Designation of Series B Convertible Preferred Stock (filed as Exhibit 3.1 of the Current Report on Form 8-K filed on February 17, 2015, and incorporated herein by reference)
3.2	Amended and Restated By-laws (filed as Exhibit 3.2 of the Annual Report on Form 10-K filed on March 31, 2014, and incorporated herein by reference)
10.1	Amendment No. 5, dated October 14, 2016, among, inter alios, Platform, MacDermid, the subsidiaries of the borrowers from time to time parties thereto, the lenders from time to time parties thereto, and Barclays Bank PLC, as administrative agent and collateral agent (filed as Exhibit 10.1 of the Current Report on Form 8-K filed on October 17, 2016, and incorporated herein by reference)
10.2	Form of Change in Control Agreement (filed as Exhibit 10.1 of the Current Report on Form 8-K filed on April 8, 2016, and incorporated herein by reference)
31.1*	Principal Executive Officer Certification Pursuant to Exchange Act Rules 13a-14 and 15d-14 as adopted pursuant to the Section 302 of the Sarbanes-Oxley Act of 2002
31.2*	Principal Financial Officer Certification Pursuant to Exchange Act Rules 13a-14 and 15d-14 as adopted pursuant to the Section 302 of the Sarbanes-Oxley Act of 2002
32.1**	Principal Executive Officer and Principal Financial Officer Certifications Pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101 TATOM	ANDLE . D

- 101. INS* XBRL Instance Document
- 101.SCH* XBRL Taxonomy Extension Schema Document
- 101.CAL*XBRL Extension Calculation Linkbase Document
- 101.DEF* XBRL Taxonomy Extension Definition Linkbase Document
- 101.LAB*XBRL Taxonomy Extension Label Linkbase Document
- 101.PRE* XBRL Taxonomy Extension Presentation Linkbase Document
- * Filed herewith.
- ** Furnished herewith.